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Intmductioll and Aims of the Thesis 
Introduction and aims of this thesis 
History of reperfusion therapy for acute myocardial infarction 
In 1949 the fibrinolytic effect of streptococcal fibrinolysin (streptokinase) was described for the 
treatment of fibrous, pUl1llent or sanguineous pleural exudations (I). The effect of this lytic agent 
in patients with acute myocardial infarction was described by Fletcher in 1958 (2). In the late 
nineteensevcnties the pathofysiologic mechanism underlying acute myocardial infarction was 
recognised. In the majority of patients with acute myocardial infarction a completely occluded 
coronary artery is present at immediate angiography (3-5), caused by the formation of a platelet 
rich thrombus on a l1Iptured atherosclerotic plaque (6,7). Reperfusion therapy is aimed at remo-
val of this obstructing clot which can be achieved by t1uombolytic agents (given directly into the 
coronary artery or intravenously) or by mechanical intervention (Percutaneous Transluminal 
Coronary Angioplasty (PTCA)) or by a combination of these two. Rentrop et aJ. described his 
experience with intracoronary administration of streptokinase in 1979 (8). In 1983 it was shown 
in small trials that the intracoronary administration of streptokinase was beneficial compared to 
placebo treatment (9,10) and later, larger randomised trials demonstrated convincingly that intra-
venous fibrinolytic therapy re·establishes coronaty patency, thereby limiting infarct size and pre-
serving left ventricular function resulting in improved survival (ll, 12). In 1982, Meyer repor-
ted a case in which he successfully re-opened an infarct related vessel with a guide wire and a 
balloon after failed thrombolytic therapy (rescue PTCA,13). One year later Hartzler was the first 
to describe his experience with primary coronary angioplasty (mechanical revascularization 
without antecedent thrombolysis) (14) 
Deferred alld Resclle Allgiop/asty 
The combination of thrombolysis and PTCA seemed attractive and was studied by different 
groups of investigators. After the disappointing results of routine angioplasty for patients in 
whom a severe residual stenosis was present after thrombolysis or in whom thrombolysis had 
failed (15-24), PTCA was regarded as the "poor relation" in the management of acute myocat·-
dial infarction. Instead large scale studies were planned to compare different thrombolytic regi-
mes and this resulted in megatrials like GISSI-2, ISIS-3, and GUSTO-I (25-27), from which the 
latter included more than 40.000 patients and was published in 1993. 
The Tluombolysis and Myocardial Infarction (TIMI) phase I trial introduced a standard for 
flow assessment in the infarct related vessel after t1uombolytic therapy (28). This angiographic 
definition of perfusion of the epicardial coronary vessel was based on the assumption that gra-
des 0 and I are effectively occluded and grades 2 and 3 provide adequate repelfusion. This sco-
ring system has been commonly used to assess the immediate effectiveness of reperfusion the-
rapy. From the trials which compared different lytic agents, it became evident that the best 
thrombolytic regime, the accelerated adlninistration of recombinant tissue Plasminogen Activa-
tor (rtPA), resulted in successful repetfusion (TIMI 2 or 3 flow) in 80% of patients and TIMI 3 
flow in only 60% of patients (29). This led to a re-evaluation of primary angioplasty as a possi-
ble more effective treatment modality (30). In 1993 t1uee randomised trials of thrombolytic the-
rapy versus primary coronaty angioplasty for acute myocardial infarction were published in the 
same issue of the New England Jou111al of Medicine (31-33). The results of these trials were in 
favour of primary angioplasty and showed that it was possible to achieve TIMI grade 3 flow 
through the infarct related vessel in more than 90% of patients which was associated with a velY 
low in-hospital mortality of 2-3%. This information influenced daily practice in many institu-
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tions with facilities for interventional cardiology around the world and raised the question whet-
her thrombolytic therapy was still the best treatment in a patient with acute myocardial infarc-
tion. 
Criticism alld res liltS from ol/tel· Mals 
Many criticised the results, suggesting that the evidence was obtained from only three, relatively 
small sized randomiscd trials, in which the work was done by highly experienced and dedicated, 
high volume operators, in selected patients (34,35). There was doubt whether these results would 
be reproducible in all day routine clinical practice, often referred to as the 'real world'. 
To address this question a substudy of the GUSTO 2 trial randomised 1138 patients to receive 
either the best thrombolytic agent so far (accelerated tPA) or pIimruy angioplasty. This study was 
perfOll11ed in 57 centres over the world. The results have recently been published and were in 
favour of the angioplasty group (36). However, the reduction in the primmy end point: a com-
bination of death, reinfarction and stroke, was not as marked as in the first randomised trials (31-
33). Later, it became evident that the relative long treatment delay (1.9 hours) and the conside-
rable number ofPTCA assigned patients, who did not undergo angiography (6%) or angioplasty 
(19%), may partially be responsible for this finding (37). Nevertheless the authors concluded 
that primary angioplasty is an effective alternative therapy. Three published registries showed 
conflicting results. The Myocardial Infarction Triage and Intervention project regishy (MIT!, 
retrospective, non-randomised, 12,331 patients from 19 centres) and the recently published 
National Registry of Myocardial Infarction-2 (NRMI, retrospective, non-randomised, including 
29,644 patients) registIy data failed to show a difference in outcome between thrombolytic the-
rapy and primary angioplasty (38,39). However, in these registries only 10-15% of patients 
underwent primary angioplasty and suggests a selection bias. In contrast, the German Arbeits-
gemeinschaft Leitender Kardiologischer Krankenhausartze (ALKK) registry, which is a good 
reflection of connnon practice in a large part of Germany (4625 patients from 63 centres), docu-
mented results for patients treated with pIimmy angioplasty comparable to the first randomised 
trials (40). A recent meta-analysis of all randOInlsed trials comparing thrombolysis and primmy 
angioplasty in myocardial infarction, comprising 2606 patients, showed a 34% reduction in total 
mortality at 30 days for patients treated with primmy angioplasty, equivalent to the saving of 21 
lives per thousand patients treated. The FTT analysis found the same mortality reduction when 
comparing fibrinolytic therapy with placebo (12). In addition it was found that angioplasty was 
associated with a significant reduction in the incidence of hemolThagic stroke (0.08 vs 1.1 %, 
p=0.0005) (41). Figure I shows a comparison of the number of lives saved for different reper-
fusion strategies. 
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Comparison of number of lives saved per lOOO patients treated at 30 days following acute myocardial infarction ~1I) for 
different reperfusion strategies and aspirin. Ace-tPA: accelerated tPA;SK: streptokinase, Asp: aspirin. The figures have been 
derived by taking the overall mortality rate in control patients as 11.5% for all Ivfls and 16.9% for anterior 1fis (taken from 
FIT's collaborators study (12». Mortality rate for primary angioplasty for the overall population and for anterior Mis was 
taken as 4.4% (from mcta-analysis of primary PTCA (41» and 7.1 % (taken from GUSTO-IIb (36»; respectively; for acce-
larated tPA as 6.3% and 8.6% respectively (taken from GUSTO I (27); for streptokinase with aspirin as 8% and 10%, res-
pectively; for streptokinase alone 10.4% and 11.3%; and for aspirin as 10.7% and 12.8%, respectively (taken from ISIS-2 
study (42). Reprinted with pcrmission from Heart (BMJ publishing group, BeaU K, et ai, Heart 1997(suppI2);78:12-15). 
Gllidelines 
Recently, the European Society of Cardiology recently stated in its guidelines that primary 
angioplasty "may have a special role in the treatment of patients with cardiogenic shock and in 
those with contra-indications for thrombolytic therapy" (43). The American College-American 
Heart Association task force recommended pdmary angioplasty as a first choice option for the 
treatment of acute myocardial infarction, provided that it can be done within a certain time win-
dow and with support from expedenced personnel in high volume centres (44). 
In summary, after an initial pedod of doubt about the role of mechanical opening of an occluded 
infarct related vessel, primary angioplasty has developed into a first choice option for many 
patients with acute myocardial infarction. 
Lessons learned from thrombolytic trials 
Tlte open ;,1!(trct-(trteJY hypothesis 
COII/piele repel/llsioll 
Rapid and sustained patency of the infarct related vessel is the main goal of therapy in patients 
with acute myocardial infarction (45,46). Tllis was illustrated in the GUSTO-I angiographic 
substudy. Front-loaded rtPA achieved earlier and more complete repelfusion than other throm-
bolytic regimes and this resulted in an absolute mortality reduction of I % at 30 days (27, 47). 
Thirty day and long telTIl (2 years) mortality could be accurately predicted from the status of per-
fusion of the infarct related artery at 90 minutes (48). Furthermore it has been shown that incolll-
plete perfusion (TIMI 2 flow) is almost as bad as no reperfusion (49-51). However, it is not only 
important to open the vessel as quick as possible but also to prevent it frolll restenosis and reoc-
clusion. A high grade stenosis of the infarct related artelY may negatively influence left ventri-
cular function and long-term prognosis (52,53). Various studies have shown the importance of 
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an open infarct related vessel for long term clinical outcome (54-56). In this regard the APRI-
COT (Antithrombotics in the Prevention of Reocclusion In COronary Thrombolysis) study has 
made an important contribution and showed the detrimental effects of reocclusion of the infarct 
related vessel on left ventricular function and clinical outcome (57). 
Figure 2 30 
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Incidence of reocclusion after thrombolysis, The x axis represents the time between the initiation of thrombolytic therapy 
and the time of follow-up angiography, Reprinted with pennission from the American College of Cardiology, J Am Call 
Cardiol 1996;27:766-73). 
Reocclusioll 
The incidence of reocclusion is high in the early days after thrombolysis and increases to about 
20-30% at 3 months to I year after infarction (Figure 2, 58). Risk factors for reocclusion are a 
severe residual stenosis of the infarct related vessel (59-61), which is not a rare phenomenon in 
patients after thrombolytic therapy, and a totally occluded infarct related vessel before the admi-
nistration of the thrombolytic agent (62). Routine angioplasty after thrombolysis with the aim to 
obtain a larger luminal diameter of the infarct related vessel and therefore to prevent reocc1usion 
did not result in a better outcome (16, 19). A recent study showed that late angioplasty or surgi-
cal revascularisation is beneficial in selected patients with inducible ischemia shortly after 
thrombolysis (63). This emphasises that PTCA after thrombolysis should only be pelformed 
when clinically indicated. The reasons why a persistently patent infarct related vessel might give 
additional years of life to a patient are threefold: it results in enhanced infarct healing (56), with 
prevention of left ventricular remodelling (64), electrical stability (65-70) and it may serve as a 
collateral conduit in patients with multivessel disease. 
Resistallce to thrombolysis 
From trials in which the thrombolytic agent was given directly into the coronary artery it beca-
me evident that not all acute occlusive coronary artery disease is the consequence of an obs-
tructing thrombus (8,9). In about 20 to 30% of patients antegrade flow cannot be accomplished 
by lytic therapy. This may have different causes. Either the thrombus is too old, or platelet rich 
(71,72), or there is a mechanical obstruction such as plaque lUpnu'e, intramural hematomas, or 
profound vasospasm (73). Inadequate fibrinolysis might be another reason for failure of therapy 
(74). A recent study showed that the extent of decrease in fibrinogen was related to patency of 
the infarct related vessel and clinical outcome (75). Another explanation might be the fact that 
thrombolytic therapy induces platelet activation by way of enhanced thrombin activity and clot 
formation, which may counterbalance its positive lytic effects (76,77). 
Cardiogellic Shock 
There is no convincing evidence that thrombolysis is effective in patients with cardiogenic 
- 13 -
Il1frodltctioll Gild Aims of the Thesis 
shock. Although subanalyses of randomised trials have shown that thrombolytic therapy is of the 
same or even greater benefit in patients with low blood pressure or tachycardia on admission 
(78), the overall mortality rate in patients with severe heart failure or cardiogenic shock remains 
unacceptable high (Killip III: 30-50%, Killip IV: 65-80%), despite treatment with lytic agents. 
The only trial which included patients with cardiogenic shock was the GISSI (Gruppo Italiano 
per 10 Studio della Streptochinasi nell'Infarcto myocardico) phase I trial and showed no benefit 
of tln'ombolysis in patients with cardiogenic shock (79). In an overview of data, it was conclu-
ded that it is unclear whether thrombolytic therapy has reduced mortality due to cardiogenic 
shock (80). A possible explanation for the lack of efficacy of thrombolyic therapy in patients 
with cardiogenic shock might be coronary hypoperfusion (74). 
Which patiellis bellefilmosl from repelillsioll Iherapy? 
The first trials comparing thrombolytic therapy with placebo in paticnts with acutc myocardial 
infarction included relative low risk patients (9,10,42,79). A recent article showed that only 13 
to 52% of patients with a final diagnosis of acute myocardial infarction receive thrombolytic the-
rapy (81). The remaining non-candidates for lytic therapy, either arrive too late (> 12 hours after 
symptom onset), or the diagnosis of acute myocardial infarction is not evident on arrival of the 
patient or there are contraindications for thrombolytic therapy. Mortality in patients considered 
ineligible for thrombolysis is up to five times higher than among those who receive treatment 
(82). More and more data suggest that reperfusion therapy, and especially TIMI grade 3 flow in 
the infarct related vessel, is beneficial in those patients who were previously excluded from 
thrombolytic therapy, i.e. patients over 75 years of age. (83). Failure to achieve early and com-
plete reperfusion in these high risk infarct patients is associated with a very high mortality. These 
patients might especially benefit from rtPA and primary angioplasly compared to streptokinase. 
(84,85). However, in contrast to rtPA, primary coronary angioplasty is associated with a decre-
ased risk of stroke (Figure 3) and should therefore be considered as primaty therapy in high risk 
patients and in patients with contraindications for thrombolytic therapy (86,87). 
Figure 3 
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One-month mortality and stroke rates after thrombolytic therapy or immediate angioplasly in patients with suspected myo-
cardial infarction treated within 0-6 h of onset of symptoms, Reprinted with permission (89. Boersma H,PhD Thesis, 
1998).SK::: streptokinase, APSAC::: anisoylatcd plasminogen streptokinase activator, rtPA::: recombinat tissue typeplas-
minogen activator, PTCA::: percutaneous transluminal coronary angioplasty; ASA::: aspirin, Hep ::: heparin 
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1,me to start of thrombolytic therapy 
The Fibrinolytic Therapies Trialists (FIT) overview, which is a pooled-analysis of large rando-
mised thrombolytic trials, showed convincingly that time to start of thrombolytic therapy is an 
important predictor of outcome (12). Whether this relationship is linear or non-linear is not cer-
tain (90, 91). Starting treatment within this first "golden hour" often results in considerable myo-
cardial salvage (92) and is therefore associated with a better outcome. The exact influence of 
time on outcome however is difficult to assess. Patients who present early are different from 
patients presenting late (93-96). For instance, the latter are more often female and more often 
have diabetes. Therefore groups with different times to treatment are not comparable. 
Pre-Hospital Thrombolysis 
The proper method to study the influence of time to therapy on outcome without disturbing con-
founders is to compare pre-hospital thrombolysis with in-hospital therapy. These trials do not 
unequivocally show a mortality reduction in pre-hospital treated patients (97-99). The time gai-
ned by pre-hospital treatment varied from 33 to 130 minutes. The only study with a large sam-
ple size was the European Myocardial Infarction Project (EMIP) trial, which was intended to 
enrol 10,000 patients (99). However, this trial was halted after enrohnent of 5300 patients becau-
se of lack of funds. A meta-analysis of all randomised trials showed a significantly lower mor-
tality for patients treated in the pre-hospital phase (100). Patients included in the random.ised 
trials were highly selected. Only 4-5% of eligible patients actually reccived the study dl1lg eit-
her in the ambulance or at the hospital. The meta analysis of all randomised trials showed that 
pre-hospital thrombolytic therapy resulted in the saving of 16-21 lives saved per thousand 
patients treated per hour (100). From data of the Grampian Region Early Anistreplase Trial 
(GREAT), the benefit of pre-hospital thrombolysis, measured at 5 year follow-up, was estima-
ted to vary between 6 lives saved per 1000 per hour to about 20 lives saved per 1000 per hour 
(10 I). If pre-hospital thrombolysis is given within the first hour after symptom onset it may even 
be 30 or more lives saved per 1000 per hour. 
Late thrombolytic Therapy 
On the other side of the spectrum the question remained whether late thrombolytic therapy 
(given later than 6 hours after symptom onset) is beneficial. Rentrop showed that, in the pre-
sence of collateral circulation, thrombolytic therapy results in myocardial salvage even when 
given relatively late (mean of 6.3 hours after symptom onset)(102). A substudy of the ISIS-2 trial 
previously had shown that thrombolytic therapy given late (between 6 and 24 hours) resulted in 
a mortality reduction (42), however, this trial was not specifically designed for late entry 
patients. Two large scale randomised thrombolytic trials tried to answer tillS question_ The Late 
Assessment of Thrombolytic Efficacy (LATE) study (103) used alteplase and the Estudio Mul-
ticentrico Estreptoquinasa Republicas de America del Sur (EMERAS) Collaborative Group 
(104) used streptokinase, and both showed beneficial effects in patients who presented up to 12 
hours after onset of symptoms, although the results of the latter were not conclusive. The mecha-
nisms by which reperfusion therapy established beyond the time of myocardial salvage is bene-
ficial are threefold: it results in improved infarct healing with prevention of infarct expansion, it 
promotes electrical stability and the open artery might serve as a conduit for perfusion of non-
infarct related regions in the presence of multi-vessel disease (105). In a substantial subset of 
patients the moment of coronal), occlusion remains uncertain. These patients with a intermittent 
coronary occlusion (106) Illay especially benefit ti'olll reperfusion therapy, despite the fact that 
the beginning of symptoms was more than 6 to 12 hours ago. 
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In sUIllmary thrombolytic trials have shown that optimal reperfusion therapy should result in 
early and sustained patency of the infarct related vessel with a low grade residual stenosis. Lin-
coff (50) showed in 1993. Verheugt in 1996 (58) and White and Van de Welf in 1998 (107) that 
tllis occurs only in a minority of patients given thrombolytic therapy and that the "ideal" throm-
bolytic agent has not yet been developed. Despite a continuing search for better thrombolytic 
drugs and more effective additional therapy, results have not improved dramatically so far 
(78,108) (Table I). 
Table 1 
Rate of TIMI grade 3 flow 90 minutes after intravenous tlu'ombolytic therapy 
1988 - 1994 (ref: 109) 
standard tPA 50% 
accelerated tPA 63% 
streptokinase 32% 
APSAC 50% 
>1994 
reteplase 60% (ref: 110) 
streptokinase + high dose hirudin 48% (ref: III) 
streptokinase + r-hirudin 41% (ref: 1l2). 
TNK tPA high dose 66% (ref: 113) 
accelarated tPA + high dose argatroban 58% (ref: 114) 
streptokinase + high dose argatroban 44% (ref: 115) 
accelarated tPA + high dose integrilin 66% (ref: 116) 
low dose tPA + abciximab + heparin 79% (ref: 117) 
streptokinase + high dose eptifibatide 52% (ref: 118) 
streptokinase + low dose integd1in 53% (ref: 119) 
60 minutes alteplase after 20 mg bolus 80% (ref: 120) 
tPA=tissue type Plasminogen Activator, APSAC=Anisoylated Plasminogen Streptokinase Activator Complex, TNK is a tPA 
molecule which is altered at 3 sites (T, N, K amino acid substitutions) 
Lessons learned from primary coronary angioplasty trials 
The Zwolle Mal 
The Zwolle trial demonstrated that by using primary angioplasty, it was possible to achieve TIMI 
grade 3 flow through the infarct related vessel in more than 90% of patients with acute myocar-
dial infarction witllin 120 minutes after hospital admission (31). Treatment with primary angio-
plasty compared to streptokinase resulted in a smaller infarct size, a better left ventricular ejec-
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tion fraction and a lower hospital mortality (2% vs 7%, 1'=0.024) (121). At follow-up recunent 
ischemia and reinfarction were also significantly reduced in this patient group. Primary angio-
plasty was most beneficial in patients with anterior myocardial infarction and in patients treated 
early after symptom onset (within 2 hours). Quantitative coronary angiography showed that 
patients treated with angioplasty had a less severe residual diameter stenosis and, a wider mini-
mal luminal diameter at follow up coronary angiography compared to patients treated with strep-
tokinase. Patency rates were 95% for patients in the angioplasty group compared to 66% for 
patients treated with streptokinase (122). At 31 months follow-up, the combined risk of death or 
non-fatal reinfarction was 4.6 times (95% confidence intervals: 2.2 - 8.3, p<O.OOI) higher in 
these patients (123). Both at 12 and at 31 months follow-up total costs for both treatments were 
analysed. The higher costs during first admission associated with primary angioplasty were com-
pensated by a reduced need for phannacological and other medical therapy during follow-up 
(123, 124). When costs were assessed in relation to event-free survival, treating patients with 
streptokinase was associated with higher costs compared to patients who underwent primary 
angioplasty (p<O.OOI). This has been confirmed later by other centres (125,126), provided that 
primary angioplasty is performed in high volume centres (> 150 infarctions annually). 
Mechallisms of belle fit of primmy allgioplasty 
One of the mechanisms by which primary angioplasty results in a lower mortality compared to 
thrombolytic treatment is the prevention of myocardialmpture. Patients with persistent occlu-
sion of the infarct related vessel are at increased risk for I11pture of the myocardial wall (127). 
Pathological findings in these patients frequently showed severe haemonhage of the infarcted 
myocardium and suggested that this occurred more often in patients treated with thrombolytic 
therapy compared to patients who had reperfusion therapy without antecedent lytic treatment 
(128). The recent findings of the Primary Angioplasty in Myocardial Infarction (PAMI) group 
confirmed these findings (129). Primary angioplasty gives another advantage over thrombolytic 
therapy. Immediate coronary angiography in patients with suspected acute myocardial infarction 
gives the opportunity for risk stratifying patients and tailoring therapy to the needs of the indi-
vidual patient. Patients without significant coronary artery lesions can be treated conservatively 
without the unnecessary risk of exposure to thrombolytic therapy. On the other hand, 2 to 4% of 
patients in the Zwolle trial underwent primary coronary bypass surgery within several hours 
after symptom onset, because of severe left main or critical triple vessel disease. Although it is 
not proven, the facility to perform immediate bypass surgery in very high risk patients, 24 hours 
a day, might attribute to the good results achieved in the total population (130). 
Limitations of primm)' corollary allgioplasty 
Primary coronary angioplasty cannot be performed in every hospital. In contrast, thrombolytic 
therapy is widely available, and can even be administered by ambulance personnel or general 
practitioners in a pre-hospital setting. Its effect is not operator dependent. However, the outco-
me of primary angioplasty varies per centre (131). In a recent study, the rate ofTIMI 3 flow of 
the infarct related vessel varied between 71 % and 94%. The success of pIimary angioplasty 
depends on laboratory angioplasty volume as well (132). Cost-effectiveness also increases with 
the number of angioplasties pelfofmed yearly (126). For the abovementioned reasons, it is unwi-
se to extend the facility to perform angioplasty to every hospital with angiography facilities. A 
recent study ii-DIn the PAMI-investigators, however, suggested that performing primary angio-
plasty at hospitals with no-surgery on-site is safe and effective in high-risk patients. Only 1.4% 
of patients needed emergent transfer for perfDIming coronary bypass surgery (133). 
- 17 -
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What //lakes (11lgioplasty after thrombolytic therapy less attractive? 
There are various reports that thrombolytic therapy has deleterious effects on reperfused myo-
cardium (76) and consequently results in a low percentage of patients with TIM13 flow and evi-
dence of tissue perfusion. A recent report, using myocardial contrast echocardiography, showed 
that primary angioplasty resulted in a significantly higher percentage of patients with evidence 
of myocardial reflow compared to patients receiving rtPA (134). Thrombolytic therapy has also 
a procoagulant effect (135,136). A recent study using coronary angioscopy suggested that throm-
bolysis exposes ulcerated plaques when the overlying thrombus has been resolved, possibly 
resulting in increased instability of the plaque (137). Routinely dilating the infarct related ves-
sel after successful thrombolytic therapy therefore might do more harm than good as was found 
in previous trials (16-18). Rescue angioplasty after failed thrombolysis has not proven to be 
beneficial (138). However, when combined with aggressive antiplatelet therapy, it might be of 
value in certain subsets of patients as was found in a substudy of the GUSTO-III trial (139). 
Impaired-ref/ow after direct corOllaty allgioplas/y 
In patients treated with primary angioplasty, impaired flow after direct PTCA has been reported 
in 2 to 34% of patients (140). This state of impaired flow after successful opening of the epi-
cardial infarct-related vessel has been called the "no-reflow" phenomenon, and may vary from 
an absence of any t10w to slow t10w in the dilated vessel, and is associated with a worse clini-
cal outcome (141). The pathofysiologic mechanism of no-reflow has been studied in humans as 
well as in the animal laboratory and is based on extensive damage to the microcirculation of the 
myocardium (142). Prolonged ischemia leads to cell death, the release of several vasoactive 
substances and neutrophils that results in vasospasm and plugging of the small arterioles 
(143,144). This is not only caused by ischemia but may also be related to the relief of ischemia 
, the reperfusion itself, so-called repelfusion injury (145-151), although tllis has mainly been stu-
died in animal models. Myocardial contrast echocardiography performed during and shortly 
after the primary coronary angioplasty procedure confirmed that in some patients, with TIMI 3 
flow of the infarct related vessel, the myocardium is not perfused after intracoronmy injection 
of sonicated microbubbles (152). Echocardiographic evidence of impaired myocardial reflow 
after successful primary angioplasty was associated with increased left ventricular dilatation and 
a worse outcome (153-157). This led to the opinion that not only epicardial flow is important 
(represented by TIMI flow grading) but that the extent of myocardial reperfusion also plays a 
role and that optimal reperfusion therapy should be aimed at both restoring epicardial and myo-
cardial flow. Monitoring myocardial flow however, is difficult and the current methods are not 
applicable in routine clinical practice. 
Time to l'epel'fusion 
Primary angioplasty offers the unique opportunity to document the exact moment of reperfusion. 
Therefore a more accurate estimation of total ischemic time (time from symptom onset to the 
first balloon int1ation) is possible, compared to patients treated with thrombolytic therapy. It is 
known that ischemic time is related to infarct size (158-161) and a recent study suggested that a 
longer ischemic time results in more haemorrhagic infarction (162). Total ischemic time consists 
of at least two time intervals: the time from onset of symptoms until arrival of the patient at the 
hospital (presentation delay), and the time from hospital an'ival until reperfusion (treatment 
delay or "door to balloon time"). 
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Preselltatioll Delay 
Presentation delay is patient related and difficult to influence (163), although it has recently been 
shown that a media and education campaign in a 90.000 inhabitants region in Switzerland resul-
ted in an impressive reduction in presentntion delay (2 hours Hnd 30 minutes vs 4 hours and 10 
minutes) and a better clinical outcome (164). Another study, also performed in Switzerland, sho-
wed a reduction in median presentation delay from 180 to 155 minutes as a result of a 12 months 
multimedia public campaign. (165). 
Treatmellt Delay 
Treatment delay, however, is easier to influence, but requires the co-operation of all personnel 
involved in logistics and treatment of patients with acute myocardial infarction. The delay may 
vary substantially from centre to centre. The pre-hospital thrombolysis studies showed that tre-
atment delay was significantly shorter for study patients compared to non-study patients (97-99) 
and in the recently (1997) completed GUSTO-ill, treatment delay was significantly shorter com-
pared to GUSTO-I (initiated 1990)(0.8 vs l.l hours, p<O.OOOI) (166). This suggests that further 
streamlining of the organisation may help and that minimising time delay for every patient pre-
senting with an acute myocardial infarction should be aimed at. For patients who are transpor-
ted from other hospitals with an established diagnosis of infarction, treatment delay can be furt-
her reduced by preparing the catheterisation room or ceu unit in advance of arrival of the 
patient (167), or by other procedural changes (168,169). The exact influence of an additional 
delay on outcome after primary angioplasty is not known. Recently, a careful time analysis of 
the GUSTO-lIb data showed that hospital delay in performing primary angioplasty was a major 
determinant of outcome, and may partly explain the little difference between thrombolysis and 
angioplasty treated patients (170). The consequence of extra delay further depends on the type 
of patient and the time from symptom onset to the beginning of the delay: a delay of 60 minu-
tes of a relatively low risk patient who already has chest pain for 4 hours has less consequences 
than a 60 minute delay in a high risk candidate for primary angioplasty who presented at a refe-
rring hospital one hour after symptom onset (Figure 4). 
FigUl'e 4 
2h 6h 18h 
Timc dependence of the value of shortening delay to reperfusion therapy. A I-hour lime saving at A is Ilkcly to produce a 
greater beneHt than u similar reduction in del~}' at n. 
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Primary AllgiojJlasty after 6 hOllrs 
Although the benefit of early reperfusion therapy has been shown convincingly, the benefit of 
late angioplasty after acute myocardial infarction is controver-sial. It is possible to achieve 
infarct vessel recanalisation in the majority of late entry patients with angiop-Iasty. However, in 
these patients a higher rate of reocclusion has been reported (171). Accordingly, late reperfu-
sion results in a somewhat lower rate of sustained patency. Data on infarct vessel patency have 
been reported in two studies (172, 173). Topol et al found a patency rate of 59% in late entry 
patients (6h - 24 h), who were either treated with thrombolytic therapy or angioplasty or both. 
In a study from Dzavik et ai, only 43 % of patients, who had angioplasty for an occluded infarct-
related vessel 2 days to 6 weeks after the infarction, had a patent artery at 4 months follow-up 
angiography. A recent study showed that additional intracoronary stenting may help in keeping 
the infarct related artery open, compared to balloon angioplasty alone (174). Late reperfusion 
may have the greatest benefit in patients with continued viability of myocardium, which has 
been described by many authors (175-178). Sabia et aJ. reported that delayed mechanical reope-
ning of the infarct related vessel, even days to weeks after infarction in selected patients with 
demon-strated collateral blood flow, may significantly improve left ventricular function (179). 
Aims of the Thesis 
MOllitorillg repeJfllsioll 
Simple and reliable angiographic and electrocardiographic parameters are useful for monitoring 
myocardial reperfusion and for risk-stratifying patients at a very early stage after reperfusion the-
rapy. High risk patients might be candidates for additional therapy, aimed at improving myocardial 
reperfusion or for aggressive left ventdcular unloading to prevent remodelling. Low dsk patients 
can be discharged early (180). We assessed the value of ST segment recovelY on the 12-lead elec-
trocardiogram after successful primary angioplasty to predict left ventricular function and clinical 
outcome in one study. Another study evaluated, whether blush of contrast of jeopardised myocar-
dimll (a marker of Inyocardial reperfusion) on routine angiography after angioplasty may have 
additional prognostic value compared to TIM! flow alone ( a marker of epicardial rcperfusion). 
Primary Allgioplasty for ",110m? 
Previous studies suggested that high risk infarct patients have the greatest advantage when trea-
ted with primary angioplasty (89). The effect of primary angioplasty compared to thrombolytic 
therapy in low risk patients is unknown. Therefore acute infarct patients with low risk characte-
ristics, i.e. inferior myocardial infarction, without haemodynamic instability were randomised to 
either treatment with streptokinase or prilllaty angioplasty. If angioplasty would turn out to be 
better for low risk patients as well, tltis may result in a marked increase in patients who are trans-
ported to hospitals with angioplasty facilities. Therefore we studied the safety and logistic con-
sequences of transportation of patients with an acute myocardial infarction. 
Additiollal/llerapy 
Although the majority of patients treated with primmy angioplasty have a good prognosis, there 
remains a substantial minOlity at lisk for adverse events. These patients might be candidates for addi-
tional therapy. Intra-a0l1ic balloon pumping results in increased diastolic coronmy flow and in after-
load reduction of the left ventricle and might therefore improve coronary reftow after reperfusion the-
rapy and could be an attractive additional therapy after ptimmy angioplasty in high risk patients. 
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Stenting has dramatically changed the practice of interventional cardiology over the last years 
(181,182). However, randomised trials in the setting of acute myocardial infarction have not yet been 
repOlted. Therefore we randomly assigned patients without contra-indications for intracoronary sten-
ting to either primary stenling or primal)' balloon angioplasty with the aim to improve clinical out-
come and to reduce restenosis and reocclusion. 
I/ljlllellce of ischemic time 0/1 o/l(come 
In patients treated with primm), coronruy angioplasty the exact time and success of l'Cperfusion is known. 
TIus gives the opportmuty to assess tile influence of ischemic time (time fium symptom onset to first ballo-
on inflation) on outcome more accurately compared to patients treated Witil thmmbolytic tilerapy. As incre-
asing numbers of patients with acute myocardial infru-ction are transpOlted to centres with angioplmlty faci-
lities, it is important to know the effect of tius extra time delay on infurct size and outcome. 
Reslenosis and Reocclllsioll 
Restenosis after elective coronmy angioplasty OCCllrs in about 30 to 40% of patients within 6 
months. The incidence of restenosis after primmy angioplasty for acute myocardial infarction 
however, is less well studied. We assessed restenosis, using quantitative coronary angiography, 
in a large cohort of patients successfully treated with primary angioplasty and determined which 
angiographic or clinical characteristics are predictive of restenosis. 
- 21 -
IntlVdllctiOIl alld Aims of the Thesis 
References 
1. Tillet WS, Sherry S. The effccts in patients of streptococcal fibrinolysin (streptokinase) and 
streptococcal desoxyribonuclease on fibrous, pumlent or sanguineous pleural exudations. 
J Clin Invest 1949;28: 173-90. 
2. Fletcher AP, Alkjaersig N, Smyrniotis FE, Sherry S. Treatment of patients suffering from 
early myocardial infarction with massive and prolonged streptokinase therapy. Tran Assoc 
Am Physicians 1958;71 :287-96. 
3. ChasO\' EI, Mateeva LS, Mazaev AV, Sargin KE, Sadovskaia GY. Tntracoronm)' adminis-
tration of fibrinoysin in acute myocardial infarction. Ter Arkh 1976;48:8-19. 
4. DeWood MA, Spores J, Notske R, MOllser LT, BUl1'oughs R, Golden MS, Lang H. 
Prevalence of total coronary occlusion during the early hours of transmural myocardial 
infarction. N Engl J Med 1980;303:897-902. 
5. DeWood MA, Spores J, Hensley GR, Simpson CS, Eugster GS, Sutherland KI, Grunwald 
RP, Shields JP. Coronary arteriographic findings in acute transmural myocardial infarction. 
Circulation 1983;68:1-39-49. 
6. Davies MJ, Woolf N, Robertson WB. Pathology of acute myocardial infarction with 
particular reference to occlusive coronary thrombi. Br Heart J 1976;38:659-64. 
7. Davies MJ, Fulton WFM, Robertson WB. The relation of coronary thrombosis to ischemic 
myocardial necrosis. J Path 1979;127:99-110. 
8. Rentrop KP, Blanke H, Karsch KR, Wiegand V, Ktistering H, Oster H, Leitz K. Acute 
myocardial infarction: intracoronary application of nitroglycerin and streptokinase. 
Clin Cardiol 1979;2:354-63. 
9. Khaja F, Walton JA, Brymer JF, La E, Osterberger L, 0' Neill WW, Colfer HT, Weiss R, 
Lee T, Kurian T, Goldberg D, Pitt B, Goldstein S. Intracoronary fibrinolytic therapy in acute 
myocardial infarction: report of a prospective randomized trial. N Engl J Med 1983;308: 
1305-11. 
10. Anderson JL, Marshall HW, Bray BE, Lutz JR, Frederick PR, Yanowitz FG, Datz FL, 
Klausner SC, Hagan AD. A randomized trial of intracoronary streptokinase in the treatment 
of acute myocardial infarction. N Engl J Med 1983;308: 1312-18. 
11. Simoons ML, Brand van den M, de Zwaan C, Verheugt FWA, Serruys PW, Remme WJ, Bar 
F, Res J, Krauss XH, Vermeer F, Lubsen J. Improved survival after early thrombolysis in 
acute myocardial infarction. A randomised trial by the Interuniversity Cardiology Institute 
in the Netherlands. Lancet 1985;ii:578-82. 
12. 'Fibrinolytic Therapy Trialists' (FTT) collaborative group. Indications for fibrinolytic 
therapy in suspected acute myocardial infarction: collaborative overview of early mortality 
and major morbidity results from all randomised trials of more than 1000 patients. 
Lancet 1994;343:311-22. 
13. Meyer J, Merx W, Dorr R, Lambertz H, Bethge C, Effert S. Succesful treatment of acute 
myocardial infarction shock by combined percutaneous transluminal coronary recanalization 
and percutaneous transluminal coronary angioplasty. Am Heart J 1982;103:132-38. 
14. Hartzler GO, Rutherford BD, MCConnay DR, Johnson WL, McCallister BD, Gura GM, 
Conn RC, Crocket JE. Percutaneous transluminal coronary angioplasty with and without 
thrombolytic therapy for treatment of acute myocardial infarction. Am Heart J 1983; I 06: 
965-73. 
15. Erbel R, Pop T, Henrichs KJ, Rupprecht HJ, Steuemagel C, Meyer J. Percutaneous transluminal 
coronary angioplasty after thrombolytic therapy: a prospective controlled randomized trial. 
J Am Coli Cardiol 1986;8:485-95. 
- 22-
Chapter 1 
16. Suryapranata H, Serruys PW, Vermeer F, de Fey tel' PJ, van den Brand M, Simoons ML, Bur 
FW, Res J, van der Laarse A, van Domburg R, Beatt K, Lubsen J, Hugenholtz PO. Value of 
immediate coronary angioplasty following intracoronary thrombolysis in acute myocardial 
infarction. Cathet Cardiovasc Diagn 1987;13:223-32. 
17. Suryapranata H, Serruys PW, de Peyter PI, van den Brand M, Beatt K, van Domburg R, 
Kint PP, Hugenholtz PO. Coronary angioplasty immediately after thrombolysis in ll5 
consecutive patients with acute myocardial infarction. Am Heart J 1988;115:519-29. 
18. Simoons ML, Arnold AER, Betriu A, de Bono DP, Col J, Dougherty FC, von Essen FR, 
Lambertz H, Lubsen J, Meier B, Michel PL, Raynaud P, Rutsch W, Sanz GA, Schmidt W, 
Serl1lYs PW, Ther), C, Debis R, Vahanian A, Vrul de Welf F, Willems GM, Wood 0, Verstraete 
M. lluombolysis with tissue plasminogen activator in acute myocardial infarction: no additional 
benetlt from immediate percutaneous coronary angioplasty. Lancet 1988;1:197-203. 
19. TIMI Research Group. Immediate vs delayed catheterization and angioplasty following 
thrombolytic therapy for acute myocru'dial infru·ction. TIMI 2Aresults. JAMA 1988;260:2849-58. 
20. Rogers WJ, Baim OS, Gore JM, Brown BG, Roberts R, Williams DO, Chesebro JH, Babb 
ID, Sheehan PH, \\lackers FJT, Zaret BL, Robertson TL, Passamani ER, Ross R, Knatterud 
GL, Braunwald E. Comparison of immediate invasive, delayed invasive, and conservative 
strategies after tissue-type plasminogen activator. results of the Thrombolysis in Myocardial 
Infarction (TIMI) phase II-A trial. Circulation 1990;81: 1457 -76. 
21. The TllvU Study Group. Comparison of invasive and conservative strategies after treatment 
with intravenous tissue plasminogen activator in acute myocardial infarction: results of the 
Thrombolysis in Myocardial Infru'ction (TIMl) Phase II trial. N Engl J Med 1989;320:618-27. 
22. SWIFT (Should We Intervene Following Thrombolysis) trial study group. SWIFT trial of 
delayed elective intervention v conservative treatment after thrombolysis with anistreplase 
in acute myocardial infarction. Br Med J 1991 ;302:555-60. 
23. Barbash GI, Roth A, Hod H, Modan M, Miller HI, Rath S, Zahav YH, Keren G, Motro M, 
Shacluu' A, Basan S, Agranat 0, Rabinowitz B, Laniado S, Kaplinsk.)' E. Randomized controlled 
trial of late in-hospital angiography and angioplasty versus conservative management after 
treatment with recombinant tissue-type plasminogen activator in acute myocardial infarction. 
Am J Cardiol 1990;66:538-45. 
24. Ellis SG, Ribeiro da Silva E, Heyndrickx GR, Talley 10, Cernigliaro C, Steg G, Spaulding 
C, Nobuyoshi M, Erbel R, Vassanelli C, Topol EJ for the RESCUE investigators. Rruldomized 
comparison of RESCUE angioplasty with conservative management of patients with early 
failure of thrombolysis for acute anterior myocardial infarction. Circulation 1994;90;2280-84. 
25. Gmppo Italiilllo per 10 Studio della Sopravvivenza nell' Inl:-u10 Miocardico GISSI-2: A factOlial 
randomised trial of alteplase versus streptokinase and heparin versus no heparin among 
12490 patients with acute myocardial infarction. Lancet 1990;336:65-71. 
26. ISIS-3 (11lird Intemational Study ofinfru'ct Survival) Collaborative Group. ISIS-3: A randomised 
comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin 
plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. 
Lancet 1992;339:753-70. 
27. The GUSTO Investigators. An international randomized trial comparing four thrombolytic 
strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82. 
28. Chesebro JB, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis HK, 
Hillis 0, Llldbrook P, Markis JE, Mueller H, Passamarli ER, Powers ER, Rao AK, Robmson 
T, RossA, Ryan TJ, Sobel BE, Willerson J, Williams DO, Zaret BL, Braunwald E. 
Tlu"01nbolysis In Myocardial Infarction (TlMI) trial, phase 1: a comparison between intravenous 
tissue plasminogen activator and intravenous streptokinase. Circulation 1987;76:723-5. 
- 23 -
intlVductioJl alld Aims of the Thesis 
29. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator. 
streptokinase. or both on coronary-artery patency. ventricular function, and survival, after 
acute myocardial infarction. N Engl J Med 1993;329:1615-22. 
30. Meier B. Balloon angioplasty for acute myocardial infarction. Was it buried alive? Circulation 
1990; 82:2243-5. 
31. Zijlstra F, de Boer MJ, Hoomtje JCA, Reiffers S, Reiber JHC, Suryapranata H. A comparison 
of immediate coronary angioplasty with intravenous streptokinase in acute myocardial 
infarction. N Engl J Med 1993;328:680-4. 
32. Grines CL, Browne KF, Marco J, Rothbaum 0, Stone GW, O'Keefe J, Overlie P, Donohue 
B, Chelliah N, Timmis GC, Vlietstra RE, Strzelecki M, Puchrowicz-Ochocki S, O'Neill 
WW. A compatison of inunediate angioplasty with thrombolytic therapy for acute myocardial 
infarction. N Engl J Med 1993;328:673-9. 
33. Gibbons RJ, Holmes DR, Reeder GS, Bailey KR, Hopfenspirger MR, Gersh BJ. Innnediate 
angioplasty compared with the administration of a thrombolytic agent followed by conservative 
treatment for myocardial infarction. N Engl J Med 1993;328:685-91. 
34. Boyle RM. Immediate angioplasty in the United Kingdom. The time has not yet come. 
Britisch Heart J 1995;73:413-14. 
35. Brooks N. Prim my PTCA in the UK: if not for all, then for whom? Heart 1997;78: 16-17. 
36. The Global Use of Strategies to Open Occluded coronmy arteries in Acute Coronary 
Syndromes (GUSTO lIb) angioplasty substudy investigators. A clinical trial comparing 
primary coronary angioplasty with tissue plasminogen activator for acute myocardial 
infarction. N Engl J Med 1997;336:1621-8. 
37. Stone GW, Grines CL, O'Neill. Primmy coronmy angioplasty versus thrombolysis. N Engl 
J Med 1997;337: 1168-69. 
38. EvelY NR, Pm'sons LS, Hlatky M, Martin JS, Weaver WD, for the myocardial infarction 
triage and intervention investigators. A comparison of thrombolytic therapy with primary 
coronary angioplasty for acute myocardial infarction. N Engl J Med 1996;335: 1253-60. 
39. Tiefenbnllln AJ, Chandra NC, French WJ, Gore JM, Rogers WJ. Clinical experience with 
ptimruy percutaneous transluminal coronruy angioplasty compared with alteplase (recombinant 
tissue-type plasminogen activator) in patients with acute myocm'dial infm·ction. A rep0l1 from 
tile second national regisuy ofmyocmdial infru'Ction (NRMI-2). JAm CoIl Crudiol 1998;31:1240-5. 
40. Zallll R, Vogt A, Neuhaus K-L, Schuster S, Senges J for the ALKK study group. Angioplasty 
in acute myocardial infarction in clinical practice: results in 4625 patients from the ALKK 
angioplasty registry. J Am Coil Cariol 1997;29: 15A. 
41. Weaver OW, Simes JR, Betrin A, Grines CL, Zijlstra F, Garcia E, Grinfield L, Gibbons RJ, 
Ribeiro EE, DeWood MA, Ribichini F. Comparison of primmy coronary angioplasty and 
intravenous thrombolytic therapy for acute myocardial infarction. A quantitative overview. 
JAMA 1997;278:2093-98. 
42. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised 
trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of 
suspected acute myocardial infm·ction. Lancet 1988;2:349-60. 
43. The task force on the management of acute myocardial infarction of the European Society 
of Cardiology. Acute myocardial infarction: pre-hospital and in-hospital management. Eur 
Hem'! J 1996;17:43-63. 
44. Ryml TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, CaliffRM, Hillis LD, Hiratzka LF, 
Rapapol1 E, Riegel BJ, O'Rnssell E, Smith III EE, WeaverWD. ACC/AHA guidelines for the 
management of patients with acute myocru"dial infarction: executive summruy. A repOlt of the 
- 24-
Chapter J 
Amelican College of Cardiology/ Ameli can Herut Association task force on practice guidelines 
(committee on management of acute myocardial infru·ction). Circulation 1996;94:2341-50. 
45. Anderson JL, Karagounis LA, Becker LC, Sorensen SG, Menlove RL, for the TEAM-3 
investigators. TllvlI peIiusion grade 3 but not grade 2 results in improved outcome after 
thrombolysis for acute myocardial infarction. Ventriculographic, enzymatic, and electrocar-
diographic evidence from the TEAM-3 study. Circulation 1993;87:1829-39. 
46. Lincoff AM, Topol EJ. Illusion of reperfusion. Does anyone achieve optimal reperfusion 
during acute myocardial infarction? Circulation 1993;87: 1792-1805. 
47. Simes RJ, Topol EJ, Holmes DR, White HD, Rutsch WR, Vahanian A, Simoons ML, MOlTis 
D, Betliu A, Califf RM, Ross AM, for the GUSTO Investigatm~. Link betwecn the angiographic 
substudy and mortality outcome in a large randomized trial of myocardial reperfusion: 
import of early and complete infarct artelY repelfusion. Circulation 1995;91: 1923-28. 
48. Ross AM, Coyne KS, Moreyra E, Reiner JS, Greenhouse SW, Walker PL, Simoons ML, 
Draoui YC, Califf RM, Topol EJ, Van de Werf F, Lundergan CF. Extended mortality benetit 
of early postinfarction reperfusion. Circulation 1998;97: 1549-56. 
49. Lendelink T, Sirnoons M, Es van G, Werf van de F, Verstraete M, Arnold AE, for the 
European Cooperative Study Group. Benefit of thrombolytic therapy is sustained throughout 
five years and is related to TIMI pelfusion grade 3 but not grade 2 flow at discharge, 
Circulation 1995;92: 1110-16. 
50. Lincoff AM, Topol EJ, CaliffRM, Sigmon KN, Lee KL, Olnnrul EM, Rosenschein U, Ellis SG, 
for the Thrombolysis ruld Angioplasty in Myocardial Infarction study group. Significance of a 
coronary m1cl), with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in 
the thrombolysis and angioplasty in myocardial iruru'ction trials). Am J Cru·dioI1995;75:871-76. 
51. Anderson JL, Kru'agounis LA, Califf RM. Meta-analysis of five repmted studies on the relation 
of early coronruy patency grades with m011ality and oucomes after acute myocardial inf:'lrction. 
Am J CardioI1996;78:1-8. 
52. Leung WH, Lau C. Effects of sevedty of the residual stenosis of the iruarct-relatcd coronruy 
artery on left ventricular dilatation and function after acute myocardial infarction. J Am ColI 
CardioI1992;20:307-13. 
53. Miyazaki S, Nakao K, Daikoku S, Hoh A, Miyao Y, Goto Y, Nonogi H. Condation of residual 
stenosis immediately after coronary angioplasty with long-term prognosis. Cathet Crudiovasc 
Diagn 1998;43:262-70. 
54. Simoons ML, Vas J, Tijssen JGP, Vermeer F, Verheugt FWA, Krauss XH, Manger Cats V. 
Long-tel111 benefit of early thrombolytic therapy in patients with acute myocardial infarction: 
5 year follow-up of a trial conducted by the Interuniversity Cardiology Institute of the 
Netherlands. J Am Coli Cardiol1989; 14:1609-15. 
55. Braunwald E. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular 
dysfunction, and impmved survival: should dIe pru'adigm be exprulded? Circulation 1989;79:441-4. 
56. White HD, Cross DB, Elliott JM, Norris RM, Yee TW. Long-term prognostic importance of 
patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial 
infarction. Circulation 1994;89:61-7. 
57. Brouwer MA, Boncke JR, Veen G, Meijer A, Eeuige van MJ, Verheugt FWA. Adverse long 
term effects of rcocclusion after coronary thrombolysis. J Am Coli Cardiol 1995;26: 1440-4. 
58. Verheugt F, Meijer A, Lagrand WK, Eenige van MJ. Reocclusion: the flip side of coronary 
thrombolysis. J Am Call CardioI1996;27:766-73. 
59. Veen G, Meijer A, Verheugt FWA, Welter CJ, Swart de H, Lie KI, Pol van der JM, Michels 
HR, Eenige MJ. Culprit lesion morphology and stenosis severity in the prediction of reocclusion 
- 25 -
Illtroducaml alld Aims of the 71Iesis 
after successful coronary tln·ombolysis: angiographic results of the APRICOT study. JAm 
Coli Cardiol 1993;22: 1755-62. 
60. White HD, French JK, Hamer AW, Brown MA, Williams BF, Ormiston JA, Cross DB. 
Frequent reocclusion of patent infarct-related arteries between four weeks and one yem: 
effects of antiplatelet therapy. J Am Coli Cardiol 1995;25:218-23. 
61. Gibson CM, Cannon CP, Piana RN, BreaU JA, Sharaf B, Flatley M, Alexander B, Diver DJ, 
McCabe C, Flaker GC, Baim DS, Braunwald E. Angiographic predictors of reocclusion 
after thrombolysis: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. J 
Am Coli CardioI1995;25:582-9. 
62. Serruys PW, Simoons ML, Suryapranata H, Vermeer F, Wijns \V, van den Brand M, BUr F, 
de Zwaan C, Krauss XH, Remme WJ, Res J, Verheugt FWA, van Domburg R, Lubsen J, 
Hugenholtz PO. Preservation of global and regional left ventricular function after early 
thrombolysis in acute myocardial infarction. J Am Call Cardiol 1986;7:729-42. 
63. Madsen JK, Grande P, Saunamaki K, Thayssen P, Kassis V, Rasmussen K, Haunso S, Nielsen 
T, Haghfelt T, Fritz-Hansen P, Hjelms E, Paulsen PK, Alstrujl P, Arendl1lp H, Niebuhr-
Jorgensen, Andersen L, on behalf of the DANAMI study groujl. Danish multicenter randomized 
study of invasive versus conservative treatment in patients with inducible ischemia after 
thrombolysis in acute myocardial infarction (DANAMI). Circulation 1997;96:748-55. 
64. Danchin N, Angioni M, Cador R, Tricoche 0, Dibon 0, Juilieres Y, Cuilliere M, Cherrier F. 
Effect of late percutaneous angioplastic recanalization of total coronary artery occlusion on 
left ventricular remodelling, ejection fraction, and regional wall motion. Am J Cardiol 1996; 
78:729-35. 
65. Solomon SD, Ridker PM, Antman EM. Ventdcular anhythmias in trials of thrombolytic 
therapy for acute myocardial infarction. A meta-analysis. Circulation 1993;88:2575-81. 
66. Moreno FLL, Karagonnis L, Marshall H, Menlove RL, Ipsen S, Anderson JL. Tlu·ombolysis-
related early patency reduces ECG late potentials after acute myocardial infarction. Am Herut 
J 1992;124:557-64. 
67. Aguirre FV, Kern MJ, Hsia J, Serota H, Janosik D, Greenwalt T, Ross AH, Chaitman BR. 
Importance of myocardial infarct artery patency on the prevalence of ventricular arrhythmia 
and late potentials after tlu"Ombolysis in acute myocrudial illtim:tion. Am J Cmdiol 1991 ;68: 1410-16. 
68. Zimmerman M, Adamec R, Ciru'oni S. Reduction in the frequency of ventricular late potentials 
after acute myocardial infmction by emly t1uombolytic therapy. Am J Ou·diol 1991 ;67:697-703. 
69. de Chillou C, Rodriguez LM, Doevendans P, Loutsides K, van den Dool A, Metzger J, Bar 
F, Smeets M. Effects on the signal-averaged electrocardiogram of opening the coronary 
artery by thrombolytic therapy or percutancous transluminal coronary angioplasty during 
acute myocardial infarction. Am J Cardiol 1993;71 :805-9. 
70. Bourke JP, Richards DAB, Ross DL, Wallace EM, McGnire MA, Uther JB. Routine pmgrammed 
electrical stimulation in survivors of acute myocardial infarction for prediction of spontaneous 
ventricular tachyarrhytlullias during follow-up: results, optimal stimulation protocol and 
cost-effective screening. J Am Coli Cardiol 1991; 18:780-8. 
71. Jang I-K, Gold HK, Ziskind AA, Fallon JT, Holt RE, Leinbach RC, May JW, Collen D. 
Diffferential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with 
recombinant tissue-type plasminogen activator: a possible explanation for resistance to 
coronary thrombolysis. Circnlation 1989;79:920-28. 
72. Coller BS. Platelets and tlu·ombolytic therapy. N Engl J Med 1990;322:33-42. 
73. Davies :MJ. Stability and instability: two faces of coronary atherosclerosis. Circulation 
1996;95:2013-20. 
- 26-
Chapter J 
74. Anderson JL. Why does thrombolysis fail? Breaking through the reperfusion ceiling. Am J 
Cardiol 1997;80: 1588-90. 
75. Tracy RP, Kleiman NS, Thompson B, Cannon CP, Bovill EG, Brown G, Collen 0, Mahan 
E, Mann KG, Rogers WJ, Sopko G, Stump DC, Williams DO, Zaret BL, for the TIMI II 
investigators. Relation of coagulation parameters to patency and recurrent ischemia in the 
thrombolysis in myocardial infarction (TIMI) phase II trial. Am Heart J 1998;135:29-37. 
76. Ohnishi Y, Butterfield MC, Salfitz JE, Sobel BE, Corr PB, Goldstein JA. Deleterious effects 
of a systemic lytic state on reper-fused myocardium. Minimization of reperfusion injury and 
enhanced recovery of myocardial function by direct angioplasty. Circulation 1995;92:500-10. 
77. Topol EJ. Toward a new frontier in myocardial reperfusion therapy. Emerging platelet 
preeminence. Circulation 1998;97:211-18. 
78. Collins R, Peto R, Baigent C, Sleight P. Aspirin, hepmin, and fibrinolytic therapy in suspected 
acute myocardial infarction. N Engl J Med 1997 ;336:847 -60. 
79. Gl1IPPO Italiano per 10 Studio della Streptoehinasi nell'Infarto Miocardico (GISSI). 
Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. 
Lancet 1986; I :397 -402. 
80. Bates ER, Topol EJ. Limitations of thrombolytic therapy for acute myocardial infarction 
complicated by congestive heart failure and cardiogcnic shock. J Am ColI Cardiol 
1991; 18: 1077-84. 
81. European Secondary Prevention Study group. Translation of clinical trials into practice: a 
European population-based study of the use of thrombolysis for acute myocardial infarction. 
Lancet 1996;347:1203-7. 
82. Cragg DR, Friedmann HZ, Bonema JD, Jaiyesima I, Ramos RG, Timmis GC, O'Neill WW, 
Schreiber TL. Outcome of patients with myocardial infarction who are ineligible for 
thrombolytic therapy. Ann Intern Med 1991; 115: 173-7. 
83. Brodie BR, Weintraub RA, Stickey TO, Le Bauer EJ, Katz JD, Kelly TA, Hansen CL 
Outcomes of direct angioplasty for acute myocardial infarction in candidates and non-
candidates for thrombolytic therapy. Am J Cardiol 1991;67:7-12. 
84. Califf RM, Woodlief LH, Harrell FE, Lee KL, White HD, Guerci A,Barbash GI, Simes J, 
Weaver WD, Simoons ML, Topol EJ, for the GUSTO-llnvestigators. Selection of thrombolytic 
therapy for individual patients: development of a clinical model. Am Hem"t J 1997; 133:630-9. 
85. Boersma E, Simoons MA. Reperfusion strategies in acute myocardial infarction. Eur Heart 
J 1997;18:1703-11. 
86. Stone GW, Grines C, Browne KF, Marco J, Rothbaum D, O'Keefe JH, Hartzler G, Overlie 
P, Donohue B, Chelliah N, Vlietstra R, Puchrowicz-Ochocki S, O'Neill WW, for the Primary 
Angioplasty in Myocardial Infm'ction (PAM I) investigators. Outcome of different repelfusion 
strategies in patients with fonner contraindications to thrombolytic therapy: a comparison of 
ptimaty angioplasty and tissue plasminogen activator. Calh Cm'diovasc Diagn 1996;39:333-39. 
87. Kahn JK. Why we get out of bed to do infarct PTCA. Cath Cardiovasc DiagnI996;39:350. 
88. The I.S.A.M. Study Group. A prospective ttial of intravenous streptokinase in acute myocardial 
infm"Ction (ISAM). M0l1ality, mOibidity, and infaI"ct size at 21 days. N Engl J Med 1986;314: 1465-71. 
89. Boersma H. Tailored reperfusion therapy of patients with evolving myocardial infarction: 
models to guide clinical decision making. PhDThesis 1998. 
90. Boersma E, Maas ACP, Deckers JW, Simoons ML. Early thrombolytic treatment in acute 
myocardial infarction: reappraisal of the golden hour. Lancet 1996;348:771-5. 
91. Califf RM, Newby K. How much do we gain by reducing time to reperfusion therapy. Am 
J CardioI1996;78[suppl 12A]:8-15. 
- 27 -
Introduction (lnd Aims of the Thesis 
92. HennellS W Th, Willems GM, Nijssen KM, Simoons ML, for the European Cooperative 
Study Group. Effcct of thrombolytic treatment delay on myocardial infarct size. Lancet 
1992;340:1297. 
93. Ncwby LK, Rutsch WR, Califf RM, Simoons ML, Aylward PE, Armstrong PW, Woodlief 
LH, Lee KL, Topol El, van de WelfF, for the GUSTO-I investigators. Time from symptom 
onset to treatment and outcomes after thrombolytic therapy. 1 Am Call Cardiol 1996;27:1646-55. 
94. Ottesen MM, Kober L, lorgensen S, Torp-Pederson C. Determinants of delay between 
symptoms and hospital admission in 5978 patients with acute myocardial infarction. Eur 
Heart 11996,17:429-37. 
95. GISSI-avoidable delay study group. Epidemiology of avoidable delay in the care of patients 
with acute myocardial infarction in Italy. Arch Intern Med 1995;155:1491-88. 
96. Weaver DW. Time to thrombolytic treatment: factors affecting delay and their influence on 
outcome. 1 Am Coli C,u·dioI1995;25[suppIJ:3S-9S. 
97. Weaver DW, Cerqueira M, Hallstrom AP, Littwin PE, Mru1in lS, Kudenchuck Pl, Eisenberg 
M, for the Myocardial Infarction Triage and Intelvention Project Group. Pre-hospital-initiated 
vs hospital-initiated tlu'ombolytic therapy. The myocardial infarction triage and intelvention 
trial. lAMA 1993;270: 1211-6. 
98. GREAT Goup. Feasability, safety, and efficacy of domiciliary thrombolysis by general 
practitioners: Grampion region early anistreplase trial. BMl 1992;305:548-53. 
99. The European Myocardial Infarction Project group. Prehospital thrombolytic therapy in 
patients with suspected acute myocardial infarction. N Engl 1 Med 1993;329:383-9. 
100. Fath-Ordoubadi F, AI-Mohammad A, Huelms TY, Beatt Kl. Meta-analysis of randomised 
trials of pre-hospital versus hospital thrombolysis. Circulation 1994;90:1-325. 
10 1. Rawles 1M. Quantification of the benefit from earlier thrombolytic therapy: the Grampion 
Regional Anistreplase Trial (GREAT). 1 Am Coli CardioI1997;30:1181-6. 
102. Rentrop KP, Feit F, Sherman W, Stecy P, Hosat S, Cohen M, Rey M, Ambrose 1, Nachamie 
M, Schwartz W, Cole W, Perdoncin R, Thornton lC. Late thrombolytic therapy preserves 
left ventricular function in patients with collateralized coronary occlusion: primary end 
point findings of the second Mount Sinai-New York university repelfusion trial. 1 Am Coli 
Cardiol 1989; 14:58-64. 
103. LATE Stndy Group. Late assessment of thrombolytic efficacy (LATE) study with aHeplase 
6-24 hours after onset of myocardial infarction. Lancet 1993;342:759-66. 
104. EMERAS (Estudio Multicenttico Estreptaquinasa Republicas de Amelica del Sur) Collaborative 
Group. Randomised trial of late thrombolysis in patients with suspected acute myocardial 
infru·ction. Lancet 1993;342:767-72. 
105. Kiln CB, Braunwald. Potential benefits of late reperfusion of infarcted myocardium. The 
open artery hypothesis. Circulation 1993;88:2426-36. 
106. Hackett D, Davies G, Chierchia S, Maseri A. Intermittent coronaIY occlusion in acute 
myocardial infarction. N Engl 1 Mcd 1987;317:1055-9. 
107. White lID, Van de Werf FJJ. Thrombolysis for acute myocardial infarction. Circulation 
1998;97;1632-46. 
108. The global use of strategies to open occluded coronary arteries (GUSTO III) investigators. 
A comparison of reteplase with alteplase for acute myocardial infarction. N Engl 1 Med 
1997;337: 1118-23. 
109. Barbagelata NA, Granger CB, Oqueli E, Suarez LD, B0I11Iei M, Topol El, Califf RM. TIMI 
grade 3 flow and reocciusion after intravenous thrombolytic therapy: a pooled analysis. Am 
Heart 11997;133:273-82. 
- 28 -
Chapter 1 
110. Bode C, Smalling RW, Berg G, Burnell C, Lorch G, Kalbfleisch JM, Chernoff R, Christie 
LG, Feldman RL, Seals AA, Weaver WD, for the RAPID II investigators. Randomized 
comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant 
plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue 
plasminogen activator) in patients with acute myocardial infarction. Circulation 1996;94: 
891-98. 
Ill. White RD, Aylward PE, Frey MJ, Adgery AA, Nair R, Hillis WS, Shalev Y, Brown MA, 
French JK, Collins R, Maraganore J, Adelman B, on behalf of the Hil1lIog Early Reperfusion/ 
Occlusion (HERO) Trial investigators. Randomized, double-blind comparison of hirulog 
versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction 
(HERO). Circulation 1997;96:2155-61. 
112. Neuhaus KL. Results of the HIT-4 study. Presented at the 13th International Workshop on 
Thrombolysis and Interventional Therapy in acute myocardial infarction, Orlando USA, 
November 8, 1997. 
113. Cannon CPo Results of the TIMI lOB trial. Presented at the 13th International Workshop on 
Thrombolysis and Interventional Therapy in acute myocardial infarction, Orlando USA, 
November 8, 1997. 
114. Van de Welf F. Results of the MINT study. Presented at the XIX cougress of the European 
Society of Cardiology, Stockholm, Sweden, August 24-28, 1997. 
115. AMI (Argatroban in Myocardial Infarction). Ferguson n. Meeting highlights. 46th Annual 
Scientific Sessions of the American College of Cardiology. Circulation 1997;96:367-71. 
116. Ohman EM, Kleiman NS, Gacioch G, Worley SJ, Navella FI, Talley JD, Anderson V, Ellis 
SG, Cohen MD, Spriggs D, Miller M, Kereiakes D, Yakubov S, Kit! MM, Sigmon KN, 
Califf RM, Krucoff MW, Topol El, for the IMPACT-AMI investigators. Combined 
accelarated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor 
blockade with integrilin in acute myocardial infarction. Results of a randomized, pJacebo-
controlled, dose-ranging trial. Circulation 1997;95:846-54. 
117. Antman EM, Giugliano RP, McCabe CH, Gibson M, Adgey An, Ghali M, Coussement P, 
Anderson KM, Scherer J, van de Werf F, Braunwald E, for the TIMI 14 investigators. 
Abciximab (Reo Pro) potentiates thrombolysis in ST elevation myocardial infarction: 
results of the TIMI 14 trial. J Am Coli Cardiol 1998;31: 191 A. 
118. Simoons ML. Eptifibatide as adjunct to streptokinase in acute myocardial infarction. 
Presented at the 13th International Workshop on Thrombolysis and Interventional Therapy 
in acute myocardial infarction, Orlando USA, November 8, 1997. 
119. Ronnel' E, van Kestem HAM, Zijnen P, Tebbe V. Molhoek P, Cuft!e C, Velti E, Lorenz T, Neuhaus 
K, Simoons lvIL. Combined OlCrapy WiOl streptokinase ruld integrilin. J Am Coli Cru-dioll998;31 : 191 A. 
120. Gulba DC, Tanswell P, Dechend R, Sosada M, Weis A, Waigand J, Uhlich F, Hauck S, lost 
S, Rafflenbeul W, Lichtlen PR, Dietz R. Sixty-minute alteplase protocol: a new accelerated 
recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial 
infarction. J Am Coli CardioI1997;30:1611-17. 
121. de Boer MJ, Suryapranata H, Hoorntje lCA, Reiffers S, Liem AL, Miedema K, Hennens 
W Th, Brand van den NI, Zijlstra F. Limitation of infarct size and preservation of left 
ventricular function after primary coronary angioplasty compared with intravenous 
streptokinase in acute myocardial infarction. Circulation 1994;90:753-61. 
122. de Boer Ml, Reiber lHC, Suryapranata H, van den Brand M, Hoorntje lCA, Zijlstra F. 
Angiographic findings and catheterization laboratory events in patients with primary coronary 
angioplasty or streptokinase therapy for acute myocru'dial infarction. Eur Heart J 1995; 16: 1347-55. 
- 29 -
Introduction and Aims a/the Thesis 
123. Zijlstra F, de Boer MJ, Beukema WP, Liem AL, Reiliers S, Huysmans D, Hoorntje JC, 
Suryapranata H, Simoolls ML. Ivlortality, reinfarctian, left ventricular ejection fraction and 
costs following reperfusion therapies for acute myocardial. Eur Heart J 1996; 17:382-7. 
124 de Boer MJ, Hout van B, Liem AL, Slll'yapranata H, Hoorntje JC, Zijlstra F. A cost-effective 
analysis of primary camilli)' angioplasty versus thrombolysis for acute myocardial infarction. 
Am J Cardiol 1995;76:830-33. 
125. Stone GW, Grines CL, Rothbaum D, Browne KF, O'Keefe J, Overlie PA, Donohue BC, 
Chelliah N, Vlietstra R, Catlin T, O'Neill WW, for the PAMI Trial Investigators. Analysis 
of the relative costs and effectiveness of primm)' angioplasty versus tissue-type plasminogen 
activator: the primary angioplasty in myocardial infarction (PAMI) trial. J Am Coli Cardiol 
1997;29:901-7. 
126. Lieu TA, Gurley RJ, Lundstrom RJ, Ray GT, Fireman BH, Weinstein MC, Parmley WW. 
Projected cost-effectiveness of primary angioplasty for acute myocardial infarction. JAm 
Coll Cardiol 1997;30: 1741-50. 
127. Cherieux EC, Swart de H, Dijkman LW, Havenith MG, Maessen JG, Engelen OJ, Wellens 
HJJ. Myocardial rupture after myocardial infarction is related to the perfusion status of the 
infarct related coronary artery. Am Heart J 1995; 129:644-50. 
128. Waller BF, Rothbaum OA, Pinkerton CA, Cowley MJ, Linnemeier TJ, Orr C, Irons M, 
Helmuth RA, Wills ER, Aust C. Status of the myocardium and infarct-related coronary 
artel), in 19 necropsy patients with acute recanalization using pharmacologic (streptokinase, 
r-tissue plasminogen activator), mechanical (percutaneous transluminal coronary 
angioplasty), or combined types of reperfusion therapy. J Am Call Cardiol 1987;9:785-801. 
129. Kinn JW, O'Neill WW, Benzuly KH, Jones DE, Grines CL. Primary angioplasty reduces 
risk of myocardial rupture compared to thrombolysis for acute myocardial int~1rction. 
Cathet Cardiovasc Oiagn 1997;42: 151-57. 
130. Zijlstra F, de Boer MJ. Chinn'gische interventies bij het acute hartinfarct. Ned Tijdschr 
Geneeskd 1996; 140: 1933-35. 
131. Cln'istian TF, O'Keefe JH, DeWood MA, Spain MG, Grines CL, Berger PB, Gibbons RJ. 
Intercenter variability in outcome for patients treated with direct coronary angioplnsty 
during acute myocardial infarction. Am Heart J 1998; 135:310-17. 
132. Grassman ED, Johnson SA, Krone RJ. Predictors of success and major complications for 
primary percutaneous transluminal coronam angioplasty in acute myocardial infarction. An 
analysis of the 1990 to 1994 society for cardiac angiography and interventions registries. J 
Am Coil Cardiol 1997;30:201-8. 
133. Wharton TP, Johnston JD, Turco MA, Souther TJ, Lew DC, BiUnoski W, Singhi SK, 
Graham M, Grincs L, \Veaver VVD, Grilles CL. Primm), angioplasty for acute myocardial 
infarction at hospitals with no-surgery on-site: the prospective multicentre PAMI-No SOS 
Registry. J Am Coli Cardiol 1998;31 :2 lOA. 
134. Agati L, Voci P, Hickle P, Vizza DC, Autore C, Fedel F, Feinstein SB, Dagianti A. Tissue-
type plasminogen activator therapy versus primary coronary angioplasty: impact on 
myocardial tissue perfusion and regional function 1 month after uncomplicated myocardial 
infarction. J Am Coli Cardiol 1998;31 :338-43. 
135. Eisenberg PR, Miletich JP, Sobel BE. Factors responsible for the differential proeoagulant 
efiects of diverse plasminogen activators in plasma. Fibrinolysis 1991;5:217-24. 
136. Pederson 00, Gram J, Jespersen 1. Plasma resistance to activated protein C regulates the 
activation of coagulation induced by thrombolysis in patients with ischaemic heart disease. 
Heart 1997;77:122-27. 
- 30 -
Chapter J 
137. Van Belle E, Lablanche JM, Battters C, Renand N, McFadden EP, Bertrand ME. Coronary 
angioscopic findings in the infarct related vessel within 1 month of acute myocardial 
infarction. Natural history and the effect of thrombolysis. Circulation 1998;97:26-33. 
138. Rescue trial, Gibson CM, Cannon CP, Greene RM, Sequeira RF, Margoden RD, Leya F, 
Diver DJ, Baim DS, Braunwald E. Rescue angioplasty in the thrombolysis in myocardial 
infarction (TlMI) 4 tdal. Am J CardioI1997;80:21-26. 
139. Miller JM, Schildcrout JS, Smalling RW, Betdu A, Califf RM. Topol EJ. Survival bcnefit 
of abciximab administration during early rescue angioplasty: analysis of 387 patients from 
the GUSTO-ill trial. JAm Coll CardioI1998;31:19IA. 
140. Mat'lilli M, Gliozheni E, Fedele S, Ungi I, Orsini E, MatTaccini P. Prevalence and prediction of 
no-rellow after direct angioplasty in acute myocardial infarction. JAm Coll Crnuiol 1997;29:90A. 
141. Morishima I, Sone T, Mokuno S, Taga S, Shimauchi A, Oki Y, Kondo J, Tsuboi H, Sassa 
H. Clinical significance of no-reflow phenomenon observed on angiography after successful 
treatment of acute myocardial inf:'lfction with percutaneous transluminal coronary angioplasty. 
Am Heart J 1995;130:239-43. 
142. Kloner RA, Ganote CE, Jennings RB. The "no reflow" phenomenon after temporary 
coronary occlusion in the dog. J Ciin Invest 1974;54:1496-1508. 
143. Neumann F, Ott I, Gawaz M, Richardt G, Holzapfel, Jochum M, Schomig A. Cardiac 
release of cytokines and inflammatory responses in acute myocmdial infarction. Circulation 
1995;92:748-55. 
144. Hansen PRo Role of neutrophils in myocardial ischemia and reperfusion. Circulation 
1995;91: 1872-85. 
145. Kloner RA, Alker KJ. The effect of streptokinase on intramyocardial hemorrhage, infarct 
size, and the no-rcflow phenomenon during coronmy reperfusion. Circulation 1984;70:513-21. 
146. Kloner RA. Does reperfusion injury exist in humans? J Am Call Cardiol 1993;21:537-45. 
147. Ferrari R. Metabolic disturbances during myocardial ischemia and reperfusion. Am J 
Cat'dioI1995;76: 17B-24B. 
148. Cobbaelt C, Hennens WT, Kint PP, Klootwijk PJ, Werf van de F, Sunoons ML. Thrombolysis-
induced coronmy reperfusioll causes acute and massive intcrstitial release of cardiac muscle 
cell proteins. Cardiovasc Res 1997;33: 147,55. 
149. Hansen PRo Myocmodial reperfusion injury: experimental evidence and clinical relevance. 
Eur Heart J 1995; 16:734-40. 
150. Manche A, Edmondson SJ, Hearse DJ. Dynamics of early postischemic myocardial 
functional recovery, evidence of reperfusion-induced injury? Circulation 1995;92:526-34. 
151. Grech ED, Dodd NJ, Jackson MJ, Morrison WL, Faragher EB, Ramsdale DR. Evidence for 
free radical generation after primary percutaneous transluminal coronary angioplasty 
recanalisation in acute myocardial infarction. Am J CardioI1996;77:122-7. 
152. Ito H, Okamura A, lwakura K, Masuyam1l T, Hori M. Takiuchi S, Negoro S, Nakatsuchi Y, 
Taniyama Y, Higashino Y, Fujii K, Minamino T. Myocardial perfusion patterns related to 
thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in 
patients with acute myocardial infarction. Circulation 1996;93: 1993-99. 
153. Ito H, Tomooka T, Sakai N, Yu H, Higashino Y, Fujii K, Masuyama T, Kitabatahe A, Minanino 
T. Lack of myocardial perfusion ulllllediately after successful thrombolysis. A predictor of poor 
recovelY ofleft ventricular function in rnlterior myocmuial infmction. Cu-culation 1992;85:1699-705. 
1-54. Ito H, Mal1lyama A, Iwakura K, Takiuchi S, Masuyama T, Hori M, Higashino Y, Fujii K, 
Minamino T. Clinical implications of the IIno retlown phenomenon. Circulation 1996;93:223-28. 
155. I1iceto S, Marangelli V, Marchese A, Amico A, Galiuto L, Rizzon P. Myocardial contrast 
- 31 -
Introduction and Aims of the Thesis 
echocardiography in acute myocardial infarction. Pathophysiological background and 
clinical applications. Eur Heart J 1996;17:344-53. 
156. Kenner MD, Zqiac EJ, Kondas GT, Dave MD, Winkelmann JW, Joftus J, Lancevilius A, 
Kybarskis A, Berukstis E, Urbonas A, Feinstein SB. Ability of the no-reflow phenomenon 
during acute myocardial infarction to predict left ventricular dysfunction at one month 
follow-up. Am J Cardiol 1995;76:861-68. 
157. Kates MA, Meza MF, Barbee RW, Revall S, Moreno CA, Peny B, Murgo JP, Cheilif J. Potential 
clinical implications of abnonnal perfusion patterns inunediately after repelfllsion in a canine 
model: a myocardial contrast echocardiography study. Am Heart J 1996;132:303-13. 
158. Willerson JT, Watson JT, Hutton I, Templcton GH, Fixler DE. Reduced myocardial reflow 
and increased coronary vascular resistance following prolonged myocardial ischemia in the 
dog. Circ Res 1975;36:771-81. 
159. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of 
ischemic cell death. I.Myocardial infarct size vs duration of coronary occlusion in dogs. 
Circulation 1977;56:786-94. 
160. Hasche ET, Felllandes C, Freedman SB, Jeremy RW. Relation between ischemia time, 
infarct size, and left ventIicular function in humans. Circulation 1995;92:710-9. 
161. Raitt MH, Maynard C, Wagner GS, Cerqueirra, MD, Selvester RH, Weaver WD. Relation 
between symptom duration before thrombolytic therapy and final myocardial infarct size. 
Circulation 1996;93:48-53. 
162. Pislal11 SV, Barrios L, Stassen T, Jun L, Pislaru C, Welf van de F. Infarct size, myocardial 
hemorrhage and recovery of function after mechanical versus pharmacological reperfllsion. 
Circulation 1997;96:659-66. 
163. Blohm MB, Hartford M, Karlson BW, Luepker RV, Herlitz J. An evaluation of the results 
of media and educational campaigns designed to shorten the time taken by patients with 
acute myocardial infarction to decide to go to hospital. Heart 1996;76:430-34. 
164. Saner H, Pfister R, Pirovino M, Castclli I, Gaspoz JM. Reduction of mortality by a media 
and education campaign in patients reporting chest pain. Eur Heart J 1997;18:124. 
165. Gaspoz JM, Unger PF, Chevrolet JC, Rutishauser W, Lovis C, Goldman L, Heliot C, 
Sechaud L, Mischler S, Waldvogel FA. Impact of a public campaign on pre-hospital delay 
in patients reporting chest pain. Heart 1996;76:150-55. 
166. Gibler WB, Gore JM, Weaver WD for the GUSTO-III investigators. Reduced time to 
thrombolytic delivery, but static time to presentation: the GUSTO experience from 1990 to 
1997. Circulation 1997;96:1-201. 
167. Miller-Craig MW, Joy AV, Adamowicz M, Furber R, Thomas B. Reduction in treatment 
delay by paramedic ECG diagnosis of myocardial infarction with direct CCU admission. 
Heart 1997;78:456-61. 
168. Garat, P, Juliard JM, Benamer H, Steg PG. Are the results of primary pereutaneous 
transluminal coronary angioplasty for acute myocardial infarction different during the off-
hours? Am J Cardiol 1997;79:1527-29. 
169. Caputo RP, Ho KKL, Stoler RC, Sukin CA, Lopez JJ, Cohen DJ, Kuntz RE, Berman A, 
Carrozza JP, Baum DS. Effect of continuous quality improvement analysis on the delivery 
of primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. 
Am J CardioI1997;79:1159-64. 
170. Berger PB, Hohnes DR, Califf RM, Criger DA. Hospital delay in achieving repelfusion 
with direct PTCA in GUSTO-lib: relationship to 30-day mortality. Circulation 1997;96:1-531. 
171. Ellis SG, O'Neill WW, Bates E, Walton JA, Nabel EG, Topol EJ. Coronary angioplasty as 
- 32 -
Chapter 1 
primary therapy for acute myocardial infarction 6 to 48 hours after symptom onset: report 
of an initial experience. J Am Call Cardiol 1989;13: 1122-6. 
172. Topol EJ, CaliffRM, Vandonnael M, Grines CL, George BS, Sanz ML, Wall T, O'Brian M, 
Schwaiger M, Aguirre FV, Young S, Popma n, Sigmon KN, Lee KL, Ellis SO, and the 
TAMI-6 Study Group. A rando-mized trial of late reperfusion therapy for acute myocar-dial 
infarction. Circulation 1992;85:2090-99. 
173. Dzavik V, Beanlands DS, Davies RF, Leddy D, Marquis JF, Teo KK, Ruddy TD, Burton JR, 
Humcn DP. Effects of late percutaneous coronary angioplasty of an occluded infarct-related 
coronary artery on left ventricular function in patients with a recent «6 weeks) Q-wave 
acute myocardial infarction (Total occlusion post-myocardial infarction intervention study 
[TOMIlS)-a pilot study. Am J Cardiol 1994;73:856-61. 
174. Bauters C, Lablanche J-M, Van Belle E, Niculescu R, Meurice T, Mc Fadden EP, Bertrand 
ME. Effects of coronmy stenting on restenosis and occlusion atier angioplasty of the culprit 
vessel in patients with recent myocardial infarction. Circulation 1997;96:2854-58. 
175. Brodie BR, Stuckey TD, Hansen C, Muncy D, Weintraub RA, Lebauer J, Kelly TA, Katz 
JD, Berry JJ. Bene-tit of late coronm), reperfusion in patients with acute myocardial infarction 
and persistent chest pain. Am J Cardiol 1994;74:538-43. 
176. Eisenhauer AC, Matthes RV, Moore L. Late direct angioplasty in patients with myocardial 
infarction lind fluctuating chest pain. Am Heart J 1992;123:553-59. 
177. Rogers WJ, Hood WP, Mantle JA, Baxley WA, Kirklin JK, Zorn GL, Nath HP. Return of 
left ventricular function after reperfusion in patients with myocardial infarction: importance 
of subtotal stenoses or intact collaterals. Circulation 1984;69:-338-49. 
178. Agati L, Voci P, Bilotta F,Luongo R, Autore C, Penco M, Iacoboni C, Fedele F, Diagianti 
A. InJluence of residual perfusion within the infarct zone on the natural histOlY of leti 
ventricular dysfunction after acute myocardial infarction: a myocardial contrast echocm"dio-
graphic study. J Am Call CardioI1994;24:336-42. 
179. Sabia PJ, Powers ER, Ragosta M, Sarembeck II, Burwell LR, Kaul S. An association 
between collateral blood flow and myocardial viability in patients with recent myocardial 
infarction. N Engl J Med 1992;327:1825-31. 
180. Grines CL, Marsalese DL, Brodie B, Gtiffin J, Donohue B, Constantini C, Balestrini C, 
Stone G, Wharton T, Esente P, Spain M, Moses J, Nobuyoshl M, Ayres M, Jones D, Mason 
D, Sachs D, Grines L, O'Neill W, for the PAMI-II investigators. Safety and cost-effectiveness 
of eady discharge after primary angioplasty in low risk patients with acute myocardial 
infarction. J Am Call CardioI1998;31:967-72. 
181. Sen11Ys PW, Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx 0, Emanuelsson H, 
Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Colombo A, GoY n, Heuyel van den 
P, Delcan J, Morel MA, for the BENESTENT study group. A compmison of balloon-
expandable-stent implantation with balloon angioplasty in patients with coronary artery 
disease. N Engl J Med 1994;331:489-95. 
182. Fislunan DL, Leon ME, Balln DS, Schantz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci 
D, Nobuyoshi M, Cleman M, Meuser R, Almond D, Teirstein PS, Fish RD, Columbo A, 
Btinker J, Moses J, ShaknovichA, HiI'Shfield J, Bailey S, Ellis S, Rake R, Goldbelg S, for the 
Stent Restenosis Study Investigators. A randomized compm"ison of coronary-stellt placement and 
balloon angioplasty III the treatment of coronmy m1ery disease. N EnglJ Med 1994;331:496-50 l. 
- 33 -

CHAPTER 2 
Part One 
Clinical Value of 12-lead Electrocardiogram after Successful 
Reperfusion Therapy for Acute Myocardial Infarction 
Arnaud WJ van 't Hof, Aylee Liem, Menko-Jan de Boer, Felix Zijlstra 
on behalf of the Zwolle lvlyocardial Infarction Study Group 
Ziekenhuis de Weezenlanden, Department of Cardiology 
Zwolle,The Netherlands 
Lal/cet 1997;350:615-/9 
- 35 -
Clinical \blue ofl2-lead Electrocanliogram after Successful Repel/lisionl7Ierapyfor Acute Myocardial Infarction 
Summary 
Background A simple clinical method to stratify risk for patients who have had successful 
reperfusion therapy after myocardial infarction is attractive since it facilitates the tailoring of 
therapy. 
Methods We investigated the clinical value of the l2-lead electrocardiogram (ECG), in 403 
patients after successful reperfusion therapy by primary coronary angioplasty, in relation to 
infarct size measured by enzyme activity, left-ventricular function, and clinical outcome. ECGs 
were analysed to find the extent of the ST-segment-elevation resolution I h after reperfusion the-
rapy. 
Findings A normalised ST segment was seen in 51 % of patients, a partly normalised ST seg-
ment in 34%, and 15% had no ST-segment-elevation resolution. Enzymatic infarct size and ejec-
tion fraction were related to the extent of the early resolution of the ST segment. The relative 
risk of death among patients with no resolution compared with patients with a normalised ST 
segment was 8.7 ((95% CI 3.7-20.1), and that among patients with partial resolution compared 
to patients with a normalised ST segment was 3.6 (1.6-8.3). 
Interpretation Our findings suggest that ECG patterns ret1ect the effectiveness of myocardial 
reperfusion. Patients for whom reperfusion therapy by primary angioplasty was successful and 
who had normalised ST segments had limited damage to the myocardium and an excellent Otltlo-
ok during follow-up. Patients with persistent ST elevation after reperfusion therapy may need 
additional interventions since they have more extensive myocardial damage and have a higher 
mortality rate. 
(Lal/ceI1997;350:615-619) 
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Introduction 
Early and sustained patency of the infarct-related coronary artel)1 has become the main goal in 
the care of patients with acute myocardial infarction (1-3). Several studies show that primary 
coronary angioplasty may offer more benefit than thrombolytic therapy (4,5). Favourable results 
for angiographic data, enzymatic infarct size, left ventricular function and clinical outcome have 
been described for angioplasty treated patients (6,7). Although clinical outcome after successful 
reperfusion therapy is good in most patients, a substantial minority are stilI at risk from adverse 
clinical events. A simple clinical method to assess the risk for these patients immediately after 
successful repelfusion therapy is, therefore, attractive since it would allow the tailoring of phar-
macological interventions, such as additional anti platelet therapy (8), mechanical support by 
stenting (9), 01' baemodynamic support by intra-aortic balloon pumping (10) in patients at high 
risk from adverse events. 
Identification of low-risk patients can lead to early discharge and, therefore, a more cost-effec-
tive use of restricted medical resources. Electrocardiography is a good candidate for this role. 
The prognostic value of the 12-lead electrocardiogram (EeG) has been documented for paticnts 
given thrombolytic therapy (11,12). However, not all of these patients have early and sustained 
successful reperfusion of the infarct-related coronmy artelY. 
In our published trials (4,6) and in continuing trials of therapies for acute myocardial infarction, 
all patients who present at or are refetTed to our hospital with ST-segmcnt-elevation myocardial 
infarction m'e registered. and clinical and angiographic data are added to a database. We inves-
tigated tbe clinical value of thc 12-lead EeG in a large cohort of these patients after successful 
repelfusion therapy by primary angioplasty, by enzymatic infarct size, left-ventricular function, 
and clinical outcome. 
Patients and methods 
Between August, 1990, and April, 1995,725 patients with acute myocardial infarction and ST-
segment-elevation of more than 0.1 mV in at least two contiguous ECG leads presented at or 
were referred to our institution. 205 patients received thrombolytic therapy as part of other ran-
domised trials that compared primary angioplasty with thrombolytic therapy, and 520 patients 
wcre candidates for primary coronary angioplasty. Of these 520 patients, 485 (93.3%) had 
angioplasty. In 18 patients (3.5%), the infarct related coronmy artelY had repelfused spontane-
ously and there were no remaining signs or symptoms of ischaemia, these patients were mana-
ged conservatively. In 17 patients (3.3%) the coronary angiogram showed extensive triple-ves-
sel coronary-artery disease or left main-coronary-artery disease that was judged to require 
immediate coronary-artery bypass surgery. Successful primary coronary angioplasty, defined as 
Thrombolysis In Myocardial Infarction 3 flow and a residual stenosis of the affected vessel by 
quantitative coronary angiography of less than 50%, was achieved in 455 (93.8%) of 485 
patients. Adequate EeG data for this stlldy, defined as available 12-lead EeGs that allowed 
assessment of the Sl'segments, as described by Scln'oder and colleagues (II), before and I h 
after primary coronary angioplasty, were obtained in 403 (88.6%) of 455 patients. In 52 
(11.4%) patients an EeG from before or after the intervention was missing or ST-segment 
resolution could not be interpreted, because of a new bundle-branch block, the lise of a ventri-
cular pacemaker or a slIstained idioventricular rhythm. The data for the 403 patients with both 
EeGs were used for this report. Radionuclide measurements of the left-ventricular ejection 
fraction were obtained in 285 (70.7%) of the 403 patients before discharge from hospital. Enzy-
matic infarct size was calculated in 126 consecutive patients as part of our previously reported 
randomised trial. 
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Electrocardiography 
ECGs were done on admission to hospital (first ECG), and in the coronary-care unit (second 
ECG), I h after the primm)' angioplasty, according to the protocol. Patients with right bundle-
branch block who clem'ly had ST-segment-elevations were included in the analysis. All ECGs 
were analysed as pairs (the observer was aware of the order) and graded for ST-segment- eleva-
tion resolution by an investigator who was unaware of the clinical data, angiographic findings, 
and outcome data. Results were not clear for 23% of patients, and a second investigator, also 
unaware of the status of patients, assessed the extent of ST-segment resolution and consensus 
was reached in all cases. The sum of ST-segment-elevation was measured 20 ms after the end of 
the QRS complex in leads I, aVL and V 1-V6 for anterior, and leads II, III, aVF and V5-V6 for 
non-anterior myocardial infarction. The findings from the coronary angiograms were used to 
confirm the infarct location. \Vhen the infarct-related artery was the left anterior descending 
coronary artery or one of its side branches, the infarct location was classed as anterior, and when 
the infarct-related coronary artery was the right or the circumflex coronary artery, the infarct 
location was judged to be non-anterior. The sccond ECGs were classified by comparison of the 
ST segments with those on the first ECGs. 
Normalised ST segmcnt was defined as no residual ST-segment elevation of 0.1 mV or marc in 
any of the 12 leads (complete ST-segment-elevation resolution); improved ST segment was defi-
ned as residual Sl'segment elevation of less than 70% of that au the first ECG (partial ST- seg-
ment-elevation resolution); unchanged ST segment was defined as a residual ST-segment eleva-
tion of 70% or more of that on the first ECG (no ST-segment-elevation resolution). 
The reproducibility of the classification of the ECGs was assessed in two ways. The ECGs of all 
patients in the study born in January, February or March (n= I 05) were reanalysed in an identi-
cal manner. Agreement between first and seconds readings was found in 93 (89%) of 105 pairs 
of ECGs. Twelve patients had a one-grade difference between the two readings. The estimated 
weighted Kappa correlation coeftlcient was 0.90 (95% CI 0.84-0.95). The ECGs of the first 60 
of these 105 patients were sent for outside review by an experienced clinical cardiologist not 
otherwise involved in our trial, and his reading was compared with our first and second reading. 
Agreement with our first and second readings was found in 53 (88%) of 60 patients and in 49 
(82%) of 60 patients, respectively, with a one-grade difterence in 7 and II patients. The weigh-
ted Kappa correlation coefficients between the independent readings and our first and second 
readings was: 0.92 (0.85- D.98) and 0.83 (0.73- 0.93), respectively. 
Em),lIIatic Ill/arct Size 
\.Ve estimated infarct size by measurements of enzyme concentrations, with lactate dehydroge-
nase (LDH) as the reference enzyme. \Ve used a two-compartment model, which has been vali-
dated in studies on the turnover of radio-labelled plasma proteins and circulating enzymes 
(13,14). Cumulative enzyme release was calculated from serial measurements up to 72 h after 
symptom onset. Samples were obtained at admission and eve!), 12 h, to 72 h. From these mea-
surements, an area under the curve was constructed, preferably from 7, but from at least 5 mea-
surenlents. These measurements and calculations were done at the department of clinical che-
mistry, without access to clinical data. Further details of these methods have been published (6). 
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Left-Veutricular Fuuctiou 
\Ve measured left-ventricular ejection fraction with a radio-nuclide technique (4) before hospi-
tal discharge. Measurement was done by the multiple-gated equilibrium method after labelling 
of red blood cells had been with [99mTc 1 pertechnetate. A gamma camera (General Electric Mil-
waukee, WI, USA) with a low-energy, all purpose, parallel-hole collimator was used. The glo-
bal ejection fraction was calculated on computer (Star View, General-Electric), with the PAGE 
™ program, version 2.3. Specialists in nuclear medicine who were unaware of the clinical data, 
gathered data on ejection fractions. 
Mortality 
Follow-up information was obtained for all patients. Records of 66% of patients who visited our 
outpatient clinic were reviewed. For all other patients, information was obtained from the 
patient's general physician. \Ve were able to contlrm that patients for whom we had not recei-
ved written confirmation of death were alive. For patients who died during follow-up, hospital 
records and necropsy data were reviewed. No patient was lost to follow-up. All deaths were 
taken to be from cardiovascular causes, except for those from necropsy-confirmed malignant 
disorders. 
Statistic({l AII({lysis 
We did chi-square analysis to test differences between proportions, with calculation of relative 
risks and 95% CIs. Diffe-rences were signifi-canl if the two-sided p value was <0.05. \Ve did 
time-to-event analysis to describe survival from the date when the patient was admitted to the 
hospital with SAS for \Vindows, version 6.1 1. Survival was represented by Kaplan-Meier cur-
ves. We did multivariate analysis with adjustments for age, sex, previous myocardial infarction 
and infarct location, (16) and trend analyses, as described by Schlessehnan (17). 
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Table 1. 
Baseline characteristics for total study population and patients for whom enzymatic 
infarct size or ejection fraction were available 
Group of patients Extent of resolution of ST-segment elevation 
Total study population Complete Partial No P 
(n=403) (N=204, 51 %) (N=139,34%) (N=60, 15%) 
Age in years (SO) 58 (II) 60 (II) 64 (12) 0.002 
Malelfemale 164 (80%)1 112 (81 %)1 39 (64%)1 0.03 
40 (20%) 27 (19%) 21 (35%) 
Anterior infarction 71 (35%) 70 (50%) 36 (60%) <0.001 
Previous infarction 35 (17%) 26 (19%) 15 (25%) 0.21 
TIiple-Vessel Disease 52 (26%) 38 (27%) 20 (33%) 0.26 
Diabetes 14 (7%) 10 (7%) 4 (7%) 0.96 
Ischaemic time* (SO) 226 (172) 278 (219) 338 (291) 0.005 
Enzymatic infarct size known Complete Partial No P 
(n=126) N=64 (51%) N=47 (37%) N=15 (12%) 
Age in years (SO) 57 (10) 61 (9) 61 (10) om 
Malelfemale 52 (81%)1 40 (85%)1 II (73%)1 0.75 
12 (19%) 7 (15%) 4 (27%) 
Anterior infarction 20(31%) 23 (49%) II (73%) 0.002 
Previous infarction 5 (8%) 7 (15%) 3 (20%) 0.13 
TIiple-Vessel Disease 14 (22%) 12 (26%) 4 (27%) 0.61 
Diabetes 6 (9%) 3 (6%) 1(7%) 0.60 
Ischaemie time* (SO) 208 (152) 266 (230) 250 (177) 0.06 
lefi-vennictdar ejection fraction Complete Partial No P 
known (n=285) N=138 (48%) N=IlO (39%) N=37 (13%) 
Age in years (SO) 58 (II) 59 (10) 62 (II) 0.05 
Malelfemale 117 (85%)1 92 (84%)1 25 (68%)1 0.05 
21 (15%) 18 (16%) 12 (32%) 
Anterior infarction 52 (38%) 57 (52%) 23 (62%) 0.003 
Previous infarction 15(11%) 17 (15%) 7 (19%) 0.15 
Triple-Vessel Disease 29 (21 %) 27 (25%) 10 (27%) 0.38 
Diabetes 13 (9%) 9 (8%) 3 (8%) 0.73 
Isehaemie time* (SO) 219 (160) 279 (221) 360(311) 0.001 
*Ischaemic time is defined as time from symptom onset until the first balloon inflation 
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Results 
The patients were classified into 3 categories by results of the 12-lead ECG. Baseline clinical 
characteristics of the 3 groups are shown in table I. Complete ST-segment-elevation resolution 
was present in 204 (51 %) patients. Partial ST-scgment resolution was seen in 139 (34%) 
patients, and 60 (15%) patients had either no resolution or showed an increase of ST-segment-
elevation on the ECG done after angioplasty. The second ECGs were recorded a mean of 144 
(SO 85) min after the first ECG and 59 (37) min after plimary angioplasty in the complete reso-
lution group; 153 (79) min after the first ECG and 59 (28) min after primary angioplasty in the 
partial resolution group; and 154 (82) min after first ECG and 56 (31) min after primary angio-
plasty in the group with no resolution. Patients in the latter group were older, there was a high 
proportion of women, and more patients had an anterior infarction than in the other two groups. 
Ischaemic time, defined as the time from the onset of chest pain to primary angioplasty. was 226 
(172) min among patients with complete resolution, 278 (219) min among patients with partial 
resolution, and 338 (291) min among patients with no resolution (p<0.005). 
Compared to patients who had no ST-segment-elevation resolution, a normalised ST- segment 
was associated with a large reduction in infarct size of 60%, as shown by serial enzyme measu-
rements. Patients with partial resolution had a reduction in infarct size of 28% compared with 
patients with no resolution (table 2). 
Table 2. 
Extent of nlyocardial infarction measured by enzymatic infarct size and 
left·ventricular ejection fraction 
Complete Partial No 
Resolution Resolution Resolution 
Enzymatic infarct size (N=65) (N=46) (N=15) 
(N=126) 703(511) 1274 (774) 1760 (1017) 
LOHQ72, U/I* (SO) 
Ejection fraction (N=285) (N=138) (N=IIO) (N=37) 
Before dischatge from hospital 51 (9%) 44 (12%) 39 (13%) 
(SO) 
P 
<0.001 
<0.001 
LDHQ72 indicates cumulative enzyme release from five to seven serial measurements up to 72 h after symptom onset. 
Preservation of left-ventricular function, measured by radionuclide left-ventricular ejection frac-
tion, was strongly related to the extent of ST-segment resolution. Patients with complete resolu-
tion of ST-segment elevation had a mean ejection fraction before discharge of 51 % (SO 9), 
patients with partial resolution 44% (12), and patients with no resolution had an ejection frac-
tion of 39% (13). 
50 (12%) patients died during follow-up. Five patients died from a malignant illness -2 patients 
from lung cancer, I from an adrenal tumour, and 2 from carcinoma of the pancreas- and these 
were all excluded from the survival analysis. In hospital, there were no deaths among patients 
with a normalised ST-segment, but 6% of patients with partial ST-segment-elevation resolution 
and 13% of patients with no resolution died. At follow-up after 3.1 (\.6) years, the rate of death 
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was 4% alllong patients with a normalised ST-segment, 14% among patients with partial reso-
lution, and 29% among patients with no resolution. 
Figure 1 
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Kaplan-i\Jeier survival curve for 398 patients who undenvcnt successful primar), angioplasty 
The figure shows the survival curves for the 3 groups. The relative risk of death among patients 
with no ST-segment-elevation resolution compared with patients with a normalised ST- segment 
was 8.7 (CI 3.7-20.1). The relative risk of death among patients with partial ST- segment-eleva-
tion resolution compared with patients with a normalised ST-segment was 3.6 (1.6-8.3). We did 
multivariate analyses with adjustments for age, sex, infarct location, and previous infarction, but 
inclusion of these adjustments had little influence on the relative risks. The relative risk of death 
among patients with no resolution was 6.4 (2.7-15.3), and among those with partial resolution 
was 3.5 (1.5-8.0). In tllis model, only age and ECG classification were independent correlates of 
survival. None of the other baseline clinical variables changed the results significantly when we 
added them to this model. 
DisclIssion 
Our principle finding was that in a large cohort of patients with documented successful reperfu-
sian therapy and TIMI 3 flow through the infarct-related coronary artery, the extent of ST-seg-
ment-elevation resolution on the 12-lead ECG is a strong predictor of clinical outcome. The clear 
relation between the ECG findings, enzymatic infarct size, and left-ventricular function show 
that the extent of ST-segment-elevation resolution reflects myocardial salvage. 
Several studies have described the relation between changes of the ECG after the start of throm-
bolytic therapy and patency of the infarct-related vessel at follow-up coronary angiography 
(18,19). Although complete ST-segment resolution predicts an open infarct artery reasonably 
well, the absence of ST-segment-elevation resolution gives no information about patency (20). 
Our study shows that ECG will not predict infarct-vessel status in many patients with these cri-
teria, since 49% of patients in our study had persistent ST-segment-elevation despite an open 
epicardial vessel with TLVII 3 flow. ST-segment changes after reperfusion therapy may, therefo-
re, renect myocardial now rather than epicardial flow and predict clinical outcome better than 
epicardial vessel patency alone in patients treated with thrombolytic therapy (11,12). 
Several techniques have been used to assess myocardial perfusion after reperfusion therapy. "No 
- 42-
Chapter 2-1 
reflow", which can be assessed with myocardial contrast echocardiography by intracoronary 
injection of sonicated microbubbles, is a predictor of clinical outcome Hnd left- ventricular func-
tion after reperfusion therapy for acute anterior myocardial infarction (21-23). Positron emission 
tomography scans can show vascular integrity in the infarcted myocardium (24), which may 
help to select patients in whom additional interventions can improve recovery of left-ventricu-
lar function (25). However, these techniques are costly and time-consuming and not available in 
routine clinical practice. We found that 12-lead EeG reflects myocardial reperfllsion and micro-
vascular integrity rather than epicardial coronary-artery patency. 
Complete ST-segment-elevation resolution is related to limited infarct size and preservation of 
left-ventricular function, whereas no resolution of ST-segment elevation is associated with exten-
sive myocardial enzyme release, substantial impairment of left-ventricular function, and, conse-
quently, a higher mortality. This mechanism is probably related to the extent of microvascular 
injury. Patients with no ST-segment resolution on ECG after angioplasty had a higher frequency 
of anterior-wall myocardial infarctions and presented late after symptom onset. Infarct location 
and ischaemic time are important determinants of infarct size (26-28). A large area at risk or an 
ischaemic time of more than 3 h results in oxidative stress, massive release of creatine phospho-
kinase from the myocardimll, and a lack of recovery of aerobic metabolism; subsequent ncu-
trophil plugging of capillaries and oedema results in an increased impedance to flow (29). 
\Ve found a strong relation between ischaemic time and the extent of ST-segment resolution. 
This relation has been assessed in studies of patients started on thrombolytic therapy (11,12,30). 
However, such investigations are confounded by the inability to assess the exact time of reper-
fusion in patients treated with thrombolytic therapy. Strong emphasis should be placed on met-
hods (initial diagnosis, transportation and where patients are treated in hospital), that lead to 
shorter time from symptom onset to patency or myocardial reperfusion. Invcstigations of throm-
bolysis before admission to hospital have shown that patients taken part in studies have a subs-
tantially shorter delay from arrival in hospital to the start of thrombolytic therapy ("door to need-
le" time), than non-study patients, and that a long delay is associated with marc depressed left-
ventricular function and a worse clinical outcome (31,32). Further streamlining of the organisa-
tion may, therefore, lead to better outcome. 
We assessed ST-segment resolution in a semiquantitative way, by comparison of t\VO 12-lead 
ECGs. Tlus approach Hught be less objective and accurate than continuous ST-segment tracking 
with automated analysis systems (18). Although these systems are attractive, they are not gene-
rally available, and whether they convey additional information has yet to be shown. Enzymatic 
infarct size and left-ventricular ejection fraction were not available for all our patients. Nevert-
heless, the samples were large enough to show s substantial difference between the groups with 
adequate statistical power. Our findings cannot be generalised to all patients presenting as emer-
gencies with acute transmural infarction, since we describe patients with successful reperfusion 
by primary angioplasty. In particular, our data should not be extrapolated to patients in whom 
reperfusion therapy is not successful, those managed conservatively, or those who undergo 
urgent coronm-y-artery bypass surgery. 
The extent of ST-segment-elevation resolution on the 12-lead ECG after successful repelfusion 
therapy for acute myocardial infarction is related to enzymatic infarct size and left-ventricular 
function and is related to clinical outcome. This relationship can be used to stratify patients for 
risk shortly after the acute event. Patients with normalised ST-segments have limited myocardial 
damage and an excellent long term clinical outcome. Additional therapeutic interventions should 
be considered for patients with persistent ST-segment elevation, despite a patent infarct-related 
vessel, since these patients have more extensive myocardial damage, can have depressed left-
ventricular function, and have a higher mortality during long-term follow-up. 
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Summary 
Baci<.gl'ound: The primmy objective of reperfusion therapies for acute myocardial infarction is 
not only restoration of blood flow in the epicardial coronary artery but also complete and sus-
tained reperfusion of the infarcted part of the myocardium. 
Methods and Resnlts: We studied 777 patients who underwent primary coronary angioplasty 
during a 6-year period and investigated the value of angiographic evidence of myocardial reper-
fusion (myocardial blush grade) in relation to the extent of ST-segmcnt elevation resolution, 
enzymatic infarct size, left ventricular function, and long-term mortality. The myocardial blush 
immediately after the angioplasty procedure was graded by two experienced investigators, who 
were otherwise blinded to all clinical data: 0: no myocmllial blush, I: minimal myocardial blush, 
2: moderate myocardial blush, and 3: nOfmalmyocardial blush. The myocardial blush was rela-
ted to the extent of the early ST-segment elevation resolution on the 12-lead electrocardiogram. 
Patients with blush grades 3, 2 and 011 had enzymatic infarct sizes of 757, 1143 and 1623 
(p<0.000 I), respectively, and ejection fractions of 50%,46% and 39%, respectively (P<O.OOO I). 
After a mean ±SD follow-up of 1.9±1.7 years, mortality rates of patients with myocardial blush 
grades, 3, 2 and 011 were 3%, 6% and 23% (P<O.OOOI), respectively. Multivariate analysis sho-
wed that the myocardial blush grade was a predictor of long-term mortality, independent of 
Killip class, Thrombolysis In Myocardial Infarction grade flow, left ventricular ejection fraction, 
and other clinical variables. 
Conclusion: In patients after reperfusion therapy, the myocardial blush grade as seen on the 
coronary angiogram can be used to describe the effectiveness of myocardial reperfusion, and is 
an independent predictor of long term mortality. 
(Circulation 1998;97:2302-2306) 
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Introduction 
Over the past decades, great effOtts have been made to improve the outcome of patients with 
acute myocardial infarction (1-7). Many tIials have relied on mortality as the end point (1,2). The 
recent data from the Global Utilization of Streptokinase and Tissue Plasminogen activator for 
Occluded coronary arteries (GUSTO) trial suggest that patency of the epicardial infarct -related 
coronary artery is an appropriate altemative end point (4). However, the primary objective of 
reperfusion therapies is not only restoration of blood flow in the epicardial coronmy artery but 
also complete and sustained rcpcrfusion of the infarcted myocardium. Echocardiographic assess-
ment of myocardial perfusion after intracoronm), injection of sonicated microbubbles is an 
investigational technique that has been used to describe myocardial reperfusion in patients with 
restored patency of the infarct-related coronmy artery. The so-called "no-reflow" phenomenon, 
an open epicardial artery without flow into the myocardium, predicts complications and left ven-
tricular dilation (8,9). A simple clinical tool that describes the effectiveness of myocardial reper-
fusion is lacking because noninvasive means so far have not been applicable in routine clinical 
practice and the widely used angiographic parameter, Thrombolysis In Myocardial Infarction 
(TIMI) flow grade, describes epicardial instead of myocardial blood flow (3,4). Therefore, we 
have introduced an angiographic parameter to describe the effectiveness of myocardial reperfu-
sian: the myocardial blush grade. To validate tlils new tool we compared the myocardial blush 
grades with 12-lead ECG, enzymatic infarct size, left ventricular function, and clinical outcome 
in a cohort of patients after primary coronary angioplasty and assessed whether this new para-
meter might give additional prognostic value compared with that of TIMI flow grade. 
Methods 
Patients 
From August 1990 until April 1997, 1206 patients fulfilled the criteria for entry into one of our 
published or ongoing trials (6,10-12). Two hundred and sixty-five patients were treated with 
thrombolytic therapy. Forty-three patients underwent primary coronary bypass surgery because 
of severe left main or three-vessel disease, and 62 patients were treated conservatively because 
of nonsignificant disease and TIMI grade 3 flow of the infarct-related vessel. In 836 patients, 
primary angioplasty was performed. In 46 patients, the quality of the coronary angiogram did 
not allow adequate assessment of myocardial blush grade and for 13 patients, angiographic data 
were missing. The remaitilng 777 patients form the basis of this report (Figure 1). 
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Figure 1. 
Flow chart of patients admitted with acute myocardial infarction and ST-segment elevation 
between August 1990 and April 1997 
N= 1206 inclusion in Zwolle Infarct Trial ! .. N=265 thrombolytic therapy or candidate for rescue PTCA 
N=941 scheduled for primary coronmy angioplasty 
! N=105 primary CABO or conservative treatment 
N=836 primmy angioplasty (PA) 
l missing film (N=13) or inadequate quality of angiogram (N=46) 
N=777 assessment of myocardial blush grade 
~ 
N= 566 multivariate analysis TIMI flow 
CABG indicates coronary artery bypass grafting 
+Myocardial blush grade 
+Enzymatic infarct size 
+Left ventricular ejection fraction 
11M1 FlolV Grades alld Myocardial Blllsh Grades 
TIM! flow grades were assessed as previously described (3,10). Both TIMI flow and myocardial 
blush were graded on the angiograms made immediately after the primary coronmy angioplasty pro-
cedure, by two experienced investigators, who were blinded to all datu apmt from the coronmy 
angiograms. Grading was done on cinefilm at 25 frames/s made in a Philips digital coronary una-
ging catheterization laboratOlY. In each patient, the best projection was chosen to assess the myocar-
dial region of the infarct-related coronary mtelY, preferably without superpositioning of noninf~ll'c­
ted myocardium. Left antetior oblique or left lateral projections were used in 49%, right mltetior obli-
que projections in 23%, both left anterior oblique or left lateral mld light anterior oblique projections 
in 23%, and a cranial view in 5%. Angiographic mns had to be long enough to allow some filling of 
the venous coronmy system, and back-t1ow of the contrast agent into the amia (Hexabtix, 5-15 mL) 
had to be present to be certain of adequate contrast ftlling ofthe epicardial coronmy ruiery. All angio-
grams were made with 7F or 8F guiding catheters in a standardized fashion after 400 mg nitrogly-
ceru} Ie had been given itmnediately after the prunmy angioplasty procedures, and tlus procedure 
allowed quantitative coronmy mtery analysis (10). lvlyocardial blush grades were deftned as follows: 
0, no myocardial blush or contrast density; 1, minimal myocmdial blush or contrast density; 2, mode-
rate myocardial blush or contrast density but less than that obtained during ~Ulgiography of a contra-
lateral or ipsilateral non-infm'ct-related coronary mtery; and 3, normal myocardial blush or contrast 
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density, comparable with that obtained during angiography of a contralateral or ipsilateral non~ 
infarct-related coronmy m1elY. When myocardial blush persisted ('Istainingl'), this phenomenon sug-
gested leakage of the contrast medium into the extravascular space (13), and was graded O. Repro-
ducibility and vmiabilities of the myocardial blush grades m'e shown in Table 1. 
Table 1. 
Reproducibility and Variabilities of Myocardial Blush Grades 
Difference 
n Agreement 1 grade >1 grade 
Reproducibility 
- 2 observers 71 60 (85%) 11 (15%) 0(0%) 
Variability 
- interobserver 30 27 (90%) 3 (10%) 0(0%) 
- intraobserver 30 29 (97%) 1 (3%) 0(0%) 
Reproducibility was assessed by reviewing a random sample of the coronary angiograms a second time by two observers. 
A random sample of 30 coronary angiograms was used to assess inter~ and intra-observer variabilities. 
ECG 
ECGs were done on admission (first ECG), and shortly after arrival in the coronary care unit 
(second ECG) after the primary coronary angioplasty procedure. The sum of ST-segment eleva-
tions was measured 20 ms after the end of the QRS complex in leads I, aVL, and VI to V6 for 
anterior and leads II, III, aVF, V5 and V6 for non-anterior myocardial infarction. The second 
ECGs were classified with regard to the ST segment in the same way as previously described 
(14): 1, normalized, defined as no residual ST-segment elevation; 21 improved, defined as a resi-
dual ST-segment elevation <70% of with that on the first ECG; and 3, unchanged, defined as a 
residual ST-segment elevation > 70% of that on the first ECG. 
Ellzymatic 1l1fal'ct Size 
The methodology for estimation of infarct size is equal to that obtained by the 
a-hydroxybutyrate dehydrogenase method and has been described previously (15). In brief, 
infarct size was estimated by measurements of enzyme activities by using lactate dehydrogena-
se as the reference enzyme. Cumulative enzyme release from t1ve to seven serial measurements 
up to 72 hours after symptom onset was calculated. A two~compartll1ent model was used, which 
has been validated in several studies with respect to the turnover of radio~labeled plasma pro-
teins and circulating enzymes (16). 
Left Venh'iculal' Function 
Before the patients were discharged, left ventricular ejection fraction was measured by radionu-
elide ventriculography. The multiple-gated equilibrium method was used after in vivo labeling 
of red blood cells of the patient with 99mTc-perteehnetate (6,17). A General Electric 300 g-
camera with a low-energy, all-purpose, parallel-hole collimator was used. Global ejection frac-
tion was calculated by a General Electric Star View computer and the fully automated PAGE 
program. Use of this software program protects against operator bias. The reproducibility of this 
method is excellent, with a mean difference (±SD) between first and second values of duplicate 
measurements of 1.2±1.1 %. 
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Mortality 
Mortality was assessed in August 1997. Records of patients who visited our outpatient clinic 
were reviewed. For all other patients, infonnation was obtained from the patients general physi-
cian or by direct telephone interview with the patient. For patients who died during follow-up, 
hospital records and necropsy data were reviewed. No patient was lost to follow-up. 
Statistical Allalysis 
Differences between group means were tested by twoHtailed Student's t test. For comparison of 
rates of discrete outcome variables, a c2 test or Fisher's exact test was used. Trend analyses were 
done as descdbed by Schlesselman (18). In our presentation of the data, continuous baseline and 
outcome variables are given as mean ±SD, whereas discrete variables are given as absolute 
values, percentages, or both. In 566 patients in whom TIMI flow as well as myocardial blush 
grading, enzymatic infarct size, and left ventricular ejection fraction (LVEF) were obtained, a 
multivariate logistic regression analysis was perfollned to determine independent predictors of 
longHtenn mortality. Continuous variables were divided into three categories, with the 25th and 
75th percentiles as cutoff points. Odds ratios and 95% confidence intervals were calculated. Sur-
vival was represented by KaplanHMeier curves. A log-rank test was done to assess significant 
differences in survival between patient subgroups. 
Tahle 2. 
Baseline Clinical and Angiographic Characteristics 
Myocardial Blush Grade 
3 2 OIl Trend 
(n=148) (n=393) (n=236) P 
Age, years 57±11 59±1I 61±11 0.0001 
Male 124 (84%) 319(81%) 186 (79%) 0.22 
MVD 79 (53%) 216 (55%) 143(61%) 0.13 
Previous MI 23 (16%) 43 (11%) 46 (20%) 0.01 
Antedor MI 53 (36%) 216 (55%) 163 (69%) <0.0001 
Killip class I 133 (90%) 346 (88%) 165 (70%) <0.0001 
Diabetes 12 (8%) 20 (5%) 26(11%) 0.14 
Ischemic time, min* 233±188 259±215 315±256 0.001 
Infarct related artery 
-RCA 78 (53%) 138 (35%) 50(21%) <0.0001 
-CX 21 (14%) 45 (11%) 24 (10%) 0.26 
-LAD 49 (33%) 206 (53%) 156 (66%) <0.0001 
-Graft 0% 3 (1%) 4 (2%) 0.08 
-Left Main 0% I (0.3%) 2 (1%) 0.17 
Patency lRV before PTCA 43 (29%) 79 (20%) 24 (10%) <0.0001 
MVD indicates multiYesscl coronary artcry disease; MI, myocardial infarction; RCA, right coronary artery; CX, circumflex 
artery; LAD, left anterior descending coronary artery. Patency of IRV before PTCA, infarct-related vessel ,vith TIl\H 2 or 3 
flow before the angioplasty procedure (PTCA). "'Ischemic time is the time fraUl thc first onset of symptoms to the first 
balloon inflation. 
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Results 
Myocardial blush grades could be assessed in 777 of the 836 patients (93%). Baseline and angio-
graphic characteristics of the patients classified by myocardial blush grade are shown in Table 
2. Myocardial blush grades 0 and I were present in 5.8% and 24.6% of patients. respectively. In 
the presentation of the results, these two groups were combined. Patients with lower blush gra-
des were older and more often presented in Killip class 2 or higher. There was a strong associa-
tion between infarct location as weB as infarct-related artery and myocardial blush grade. Furt-
hermore, patients with higher blush grades had a higher incidence of antegrade flow into the 
infarct zone before the angioplasty procedure. There is an inverse relation between ischemic 
time and myocardial blush grade. TIMI flow of the infarct-related vessel could be assessed in all 
patients. Interpretable ECGs on admission as well as those performed after the primary coronary 
angioplasty procedure were available for 647 patients (83%). In 2% of the patients one or both 
ECGs did not allow an assessment of the ST-segments owing to rhythm or conduction abnor-
malities. The results of the TIMI flow classification and extent of ST-segment elevation resolu-
tion are shown in Table 3. TIM! flow, and LVEF were no longer independent predictors of mor-
tality after inclusion of myocardial blush grade into the multivariate model. 
Table 3. 
TIM! flow and ST Segments on the 12-lead ECG After Primmy Coronmy Angioplasty. 
Myocardial Blush Grade 
3 2 Oil Trend Analysis 
(n=148) (n=393) (n=236) P 
TIMI flow (n=777) 
3 99% 98% 67% <0.0001 
2 1% 1% 21% <0.0001 
0-1 0% 1% 12% <0.0001 
ST-segment elevation (n=647) 
Normalized* 65% 54% 27% <0.0001 
Improved* 28% 34% 45% 0.002 
Unchanged* 7% 12% 28% <0.0001 
* Defined as previously described in Reference 14. 
Trend analysis revealed a distinct relation between TIM! flow. ST-segment recovery. and myo-
cardial blush grades. Enzymatic infarct size, LVEF, and long-tenn mOltality at 1.9±1.7 years after 
the event are shown in Table 4. 
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Table 4. 
Enzymatic Infarct Size, LVEF, and MOltality 
Myocardial Blush Grade 
3 2 Oil Tl1,nd Analysis 
P 
LDHQ72 757±582 1143±879 1623±1147 <0.0001 
LVEF, % 50±10 46±11 39±12 <0.0001 
Mortality, % 3 6 23 <0.0001 
LDHQ72 indicates enzymatic infarct size from serial lactate dehydrogenase measurements up to 72 hours after angioplasty. 
LVEF was measured by predischarge radionuclide ventriculography; lolal mortality was assessed after a follow-up of 1.9 ± 
1.7 years. 
Enzymatic infarct size could be measured in 659 patients (85%). LVEF measurements were obtai-
ned for 584 patients (75%). There was a relation between myocardial blush grade, infarct size, 
and LVEF: the higher the blush grade, the lower the infarct size and the better the LVEF. During 
follow-up, 81 patients died (10%). There was also an inverse relation between myocardial blush 
grades and long-term mortality. In 566 patients, TIMI flow, myocardial blush grade, enzymatic 
infarct size, and LVEF were known. Multivariate analysis showed that the myocardial blush grade 
predicted mortality, independent of other-well known variables associated with long-term outco-
me aner myocardial infarction, such as age and Killip class (Table 5). 
Table 5. 
Multivariate Analysis for 566 Patients With Available TIMI Flow, Myocardial Blush Grade, 
Enzymatic Infarct Size and LVEF 
Odds Ratio 95% CI P 
Age (per class) 2.6 1,4-5,4 0.003 
Killip class (per class) 3.6 1.5 - 8.5 0.004 
Myocardial blush grade (per class) 2.6 1.2 - 5,4 0.01 
LDHQ72 (per class) 1.8 1.0-3.3 0.05 
Multivessel disease 2.0 0.8 - 4.8 0.12 
Anterior infarction 0.6 0.2 - 1.5 0.23 
Female sex 1.8 0.7 - 4.5 0.24 
TIMI flow before PA (per class) 1.7 0.6 - 5.1 0.33 
LVEF (per class) 1.3 0.7 - 2,4 0,44 
Diabetes 1,4 0.5 - 3.8 0,47 
TIMI flow after PA (per class) 0.8 0,4 - 1.8 0.81 
Ischemic time (per class) l.l 0.6 - 1.8 0.81 
Previous infarction 1.0 0.3 - 2.9 0.95 
CI indicates confidence interval; LDHQ72, enzymatic infarct size from serial lactate dehydrogenase measurements up to 72 
hours after angioplasly; and PA, primary coronary angioplasty. Ischemic time was measured from symptom onset to first 
balloon inflation. 
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Discussion 
The principle finding of our study is, that in patients after primary angioplasty for acute infarc-
tion, myocardial pelfusion, as described by the myocardial blush grade, is reflected by the reso-
lution of ST-elevations on the l2-lead ECG; the extent of damage to the infarcted myocardium, 
as evident from enzymatic infarct size; and radionuclide ventriculography, and is independently 
related to long-term mortality. The myocardial blush grade can therefore be used as a prcdictor 
of clinical outcome. 
Myocardial PeJillsiol/ 
We previously described the relation between myocardial flow reserve assessed by densitome-
tric analyses of contrast-medium passage in the infarcted myocardium, and left ventricular func-
tion (19). However, this semiquantitative method has several pitfalls and limitations and may not 
be applicable in routine clinical practice (20). Several studies have shown that myocardial per-
fusion can be assessed visually with intracoronary injection of sonicated lnicrobubbles dming 
echocardiography in the catheterization laboratory. This technique has been used to describe the 
effectiveness of myocardial reperfusion and predict clinical outcome (8,9). Myocardial contrast 
echocardiography can be used to categorize patients as having reflow or no-reflow, and it has 
been shown that even in the presence of TIM! 3 flow in the epicardial coronary artery, a patient 
may have no-reflow into the myocardium (21). Because the venous phase of the coronary angio-
gram is often clearly visible in patients with no-reflow, the echocardiographic or angiographic 
contrast agent passes from the arterial coronary vessels into the venous system by another route 
than the myocardial microcirculation in the infarct zone. We developed the angiographic myo-
cardial blush grade based on the visually assessed contrast density in the infarcted myocardium 
after reperfusion therapy. The angiographic myocardial blush grades are analogous to the TIM! 
grades for flow in the epicardial infarct-related coronary artery. Tilis information can be obtai-
ned during routine high- quality coronat)' angiography and can be used to describe the effecti-
veness of reperfusion therapies. 
The pathophysiology of the ,wore flow phel/omel/ol/ 
Coronary occlusion leads to cellulat· necrosis and myocardial damage. During a short period of 
occlusion, a variable amount of myocytes may become necrotic while the microvascular net-
work is still intact. If coronary occlusion is prolonged, the microvasculature shows loss of its 
anatomic integrity (9,22). At the time of coronary reopening, myocardial repelfusion is achieved 
only in areas with anatomically preserved microvasculature, whereas reflow does not occur in 
myocardium with extensive microvascular damage. The no-reflow phenomenon is therefore 
associated with relatively more extensive necrosis and, as a consequence, is a predictor of poor 
regional and global contractile function (8,9). Contrariwise, adequate myocardial reflow shortly 
after epicardial coronary repelfusion is an accurate indication of nlicrovascular integrity and 
consequently, of regional and overall functional recovery in patients with acute myocardial 
infarction (9,19). 
Comparison of myocardial billsh grades with TIMI flolV grades 
Myocardial blush grade was related to TIM! flow. However, from Table 3, it is clear that the 
majority of patients with myocardial blush grade < 2 had "nonnal" TIMI flow. The patients with 
TIMI 3 flow but low blush grades can be regarded as having no-reflow in a comparable way as 
patients who lack myocardial contrast on their echocardiogram after intracoronary injection of 
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sonicated micro bubbles (8,9). A recent study from our group showed that a substantial number 
of patients with TIMI 3 flow have persistent ST-segment elevation on the post-angioplasty EeG, 
suggesting impairment of myocardial reperfusion (14). A further differentiation amongst patients 
with TIMI 3 flow is, therefore, needed and of clinical relevance. Multivariate logistic regression 
analyses showed that the myocardial blush grade was related to long-term mortality independent 
of TIMI flow. Therefore, an angiographic variable that takes the extent of myocardial reperfu-
sion into account is of additional prognostic value. Figure 2 shows Kaplan-Meier curves and log-
rank analysis for TIMI and myocardial blush grade, and it illustrates that survival in patients with 
TillI 3 flow is not as high as survival in patients who have a high blush grade of the myocar-
dium after primary angioplasty. Furthermore, it shows that myocardial blush grading might iden-
tify a much larger population at risk for adverse outcomes: n~236 (30%) with blush grades 0-1 
versus n~87 (II %) with TIMI flow 0-2. 
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Kaplan Meier survival curves for 777 patients with known TIMI flow and myocardial blush grades. Myocardial blush grade 
o or 1 indicates no or minimal blush or contrast density of myocardium supplied by infarct-related vessel on post angio-
piasty angiogram. Blush grade 2 indicates moderate blush or contrast density, and blush grade 3 indicates normal blush or 
contrast density, comparable with blush obtained during angiography of contralateral or ipsilateral non-infarct-relatcd coro-
nary artery. TIM! flow is defined as previously described (3). Cum. Survival indicates cumulative survi\'al. 
Limitations 
The inter-observer and intra-observer vmiabilities associated with subjective angiographic 
assessments are certainly a limitation of the myocardial blush grades and are comparable with 
the variabilities in TIMI flow grades for epicardial cOl'Onmy blood flow (3,23). 
Implications 
Early and sustained restoration of flow into the infarcted myocardium is the aim of reperfusion 
therapies for acute myocardial infarction. Angiographic studies of reperfusion therapies should 
assess myocm'dial pClfusion as well as flow in the epicardial infarct-related coronaty artelY. A 
new standard for success of reperfusion therapy has been proposed: "90% TIMI 3 flolV at 90 
minutes" (24). We think that the future standard should include the phrase, "with evidence of 
adequate myocardial reperfusion". 
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Summary 
Background: Although the benefits of primary angioplasty in acute myocardial infarction have 
been demonstrated, several areas for improvement still remain. Therefore, a prospective rando-
mized trial comparing primary stenting with balloon angioplasty in patients with acute myocar-
dial infarction was conducted. 
Methods and Results: Patients with acute myocardial infarction were randomly assigned to 
undergo either primary stenting (n=112) or balloon angioplasty (n=115). The clinical endpoints 
were death, reCUlTent infarction, subsequent bypass surgery or repeat angioplasty of the infarct-
related vessel. The overall mortality rate at 6 months was 2%. Recurrent infarction occuned in 
8 patients (7%) after balloon angioplasty, and in one (I %) after stenting (p=0.036). Subsequent 
target vessel revascularization was necessary in 19 (17%) and 4 (4%) patients, respectively 
(p=0.0016). The cardiac event-free survival rate in the stent group was significantly higher than 
in the balloon angioplasty group (95% vs 80%; p=0.012). 
Conclusion: In selected patients with acute myocardial infarction, primary stenting can be 
applied safely and effectively, resulting in a lower incidence of recunent infarction and a signi-
ficant reduction in the need for subsequent target vessel revascularization, when compared to 
balloon angioplasty. 
(Circulation, 1998;97:2502-2505) 
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Introduction 
Primmy angioplasty in acute myocardial infarction (M1) has been shown to result in lower rates 
of mortality, reCUlTent MI and stroke, when compared to thrombolysis [1-3). However, reCUl1'ent 
ischemia and early reocclusion of the infarct-related vessel (lRV) occurs in 10 to 15%, after ini-
tially successful angioplasty. \Vhereas late restenosis (25 to 45%), requiring repeat revasculariza-
tion in the first 6 months, remains disappointingly high (1-3). Although coronary stenting may 
potentially overcome some of major limitations of balloon angioplasty (4,5), cUlTently available 
data on stenting in acute MI have been obtained from non-randomized trials or from retrospecti-
ve analysis of patients undergoing stenting as a bail-out procedure (6-13). Therefore, a prospec-
tive randomized trial comparing stenting with balloon angioplasty in acute MI was conducted. 
Methods 
The protocol was approved by our institutional review board. The inclusion criteria were: 
patients with acute Ml, presenting within 6 hours after symptom-onset, or between 6 and 24 
hours if they had persisting symptoms with evidence of on-going ischemia, and in whom the cul-
prit lesion was located in a native coronary artery that was considered suitable for stenting. The 
clinical exclusion criteria were: inability to give informed consent due to prolonged cardiopul-
monary rescusitation or cardiogenic shock (Killip class 4 at admission requiting Inechanical 
ventilation), participation in another study, life expectancy of less than one year, factors making 
follow-up unlikely, and known sensitivity to Aspirin, Ticlopidine, or Wmfarin. History of pre-
vious coronary bypass surgery, coronary angioplasty, or previous MI were no reasons for exclu-
sion. The decision to include a patient was made after the IRV was identified and reperfusion 
was achieved with a guidewire and a balloon. The angiographic exclusion critetia were: unpro-
tected left main disease or severe triple vessel disease necessitating urgent bypass surgelY, tar-
get lesion located in a bifurcation with a large side branch or located in a diffuse sclerotic IRV, 
excessive proximal vessel tortuosity, inability to cross the target lesion with a guide wire, the no-
reflow phenomenon or extensive tln'ombus throughout the IRV. After informed consent, patients 
were randomized to undergo primary stenting or balloon angioplasty by means of a closed enve-
lope system. 
Bare Palmaz-Schatz stents (Cordis, a Jollllson & Jolmson company, Wal1'en, NJ, USA) were 
mounted on the balloon used for predilatation. If necessary, high-pressure inflation was perfor-
med with a bigger sized balloon. Angiographic success, subacute occlusion, and bail-out sten-
ting were defined as previously described (5). Prolonged inflation had to be attempted before 
bail-out stenting was considered. Bail-out stenting did not constitute an endpoint, as it is percei-
ved as an integral part of an angioplasty strategy. Quantitative coronary angiography was analy-
zed by an independent core laboratory (Cardialysis, Rotterdam, The Netherlands), blinded to all 
clinical data and outcome. 
The initial post-stenting regimen was as follows: Heparin infusion was started 2 hours after she-
ath removal and continued until the International Normalised Ratio values had reached the the-
rapeutic levels. Coumadin was given for at least 3 months and Aspirin (80mg daily) indefinitely. 
However, as it became clear that Ticlopidine is more effective in preventing stent thrombosis 
(14), and the fact that anticoagulation therapy increases the tisk of major bleeding complications 
(4,5), our post-stenting regimen protocol has been modified accordingly. From January 1996, 
only Ticlopidine (250mg daily for at least 2 weeks) and Aspirin were given after stenting, and 
Coumadin derivates were no longer used. Heparin infusion (1mglkglhour) or subcutaneous low 
molecular weight Heparin (0.6cc b.i.d.) was given for 48 hours after sheath removal in all 
patients, regm'dless of initial treatment allocation. Thrombolytic therapy, platelet glycoprotein 
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IIblIIIa receptor-antagonists, or intravascular ultrasound were not used. 
Clinical endpoints were: death of any cause, reCUlTent MI, subsequent bypass surgety or repeat 
angioplasty of the TRY. Recurrent MI was defined as previously described (I). The indication for 
a second intervention had to be substantiated by symptoms an(Vor by electrocardiographic or 
scintigraphic evidence of ischemia at rest or during exercise. Subsequent revascularization 
involving other coronary arteries did not constitute an endpoint. All events wcre reviewed by 2 
cardiologists blinded to the treatment assigIllnents. 
Using an anticipated two-sided test for differences in independent binomial proportions at the 
5% significance level with a power of 90%,211 patients (105 in each group) were required to 
detect a reduction in a composite end point from 35% to 16%. Data were analyzed using a sin-
gle comparison between the groups according to the intention-to-treat principle. Continuous 
variables were expressed as means ± SD and compared using the Student's t-test, whereas dis-
crete variables wcre given as absolute values and percentages. The Chi-square test was used to 
compare proportions, or a Fisher's exact test when appropriate. The differences in event rates 
between the groups, dllling the follow-up period, were assessed by the Kaplan-Meier method 
using the log rank test. Multivariate analysis was performed using the Cox proportional hazard 
method, permitting calculation of odds ratios that may be interpreted as relative risks with 95% 
confidence intervals. All statistical tests were two-tailed. 
Table 1. 
Reasons for exclusion in candidates for primary angioplasty (n~225) 
n % 
Clinical exclusion criteria: 
Prolonged cardiopulmonary resclisitation or cardiogenic shock 19 8 
Factors making follow-up unlikely 7 3 
Life expectancy < I year 3 I 
Angiograpbic exclusion criteria: 
Small IRY « 3.0 nun) 77 34 
Diffuse sclerotic TRY 47 21 
Target lesion involving a major side branch 25 II 
No-reflow phenomenon or extensive thrombus throughout IRY 17 8 
Left main or severe 3-vessel disease necessitating subsequent surgery 13 6 
Excessive proximal vessel tortllosity 12 5 
Inability to cross target lesion with a guide wire 5 2 
IRV = infarct-related vessel 
Results 
From June 1995 to March 1997, a total of 532 patients with acute MI have been admitted to our 
institution, of whom, 498 patients underwent immediate coronruy angiography. One patient died 
before angiography could be petformed; wlrile in 12 patients, involved in another trial, and in 21 
patients, presenting more than 24 hours after symptom-onset, coronruy angiography was not per-
formed. From those 498 patients undergoing coronary angiography, 25 patients with a small patent 
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IRV were treated conservatively, and 21 with severe triple vessel disease were referred for imme-
diate bypass surgery. The remaining 452 patients did undergo pIimmy angioplasty. Of these, 225 
were excluded from the tIial for various reasons (Table I) and 227 eligible patients were randomi-
zed to undergo primary stenting (n=1I2) or balloon mrgioplasty (n=1I5). Most of randomized 
patients, 89 (79%) in the stent group and 92 (80%) in the balloon angioplasty group, were recmited 
in the trial after the protocol amendment and the modified post-stenting regimen was adopted. The 
baseline characteristics and in-hospital outcome are listed in Table 2, and are compm·ed to those 
excluded from the trial. 
Table 2. 
Baseline chm·acteristics and in-hospital events 
Randomized 
Stent Balloon Excluded 
(n - 112) P-value (n-115) (n-225) 
Age (yr) 59 ± 11 ns 57 ± 11 60 ± 12 
Male 93 (83%) ns 98 (85%) 173 (77%) 
Previous infarction 15 (13%) ns 15 (13%) 40 (18%) 
Previous bypass surgery/angioplasty 17 (15%) ns 13 (11 %) 21 (9%) 
Multivessel disease 49 (44%) ns 51 (44%) 138 (61 %)* 
Killip class 4 3 (3%) ns 2 (2%) 15 (7%)t 
Symptom-onset to admission (min) 217 ± 222 ns 211 ± 242 236 ± 228 
Admission to reperfusion (min) 62 ± 82 ns 62 ± 63 74 ± 122 
IRV: - Left main or vein graft 0 ns 0 4 (2%) 
- Left anterior descending 66 (59%) ns 70 (61 %) 116 (52%) 
- Right coronary artery 34 (30%) ns 35 (30%) 70(31%) 
- Circumflex 12(11%) ns 10 (9%) 35 (16%) 
Mean balloon size (mm) 3.36 ± 0.34 0.011 3.25 ± 0.28 2.97 ± 0.48* 
Mean balloon/artery ratio 1.08±0.12 ns 1.09 ± 0.15 -
Maximal inflation pressure Catm) 13.2 ± 2.4 0.0001 11.6 ± 2.5 -
Angiographic success 110 (98%) ns 110 (96%) 200 (89%)'1 
Subacute occlusion 1(1%) ns 5 (4%) 14 (6%) 
Cross-over (Bail-out) 2 (2%) 0.0016 15 (13%) 17 (8%) 
Intra-aortic balloon pumping 17 (15%) ns 8 (7%) 64 (28%)* 
Nlajor bleeding complication 7 (6%) ns 3 (3%) 12 (5%) 
Peak creatine-kinase (UlL) 1880 ± 1752 ns 1743 ± 1495 1634± 1681 
Radionuclide ejection fraction (%) 44 ± 10 ns 45 ± II 44 ± 13 
Mean hospital stay (day) 5.3 ± 3.9 ns 4.8 ± 4.4 8.9 ± 9.8* 
In-hospital death 2 (2%) ns 3 (3%) 16 (7%)t 
Recurrent infarction I (1%) ns 5 (4%) 15 (7%)t 
IRV=infarct-rclated vessel; P-values are between the two randomized groups;"p<O.OOO2 and tp<O.05 between patients ran-
domized and those excluded from the trial;Plus-minus values are means ± standard deviations. 
Subacute occlusion occurred in 5 patients allocated to balloon angioplasty: at the smne day of the 
initial procedure in 4 and at day 9 in one. Repeat angioplasty followed by stenting was performed 
in al( patients. but 4 had a recunent :rvII. Only one stent patient had subacute occlusion and recunent 
NIl at day 4, and underwent bypass surgely. Quantitative angiographic results are shown in Table 3. 
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Table 3. 
Quantitative angiographic results 
Stent Balloon 
(n = 112) (n = 115) P-value 
Minimal luminal diameter (mm): Pre 0.23 ± 0.45 0.35 ± 0.54 0.1 
Post 2.57 ± 0.37* 2.17 ± 0.45* < 0.0001 
Reference diameter (mm): Pre 3.06 ± 0.56 3.05 ± 0.56 0.35 
Post 3.15 ± 0.46 3.14 ± 0.66 0.16 
Diameter stenosis (%): Pre 92.1 ± 15.1 88.6 ± 17.4 0.14 
Post 17.9 ± 6.8* 28.8 ± 9.1 * < 0.0001 
*p < 0.0001 Post YS Pre procedure. Plus~minus values are means ± standard deviations. 
Figure I sholVs the clinical outcome at 6 month. There were only 5 deaths (2%). ReClllTent MI occu-
lTed in one patient after stenting and in 8 after balloon angioplasty (p=0.036). Subsequent target ves-
sel revascularization was necessary in 4 and 19 patients, respectively (p=0.0016). Consequently, the 
cardiac event-free survival rate of 95% in the stent group was significantly higher than that of 80% 
in the balloon angioplasty group (p=0.OOI2). 
Figure 1. 
Clinical outcome at 6 month in both study groups 
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Figure 2 shows the Kaplan-Meier survival curves in both groups. No patient was lost dming follow-
up. Non-target vessel revascularization lVas pelformed in 6 (5%) and 4 (3%) patients, respectively. 
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Figure 2. 
SlIn'jval without l'ecul'l'ent MI (%) 
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Kaplan-!\'Ieier cardiac event-free survival curves in both study groups during the 6 months follow-up period.The left panel 
represents patients without d~ath or recurrent myocardial infarction ~n), and the right panel represents those without any-
cardiac events (death, recurrent 1U, or subsequent target vessel revasclilarization). 
Table 4 shows the multivariate analysis of predictors of cardiac events in all patients, regardless of 
treatment allocation. 
Table 4. 
Multivariate analysis of predictors of adverse cardiac events 
Relative Risk 95% CI 
Allocated to balloon angioplasty 3.2 1.2 - 8.5 
Male gender 4.9 1.1-22.5 
Age (per year) 1.03 0.99 - 1.07 
Diabetes 1.4 0.3 - 6.6 
Killip class >2 at admission 2.9 l.l - 7.7 
Left anterior descending artery 0.7 0.3 - 1.5 
Residual minimal luminal diameter < 2mm 2.0 0.8 - 4.8 
Reference diameter < 3mm 2.3 0.9 - 5.8 
Cardiac event was defined as: any death, recurrent infarction, or subsequent target vessel revascularization; CI = confiden-
ce interval. 
Discussion 
The present trial indicates, for the first time in a prospective ,randomized manner, that primary 
stenting can be applied safely and effectively in selected patients with acute MI, resulting in a 
significant reduction in recurrent MI and subsequent target vessel revascularization, when com-
pared to balloon angioplasty. 
However, the major limitation of the present trial is the fact that the results were obtained from 
a single high-volume centre, involving a limited number of patients, and might be biased by the 
selection of those patients who were in relatively stable hemodynamic condition and in whom 
the IRV was considered to be technically and anatOlnieally ideal for stenting. In fact, tltis limi-
tation prevented at least half of patients, deemed suitable for primary angioplasty, from being 
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randomized. Therefore, the results may not be generalizable to all patients with acute NIl. To 
address this limitation, in our currently on-going trial, all patients with acute MI are now rando-
mized before coronary angiography. 
Although the mortality rate (2%) was comparable to our previous lrial (I). no difference could 
be observed belween Ihe groups. In facl, it would be unlikely that stenting could furlher reduce 
the low mortality rate achieved by balloon angioplasty. To determine the predictors of adverse 
events, multivariate analysis was pelfofmed by combining both study groups. Male gender, 
Killip class >2, and treatment with balloon angioplasty were associated with an increased risk of 
adverse cardiac event (Table 4). As most patients excluded from the trial had more complex 
coronary anatomy, multi vessel disease, Killip class 4, and an intra-aortic balloon pump was 
more often needed, the initial success was lower when compared to the study population (Table 
2). All of Ihese may have contributed to the higher rates of death, reCUll'ent MI, and subsequent 
target vessel revascularization, as well as a longer hospital stay. Despite this fact, the mortality 
rate in patients excluded from our study compares favorably with patients treated with throm-
bolytic therapy (1-3). Although the mean diameler stenosis after stenling of 17.9% seems to be 
relatively high for a low incidence of tmget vessel revascularization (4%), this is still lower than 
Ihal of 22% reported in patients with slable angina (5). In addilion, palienls selecled for this lrial 
had a bigger vessel size, with post-stenting reference diameter of 3.15 mm, when compared to 
other randomized lrials (4,5). Most of randomized patients (80%) were included afler our posl-
stenling regimen was modified. This has led to less bleeding complications and a shorter hospi-
tal slay, when compared to earlier reports (4,5). In fact, all bleeding complications occurred in the 
beginning of our trial, before this strategy was adopted and aggressive anticoagulation was used. 
This protocol amendment was supported by studies reporting stenting in acute NIl without con~ 
ventional anticoagulalion (6,7). Finally, Ihe implicalions of Ihe present sludy wilh respecllo cosl 
effectiveness require a formal analysis, which will be performed after one year of follow-up. 
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Sir- The role of stenting for acute myocardial infarction (AMI) has been investigated in rando-
mised trials (I). Preliminary results seem promising. and stenting may overcome some of the 
limitations of primary angioplasty therapy for AMI (2). We have recently completed the initial 
phase of a randomised trial of stenting versus balloon angioplasty for AMI (3). On theoretical 
grounds, stenting may be cost-effective in various settings (4), but so far there are no published 
data available on the actual costs and cost-effectiveness of stenting for AMI. 
Table 1. 
Costs per patient (Dfl) of coronary stenting versus balloon angioplasty for acute myocardial 
infarction. 
Balloon Stellt 
In-hospital costs (N=115) (N=II2) 
Hospital stay 5000 5400 
Angioplasties 9000 9000 
Stents 365 2304 
Additional balloons 104 161 
IABP 196 349 
Re-PTCA 500 103 
CABG 157 161 
Total costs 15322 17508 
Follow-up at 1 year 
Balloon Stent 
Re-MI 443 45 
Follow-up angiogram 1739 2033 
Re-PTCA 1607 412 
CABG 2996 1420 
Costs Follow-Up 6785 3910 
re-MI:::recurrent myocardial infarction, IABP-=intra-aortic balloon pumping, PTCA:::percutaneous coronary angioplasty, 
CABG:::coronary bypass surgery. All costs are per patient. 
We have now completed 12 months follow-up in our randomised trial, including initial in-hos-
pital and follow-up costs. We calculated costs by counting the numbers of hospital days and pro-
cedures, as previously descIibed (5). Results are shown in the table. Our data show that, at least 
in the setting of a Dutch (non-academic) hospital with an existing infrastructure for angioplasty 
and stenting, there is no difference in costs after 1 year between balloon angioplasty and sten-
ting for AMI. Although the initial in-hospital costs of stenting are higher, this is compensated by 
the lower costs during follow-up which makes stenting a good investment. 
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Summary 
Aillls. Intra-aortic balloon pumping (IABP) reduces afterload and Illay be effective in improving 
reperfusion in high risk infarct patients treated with priInm)' angioplasty. 
Methods. High risk infarct patients referred from other centres for primary PTCA were rando-
mised to treatment with or without IABP. The primary end point consisted of the combination 
of death, non-fatal re-infarction, stroke or an ejection fraction < 30% at 6 month follow-up. A 
weighted unsatisfactor), outcome score (as previously described by Braullwald), enzymatic 
infarct size and left ventricular ejection fraction were secondm), end points. 
Results. During a 3.5 year period, 238 patients were randomised, 118 to IABP therapy and 120 
to no IABP therapy. Major complications occurred in 8% of patients who were treated with 
IABP. None of the outcome measures were significantly different between the treatment groups. 
Conclusion. Systematic use of intra-aortic balloon pumping after primm)' angioplasty does not 
lead to myocardial salvage or to a better clinical outcome in high risk infarct patients. Use of 
intra-aortic balloon pumping after primary PTCA for acute myocardial infarction should be 
reserved for patients with severe hemodynamic compromise. 
(Submitted for publication) 
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Introduction 
Primary angioplasty has been shown to be an effective reperfusion strategy for patients with 
evolving myocardial infarction (1,2). TIMI 3 flow of the infarct-related vessel is obtained in the 
large majority of patients and the reocclusion rate is low compared to patients treated with 
thrombolytic therapy (3). However, in a substantial minority of patients ST-segment elevation 
persists after primary angioplasty, despite restored flow of the infarct-related epicardial vessel, 
suggesting impaired myocardial reflow (4). This occurs especially in patients with large anterior 
infarction, and in other high risk patients. Intra-aortic balloon pumping results in afterload reduc-
tion and an increase in diastolic coronary flow (5). Therefore, its use in the setting of acute myo-
cardial infarction might be beneficial. Previous reports showed that intra-aortic balloon pumping 
after repcrfusion therapy prevented reocclusion of the infarct vessel. However, it did not affect 
left ventricular function, and did not prevent hemodynamic deterioration (6-8). We conducted a 
randomised trial to evaluate the value of systematic use of intra-aortic balloon pumping in high 
risk myocardial infarct patients treated with primary coronary angioplasty. 
Methods 
RalldomisatioJl aJld sh'atificatioJl 
All high risk patients who were transferred to the Weezenlanden hospital for treatment with pri-
mary or rescue angioplasty were considered for entry into the study. SpecifIC inclusion criteria 
were: I) arrival in the hospital within 3 hours after start of symptoms, 2) age younger than 70 
years, 3) anterior infarct location or non-anterior infarction with cumulative ST-segment devia-
tion of more than 20 111m. Patients were randomised prior to angiography and angioplasty and 
were allocated to either intra-aortic balloon pumping or no intra-aortic balloon pumping. For 
patients who were allocated to standard treatment but who had signs of cardiogenic shock (pul-
monary wedge pressure> 18 mm Hg, systolic hypotension < 90 mm Hg and/or mixed venous 
blood oxygen saturation < 65%), cross-over to balloon pumping lVas prespecified. 
CO/'OI/my al/giography {ll/d coral/my {ll/gioplasty 
All patients were treated with 300 mg intravenous acetylsalicylic acid and intravenous nitrogly-
cerin in a dose to maintain a systolic blood pressure of around 110 tlllll Hg. Intravenous heparin 
was given in a bolus of 10000 U and thereafter in a continuous infusion in a dosage to keep the 
activated partial thromboplastin time between 2 and 3 times the norillal value for at least 2 days. 
Coronary angiography and angioplasty lVas performed using standard techniques. Flow through 
the infarct-related vessel was scored according to the Thrombolysis in Myocardial Infarction 
(TIMI) classification. Data of the coronary angiography and angioplasty procedures were collec-
ted and graded by two of the investigators. Consensus on collateral flow, procedural success, 
TIMI flow before and after the angioplasty procedure, identification of the infarct-related ves-
sel, and extent of coronary artery disease was reached in all cases. TIMI flow before angioplasty 
was judged at first injection of contrast agent. 
Defil/itiolls 
Successful PTCA lVas defined as a visually assessed <50% residual stenosis and TIMI grade 3 
flow. Recull'ent myocardial infarction was defined as chest pain, changes in the ST-T segment at 
rest, and a second increase in the creati-ne kinase level to more than two times the upper limit of 
normal, or an increase of more than 200 U per litre over the previous value if the level had not 
dropped below the upper limit of normal. M(\jor bleeding was defined as requirement of blood 
transfusion during hospitalisation. Heart failure was defined as Killip class 2 to 4 heart failure. 
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II/tra-aortic ballool/ pl/mpil/g 
The intra-aortic balloon pump (Datascope) was inserted via the femoral route after replacement 
of the 7 or 8 French sheath, used for angiography or PTCA, by a 12 French sheath. Aortic coun-
terpulsation was continued for 48 hours. In case of limb ischemia or major hemOlThage at the 
access site the IABP was removed earlier. 
Statistical al/alysis 
The primary end point was defined as the combined incidence of death, reinfarction, stroke or 
an ejection fraction less than 30% at 6 months follow-up. The trial was designed to detect a 
reduction in the ptimary end point from 30% to 15%. With 80% power and a~.05 it was esti-
mated that 266 patients were required. Differences between group means were tested by a two-
tailed Student t test. A chi-square method was used to test differences between proportions. The 
Fisher exact test was used if there was an expected cell value < 5. Statistical significance was 
defined as a P value < 0.05. In the presentation of the data, continuous variables are given as 
mean value ± SD, whereas discrete variables are given as absolute values and percentages. 
Analysis was performed on an intention-to-treat basis. A secondary end point was the weighted 
unsatisfactory outcome score of different clinical and angiographic end points, previously des-
cribed by Braunwald (9). Each patient is assigned a score that represents the single most serious 
outcome. TillS score included death, stroke, heart failure, ejection fraction <30%, reinfarction, 
reocclusion of the infarct related vessel, or major hemorrhage. Additional secondary endpoints 
were enzymatic infarct size and left ventricular ejection fraction at 6 month follow-up. 
EI/zymatic Illfarct Size 
The methodology for estimation of infarct size has been descdbed previously (10). In brief, 
infarct size was estimated by measurements of enzyme activities using lactate dehydrogenase 
(LDH) as the reference enzyme. Cumulative enzyme release from five to seven serial measu-
rements up to 72 hours after symptom onset (LDHQ72) was calculated. A two-compartment 
model was used, which has been validated in several studies on the turnover of radio-labelled 
plasma proteins and circulating enzymes (11). 
Left Velltriclll((r FIIl/ctiol/ 
Left ventricular ejection fraction was measu-red with a radio-nuclide technique at 6 month follow-
up. 11le technique used in our hospital has been des-ed-bed previ-ously (4). Bdefly, it involved the 
multiple-gated equilibrium method after the labelling of red blood cells with (99mTc) pertechne-
tate. A gamma camera (General Electtic, Milwaukee) with a low-energy, all purpose, parallel-hole 
collimator was used. The global ejection fraction is calculated automatically by computer (Star 
View, General-Electric), with the PAGE ™ program. The data on ejection fractions were gathered 
by a specialist in nuclear medicine, who was blinded to the clinical data. 
Results 
In October 1996, after evaluation of the in-hospital results of 238 included patients, the trial was 
stopped. Our results, in combination with the results of a similar randomised trial (12), made it 
very unlikely that a clinically relevant difference would be obtained in favoun' of intra-aortic 
balloon pumping. Patient recl1litment for the trial is described in Figure 1. 
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Figure 1. 
Flow chart 
N=751 inclusion Zwolle Infarction Trial (April 1993 - October 1996) 
r N",," """~,,,,,.,,",, ,.,',"" 
N=275 transferred from other centres ~ N=512 IABP when indicated 
/ r No," ,N" "" mw '''''''0'' ", ... ,,,' "'Be N'o' 
N=238 randomized 
Between April 1993 and October 1996, 751 patients were candidates for performing primary 
angioplasty according to the inclusion criteria of the Zwolle Infarction Trial (I). Two hundred 
and seventy-five patients (37%) were transferred from other centres. From these, 37 patients 
(13%) did not meet inclusion criteria for entry into the JABP trial. These patients had non-ante-
rior infarctions and less than 20 mm of cumulative ST segment elevation and were transferred 
because of contra-indication(s) for thrombolytic therapy. The remaining 238 patients form the 
basis of this report. 
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Table 1. 
Baseline and angiographic characteristics 
IABP P No IABP 
(N=1l8) value (N=120) 
Age 59±1O 0.04 56±1l 
Male gender 99 (84%) 0.95 lOl (84%) 
Allterior infarction 102 (86%) 0.96 104 (87%) 
Killip class 
I 88 (75%) 90 (75%) 
2 16 (14%) 15 (13%) 
3 5 (4%) 5 (4%) 
4 9 (8%) 0.89 10 (8%) 
Diabetes 12 (10%) 0.47 9 (8%) 
Previolls infarction 17 (14%) 0.81 16(13%) 
Multi vessel disease 70 (59%) 0.35 64 (53%) 
IRV 
LAD 100 (85%) 99 (83%) 
CX 3 (2%) 4 (3%) 
RCA 12 (10%) 15 (13%) 
graft 1(1%) I (1%) 
Left tvlain 2 (2%) 0.82 1(1%) 
Primary CABO 3 (3%) 7 (6%) 
Conservative therapy 4 (3%) 9 (8%) 
Rescue angioplasty 16 (14%) 23 (19%) 
Primary angioplasty 95(81%) 0.15 81 (68%) 
Successful angioplasty 103 (87%) 0.61 102 (85%) 
IABP =: Intraaortic balloon pump, IRV =: Infarct related vessel, LAD = Left anterior desccnding artery, ex = Circumflex 
artery, RCA = Right coronary artery, CAllG = Coronary artery bypass surgcry, Th\U = Thrombolysis In 1\'1yocardiallnfarc-
lion 
One hundred and eighteen patients were allocatcd to IABP and 120 to standard therapy. The 
baseline clinical and angiographic characteristics are described in Table I and were not different 
between the 2 groups, apart from a higher age of patients in the IABP group. Fifty patients (21 %) 
had received previous thrombolytic therapy in the referring hospital. After immediate angio~ 
graphy 13 patients (5%) were treated conservatively because of non-significant stenosis of the 
infarct related vessel and TIM I 3 flow. Ten patients (4%) underwent primary coronary bypass 
surgery because of significant left main disease or severe triple vessel disease. Cross-over occu-
rred in both treatment arms. In the no-IABP group, 37 patients (31 %) did receive an IABP. Four-
teen patients had severe left main or 3-vessel disease, 2 patients had inadequate reflow after 
angioplasty, and in 21 patients hemodynamic instability was the reason for cross-over. In the 
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group assigned to IABP 30 patients (25%) did not receive an lABP, because of peripheral ves-
sel disease (8), IABP device unavailability (9), patient refusal (2), physician preference (4), or 
relative contraindications for the device (7). 
The primary end point, the combination of death, recurrent myocardial infarction, stroke or an 
ejection fraction less than 40% at 6 month follow-up, occurred in 31 (26%) patients assigned to 
IABP and in 31 (26%) patients assigned to the no-IABP group (p=0.94)(Table 2). Calculation of 
LDHQ72 was performed in 163 (68%) patients and was not significantly different between both 
groups. The left ventricular ejection fraction was measured at discharge in 127 (53%) patients 
and at 6 months follow-up in 168 patients (80% of patients alive). No difference in ejection frac-
tion was found in both groups of patients. 
Table 2, 
Enzymatic infarct size, left ventticular function and clinical outcome 
IABP P NoIABP 
(N=118) value (N=120) 
IABP 89 (75%) 37 (31%) 
LDHQ72 (N=163) 1616 (1148) 0.96 1608 (1163) 
EF pre discharge (N=127) 39 (12) 0.21 36 (13) 
EF Follow Up (N=168) 42 (13) 0.51 40 (14) 
re-PTCA 24 (20% 0.70 22(18%) 
CABG 17 (14%) 0.63 20 (17%) 
re-MI 7 (6%) 0.16 3 (3%) 
stroke 1(1%) 1.00 I (I %) 
major bleeding* 10 (8%) 0.78 9 (8%) 
heart failure 10 (8%) 0.41 14(12%) 
death 12 (10%) 0.47 9 (8%) 
primary end point** 31 (26%) 0.94 31 (26%) 
WUO-score= 0.23 (0.36) 0.79 0.24 (0.36) 
IABP::: Intra-aortic balloon pump, LDHQ72 ::: Enzymatic infarct size, calculated as release of Lactate Dehydrogenase in 72 
hours, EF::: Ejection Fraction, PTCA = Percutaneous tnlOsluminal coronary angioplasty, CABG ::: Coronary artery bypass 
grafting. ~H ::: Myocardial infarction, IRV ::: Infarct related vessel, "'bleeding during admission requiring transfusion, ** 
combination of death, non-fatal reinfarctioll, stroke or an ejction fraction<30% at 6 months follOW-lip. =WUO: Weighted 
Unsatisfactory Outcome score as defined by Braunwald (9) 
The results of the weighted unsatisfactory-outcome score are described in Table 3. Patients 
assigned to IABP had a score of 0.23 (0.36). This was 0.24 (0.36) for patients assigned to the 
no-IABP group (p=0.79). 
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Table 3. 
Weighted UnsatisfactOly-Outcome end point, 6 months after randomization 
Event Score IABP No IABP 
(N=1l8) (N=120) 
1. Death 1.0 12 9 
2. Intracranial hemorrhage with severe 1.0 I 0 
permanent nuerological deficit 
3. Development of severe, sustained 0.8 2 10 
CHF or cardiogenic shock 
4. Ejection li'action < 30% * 0.6 16 13 
5. Reinfarction 0.5 2 2 
6. Occlusion or reocclusion of IRV at 0.4 I 2 
FU angiography 
7. Major hemOlThagc requiring 0.3 3 4 
blood transfusion or intracranial 
hemolThage without severe or 
permanent neurological deficit 
None of the above 0.0 81 80 
IABP = Intra-Aortic Balloon Pumping, CHF = Congestive Heart Failure, IRV = Infarct Related Vessel, FU = Follow Up, »< 
determined by radionuclide technique at 6 months follow-up. The mean score of IABP assigned patients was 0.23 (0.36). 
The mean score of patients not assigned to IABP was 0.24 (0.36), p=0.79. 
Complicatiolls of IABP 
A total of 126 patients were treated with intra-aortic balloon pumping. The mean duration of intm-
aOltic balloon pumping was 56 hours (range 14-216). Serions complications occUlTed in 10 patients 
(8%). In 4 patients the device had to be removed within 48 hours because oflimb ischemia or hemOlT-
hagic complications. Another 2 patients developed a large groin hematoma after removal of the she-
ath for which surgical intervention was necessruy. Four patients had symptoms of infection at 52, 96, 
126 and 192 hours (with positive tip and blood cultures) for which the device was removed. 
DisclIssion 
In this study frequent use of intra-aortic balloon pumping in high risk myocardial infarct patients 
(70% of patients) did not lead to salvage of myocardium or to a better clinical outcome when 
compared to elective use in 30% of patients. Enzymatic infarct size and left ventriculru' ejection 
fraction did not differ between both patient groups. Only patients, in whom the time between 
onset of symptoms and arrival in our hospital was less than 3 hours, were included, because it 
was hypothesised that insertion of an IABP might lead to myocardial salvage in this group of 
high risk infarct patients who presented early. However, this was not found. Although a number 
of other studies have addressed the value of intra-aortic balloon pumping in high risk infarct 
patients, no improvement in clinical outcome has consistently been found. Most of these studies 
were non-randomised (5-8), however. Two randomised trials have been published. One study in 
182 consecutive infarct patients, found a higher patency rate of the infarct-related vessel in the 
IABP group at 5- to I O-day follow-up angiography (92% vs 79% TIMI 2/3 110w, p<0.05), toget-
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her with a significant reduction in the composite clinical end point of death, stroke, reinfarctiol1, 
recurrent ischemia or repeat revascularization (13). A recent study showed that only thromboly-
tic treated patients benefit from intra-aortic balloon pumping, compared to patients treated with 
primary angioplasty (14). As the study of Ohman et al (13) mainly included patients who had 
undergone rescue PTCA for failed thrombolysis, this may be the explanation for the beneficial 
results for patients allocated to IABP therapy in this study. A more recently conducted randomi-
sed trial, comprising 437 high lisk patients, all treated with primary coronary angioplasty, did 
not find a reduction in the primary end point of death, stroke, recurrent infarction, reocclusion 
or heart failure (15). The cutTent trial confirmed these results and found no benefit of prophy-
lactic intra-aortic balloon pumping after primary angioplasty for acute myocardial infarction in 
high lisk patients. The primary end point was not different between patients allocated and not 
allocated to the device. Moreover 8% of patients had complications dne to the inseltion of the 
IABP. This complication rate is lower compared to a report of 1993 from our group, ill which 
selious complications occurred ill 16% of 200 consecutive patients treated with IABP (16). 
However, these patients had different clinical characteristics. 
During the study period, 512 patients were not eligible for the study (Figure 1). From these, 95 
patients (21 %) were treated with intra-aortic balloon pumping because of severe left main or tri-
ple vessel disease, failed reperfusion or cardiogeruc shock. Baseline characteristics and outcome 
are described in Table 4. 
Table 4. 
Comparison of baseline characteristics and outcome of patients who received an intra-aortic 
balloon pump on indication compared to patients randomised to IABP. 
IABP P Randomized 
on indication value to IABP 
(N=95) (N=Il8) 
Age 61 (Il) 0.14 59 (10) 
Male gender 74 (78%) 0.26 99 (84%) 
Multi vessel disease 66 (69%) 0.13 70 (59%) 
Anterior infarction 52 (55%) <0.0001 102 (86%) 
Killip class 1 56 (59%) 0.02 88 (75%) 
Open IRV before A 3 (3%) 0.003 18 (15%) 
Primary angioplasty 80 (84%) 0.48 95 (81 %) 
T1M13 flow 78 (80%) 0.19 103 (87%) 
re-PTCA Il (12%) 0.09 24 (20%) 
CABG 30 (32%) 0.003 17 (14%) 
re-MI 4 (4%) 0.57 7 (6%) 
stroke I (1%) 0.88 1 (1%) 
m'\ior bleeding* 15 (16%) 0.10 10 (8%) 
death 12 (13%) 0.57 12 (10%) 
IRV = Infarct related vessel, A = Angioplasty, LDHQ72 = Enzymatic infarct size, calculated as release of Lactate Dchy-
drogcnase ill 72 hours, EF = Ejection Fraction, PTCA = Percutaneous translurninal coronary angioplasty, CABO = Coro-
nary artery bypass grafting, ?ton = lvIyocardial infarction, *bleeding during admission requiring transfusion 
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The patients who received an IABP after the angioplasty procedure on indication, were of a hig-
her risk category compared to the patients who were part of the randomised trial (systematic 
IABP use based on clinical high risk criteria): they were older, were in a higher Killip class on 
admission, less often had a successful angioplasty procedure and had a highe!' rate of bleeding 
complications. Despite this, mortality at 6 months follow-up (13%) was not significantly higher 
and compares favourable to previous reports in similar patients, with mortality rates of 15% and 
40% (8,14,17). Tltis low mortality ntight be atttibuted to the intra-aortic balloon pump, wltich 
has been shown to be of value in patients with cardiogenic shock (15), but might also be related 
to the high rate of repeat revascularization witltin 6 months. In 49% of IABP treated patients (411 
83 patients alive) a second revascularization procedure was pelfonned within 6 months, either 
a re-PTCA because of restenosis or an additional revascularization becuase of severe triple ves-
sel disease and inducible ischemia. 
Limitations 
The main lintitation of this randomised study is the fact that in a substantial ntinOlity (25%) of 
patients assigned to IABP therapy, the device was not inserted. This might be related to the fact that 
randomisation was done prior to angiography and therefore the operator was not infOlmed about the 
coronruy and peripheral vessel status of the patient. Also it shows that in clinical practice, a number 
of patients, in which an intra-aortic balloon pump is indicated on hemodynamic grounds, might not 
receive the device, mainly because of peripheral vessel disease and device unavailability. 
The older age in the patients allocated to IABP therapy may underestimate the effect of IABP 
therapy, however, it is unlikely that tIllS influenced outcome in a significant manner. 
Tltis study was designed to include 266 patients. After inclusion of 90% of the patients, the study 
was stopped. However, it is unlikely that the primary or secondary end point would be benefi-
cial for IABP treated patients after inclusion of all 266 patients. 
Conclusion 
The systematic use of intra-aortic balloon pumping after primary angioplasty for acute myocar-
dial infarction in high risk patients does not affect infarct size or left ventricular function and 
does not lead to a better clinical outcome when compared to elective use of the IABP. 
The use of an intra-aortic balloon pump in patients after primary angioplasty should be reserved 
for patients with hemodynantic instability. 
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Summary 
Objectives. We sought to compare primary coronmy angioplasty and thrombolysis as treatment 
for low risk patients with an acute myocardial infarction. 
Background. Primary coronmy angioplasty is the most effective reperfusion therapy for 
patients \vith acute myocardial infarction; however, intravenous thrombolysis is easier to apply, 
more widely available and possible more appropriate in low risk patients. 
IVlethods. We stratified 240 patients with acute myocardial infarction at admission according to 
risk. Low risk patients (n=95) were randomized to primmy angioplasty or thrombolytic therapy. 
The primary end point was death. nonfatal stroke or reinfarction during 6 months of follow-up. 
Left ventricular ejection fraction and medical charges were secondary end points. High risk 
patients (n=145) were treated with ptimary angioplasty. 
Results. In low risk patients, the incidence of the primary clinical end point (4% vs. 20%, p < 
0.02) was lower in the group with primary coronary angioplasty than in the group with throm-
bolysis. because of a higher rate of reinfarction in the latter group. Mortality and stroke rates 
were low in both treatment groups. There were no differences in left ventricular ejection frac-
tion or total medical charges. High risk patients had a 14% incidence rate of the primary clini-
cal end point. 
Conclusions. Simple clinical data can be used to risk-stratify patients during the initial admis-
sion for myocardial infarction. Even in low risk patients, primary coronary angioplasty results 
in a better clinical outcome at 6 months than does thrombolysis and does not increase total medi-
cal charges. 
(J Alii Call COl'dioI1997;29:908-12) 
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Introduction 
Primmy angioplasty, defined as angioplasty for acute myocardial infarction without prior or 
concomitant thrombolytic therapy, results in a higher patency rate of the infarct-related vessel, 
smaller enzymatic infarct size, better preserved left ventricular function and better clinical out-
come when compared with intravenous thrombolytic therapy (1-4). However, the logistic bur-
den of offering primmy angioplasty to all patients with acute myocardial infarction is conside-
rable (5-12). Previous studies (1,7,13) have shown that the increased benefit of primary angio-
plasty over that of thrombolytic therapy has been found in particular in high risk patients but is 
less certain in low risk patients. Therefore, we randomized patients at low risk to thrombolytic 
therapy or primary angioplasty. Several retrospective analyses (1,7,14-17) have shown that sim-
ple clinical and electrocardiographic CECG) variables, assessed during initial presentation, can 
be used to stratify patients with acute myocardial infarction according to risk. We describe the 
clinical outcome and cost-effectiveness of primary angioplasty versus thrombolysis in low risk 
patients and compare these findings with those in a concomitant series of patients at high risk of 
untoward events. 
Methods 
Study patients: Inclusion criteria were symptoms of myocardial infarction for> 30 min, within 6 
h of symptom onset or between 6 and 24 h if there were signs and symptoms of ongoing ische-
mia with> 0.1 mV ST segment elevation in more than two leads. No specific exclusion criteria 
were used. Only patients with a life expectancy of < 6 months or conditions resulting in severe 
impainnent of quality of life were excluded. Oral informed consent was obtained from all 
patients. The trial was approved by the committee on ethics and research at our institute. During 
the emollment period, 17 patients who fulfilled the entry criteria did not participate in the study 
because of patient refusal or preference of the patient or physician, or both, for a specific therapy. 
Sample size: Assuming an incidence rate of death and nonfatal stroke of 3% and nonfatal rein-
farction of 12% after 6 months of follow-up (17-22) for low risk patients treated with throm-
bolytic therapy, and a 0.4 relative risk of the primary clinical end point (death, nonfatal stroke 
or reinfarction), a sample size of 296 low risk patients was calculated (one-sided alpha level of 
0.05, and a power of 80%), with an expected total of> 500 patients in the trial. Interim analysis 
was planned after inclusion of 150 patients. 
Statistical analysis 
All end points were analyzed according to the intention to treat principle. Results are expressed 
as absolute numbers and mean values + SD. Differences between group means were tested by 
unpaired Student's t-test. A chi-square method or Fisher exact test was lIsed to test differences bet-
ween proportions. Statistical significance was defined as a p value < 0.05. 
Randoll/ization and sh'ati!icatioll 
Between May 1993 and April 1995,240 patients were considered for tlus trial. All patients were 
classified as at high or low risk. Patients were regarded as at high risk if one of the following 
criteria were present: 1. contraindications for tlnull1bolytic therapy (14,16), 2. Killip class> 2 
(1,13),3. EeG evidence of anterior ,vall infarction or evidence of extensive nonanterior infarc-
tion defined as eight or more leads with > 0.1 m Volt ST elevation or depression. or both 
O,13,l7). All high risk patients underwent immediate coronary angiography and were treated 
with primary angioplasty if the coronary anatomy was suitable. The low risk patients were ran-
domly allocated by telephone to either primary angioplasty or intravenous streptokinase, after 
they gave informed consent. 
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Treatmellt 
All patients received heparin intravenously and aspirin. Beta-adrenergic blocking agents were 
given unless contraindicated. All patients with clinical signs of heart failure or a left ventricular 
ejection fraction < 40% received angiotensin-converting enzyme inhibitors. Allgioplasty was 
performed by standard techniques. Angioplasty success was defined as a residual lesion of < 
50% in the infarct-related vessel, with Thrombolysis in Myocardial Infarction (TIMI) grade 3 
flow. Thrombolytic therapy consisted of 1.5 million m of streptokinase. Patients given throm-
bolytic therapy had coronary angiography between day 3 and day 7, or immediately if symptoms 
and signs of rectll1'ent ischemia appeared. Patients treated with primary angioplasty underwent 
follow-up coronary angiography 3 and 6 months after angioplasty. Additional revascularization 
procedures were pelformed for left main and extensive triple-vessel coronary artelY disease 
depending on coronmy anatomy. In patients with less extensive coronary artelY disease, revas-
cularization during follow-up depended on angina and noninvasive evidence of myocardial 
ischemia. 
Primmy elld poillt 
This was defined as death, nonfatal stroke or reinfarction at 6 months. All patients with possible 
or suspected stroke were revie\ved by a neurologist and underwent a computed tomography 
scan. Reinfarction was defined as a second episode of chest pain of> 30 min with a second cre-
atine kinase (CK) rise to more than two times the upper limit of normal, or an increase of> 200 
UlHter over the previous value if the level had not dropped below the upper limit of normal, and 
either concomitant ST-T wave changes or new Q-waves (3). 
Secolldm), elld poillts 
The two secondary end points were left ventricular ejection fraction and total medical charges at 
6 months. 1. Left ventricular ejection fraction was measured with a radionuclide technique at day 
5 and at 6 months. The multigated equilibrium method was used after in vivo labeling of red 
cells with 99m-Tc-pertechnetate (3) using a gamma camera (General Electdc) with a low energy, 
all purpose, parallel-hole collimator. Global ejection fraction was calculated automatically by 
computer (Star View, General Electric) with the PAGEnf program. The data on ejection fraction 
were analyzed by a nuclear medicine specialist who had no knowledge of the clinical data. 
2. Total medical charges at 6 months were calculated by using estimates of unit costs concerning 
all aspects of medical care, as previous descdbed (23-25). In the Dutch medical system the 
patient pays the charges of the hospital and those of independent physicians and the pharmacy; 
health insurance covers almost all of these expenses. Charges were considered from the pers-
pective of the patient. Tllis methodology has been descdbed (25). 
Results 
After complete evaluation of the first 150 patients (26), and after consultation with the institu-
te's committee on ethics and research, a decision was made to stop the trial. Of these 150 
patients, 73 were at low risk and were randomized to primary angioplasly or streptokinase. The 
interim results indicated that primary coronary angioplasty in low risk patients facilitated early 
discharge and did not result in higher medical charges (27). Subsequently, a general policy of 
primaty coronalY angioplasty was adopted. At completion of the trial a total of 240 patients had 
been enrolled. 
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Table 1. 
Baseline Clinical and Angiographic Characteristics 
Low Risk Group High Risk Group 
(n = 95) 
Angioplasty Thrombolysis 
(n=45) (n=50) (n= 145) 
Age (years) 63+11 59+12 62+12 
Male 80% 74% 74% 
Previous MI 18% 20% 15% 
Anterior M1 0% 0% 63% 
Killip class> 2 0% 0% 28% 
c.1. for tln"Ombolysis 0% 0% 8% 
Infarct related vessel 
LMCA 0% 0% 3% 
LAD 0% 0% 54% 
RCA 85% 92% 30% 
LCx 13% 8% 10% 
Graft 2% 0% 2% 
Multivessel disease 71% 50% 57% 
C.l. :=: contraindications, multi vessel disease wa.~ defined as at least one 50% lesion in a major noninfarct-related coronar), 
<lrtery. Data are presented as mean value + SD or percent of patients. LAD=left anterior descending coronar), artery; LCx=left 
circumflex coronary arteI)'; UvlCA=left main coronary arteI)'; ~H=myocardial infarction; RCA=right coronary artcI)'. 
Baseline clinical and angiographic characteristics arc shown in Table I. In the low risk group 
randomized to angioplasty the proportion of patients with multi vessel disease was higher than in 
the thrombolysis group; otherwise, the patient groups were well matched. The design of the trial 
resulted in a high proportion of low risk patients with the right coronary artery as the infarct-
related vessel, whereas the left anterior descending coronary artery was usually the infarct-rela-
ted vessel in the high risk patients. 
Of the total of 240 patients, 95 (39%) were considered at low risk; 50 of the 95 patients were 
randomized to tln'ombolytic therapy and received this treatment. The time from hospital admis-
sion to start of the streptokinase infusion was 29±17 min. Forty-five patients were randomized 
to primary coronary angioplasty, and all underwent immediate coronary angiography that was 
followed by primary angioplasty in 92% with procedural success in 93%. The time from hospi-
tal admission to the first balloon inflation was 68±21 min. In three patients a conservative ini-
tial strategy was followed as spontaneous reperfusion of the infarct-related vessel was evident 
on the angiogram; one patient with left main coronary artery disease had emergency coronary 
artery bypass grafting. DUling the 6-month follow-up period, 13% of the low risk patients under-
went bypass grafting for triple- vessel or left main coronary artery disease. 
Of the total of 240 patients, 145 (61 %) had one or more of the high risk characteristics. High risk 
patients with one high risk characteristic (n= Ill) had a 10% incidence of the pdmary clinical 
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end point; those with more than one high risk charactelistic (n=34) had a 29% incidence. Addi-
tional revascularization procedures and clinical outcome at 6 months are shown in Table 2. 
Table 2. 
Results at 6 months 
Low Risk Group High Risk 
(n = 95) Group 
Angioplasty Thrombolysis 
(n=45) p-value* (n=50) (n = 145) 
Revascularization 
Procedures 
CABG 6 (13%) I 7 (14%) 23 (16%) 
(re)PTCA 9 (20%) <0.001 30 (60)% 20 (14%) 
Clinical Outcome 
Death I (2%) 0.47 0(0%) 16(11%) 
Stroke 1(2%) I 2 (4%) 0(0%) 
Reinfarction 0(0%) <0.01 8 (16%) 4 (3%) 
Primary End point** 2 (4%) <0.02 10 (20%) 20 (14%) 
*Comparing the angioplasty and thrombolysis low risk group. "''''Defined as death. nonfatal stroke or reinfarction within 6 
months, Data arc presented as number (%) of patients. CABG=coronary artery bypass grafting; (re)PTCA= initial or rcpe-
at percutaneous trallsluminal coronary angioplasty, 
Primary end point: The primary end point of death, nonfatal stroke or reinfarction was reached 
in 4% of low risk patients randomized to angioplasty in contrast to 20% in low risk patients ran-
domized to thrombolytic therapy (relative risk 0.19, 95% confidence interval 0.04-0.90, p < 
0.02). Only one low risk patient (1%) died from cardiac l1lpture (at the age of 75 years, 5 days 
after failed primary coronary Hngioplasty). Three patients had an ischemic stroke, 5, 7 and 14 
days, respectively, after the acute event, and none of these strokes were related to the initial the-
rapy. There were no strokes due to intracerebral hemolThage. Eight of the low risk patients ran-
domized to streptokinase had a reinfarction. All of these patients were readmitted to the coro-
nary care unit, had ST-T abnormalities and CK elevation, and six of these eight had new Q 
waves. Five of the eight reinfarctions occUlTed within the 1st week after randomization. There 
were no reinfm'ctions in low risk patients randomized to primary angioplasty. The incidence of 
the primary clinical end point is lower in high risk patients treated with primary angioplasty 
(14%) than in the low risk patients assigned to thrombolysis, primarily because of a lower rein-
farction rate in the high risk group. 
Secondat)1 end points: Left ventricular ejection fraction was measured in 93 (98%) of the 95 low 
risk patients and in 116 (80%) of the 145 high risk patients. At 6 months left ventricular ejection 
fraction in the low risk angioplasty group was 51±9% and 48±10% in the thrombolysis group 
(p=O.II). It was lower in the high risk group (43±11 %). 
Total medical charges at 6 months were lower in the low than in the high risk group. There was 
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no difference in total charges/patient or total charges/survivor between the two low risk groups, 
although the charges/ event-free survivor were lower in the angioplasty group (Table 3). 
Table 3, 
Total Medical Charges in Dutch Guilders 
Low Risk Group High Risk 
(n = 95) Group 
Angioplasty Thrombolysis 
(n=45) (n=50) (n = 145) 
All patients 22.808 22.437 29.467 
Survivors 23,327 22.895 33.122 
Event-free sm"vivors 23.869 28.765 34.182 
Charges were calculated as previously described (23-25). 
Discussion 
Previous studies (1-7) have shown that primary coronary angioplasty offers certain advantages 
over thrombolytic therapy. High risk patients treated with primary angioplasty have a lower mor-
tality rate and a lower risk of intracranial hemorrhage. Our study shows that 10\\' risk patients 
benefit in terms of a lower risk of reinfarction, without an increase in total medical charges. 
During long-term follow-up, nonfatal reinfarction has been shown (28) to have independent 
prognostic information. 
Stl'eptokillase The Global Utilization of Streptokinase and TPA for Occluded arteries (GUSTO) 
data (29,30) have shown that thrombolytic therapy with front-loaded tissue plasminogen activa-
tor is more effective than therapy with streptokinase, with a higher 90-min patency rate and a 
lower mortality rate. However, in low risk patients the cost-effectiveness of tissue plasminogen 
activator is less than that of streptokinase (31,32). The main advantage of primary angioplasty 
over thrombolysis in low risk patients is the lesser risk of reinfarction. In this regard the choice 
of tln'ombolytic agent is irrelevant. A detailed analysis of the Gmppo Italiano per 10 Studio della 
Sopravvivenza nell'jnfarto Miocardico II (GISSI-2) working group has illustrated the difficul-
ties in predicting reinfarction, but they did not find a difference between these two thrombolytic 
agents in the rate of reinfarction (33). There is a small difference in the risk of stroke between 
these two drugs in favor of streptokinase (34). Finally, the benefits of pIimary angioplasty over 
thrombolytic therapy exceed the survival advantage of one thrombolytic agent over the other by 
an order of magnitude. 
Risk sh'aHjicaHolI Many retrospective analyses (13-17) have shown that patients with acute 
myocardial infarction can be stratified with regard to risk on the basis of clinical and ECG data 
available on initial presentation. Our data confirm that patients classilled as low risk do have a 
low risk for untoward events up to 6 months, with a mortality rate of only 1 %. With our criteria 
only 40% of patients were considered to be at low risk, a lower proportion than we anticipated. 
Tn particular, patients with contraindications for thrombolytic therapy and patients in higher 
Killip classes are often excluded from reperfusion trials, whereas in ollr trial almost all patients 
with acute ST segment elevation myocardial infarction were included. The most important limi-
tation of risk stratification during acute myocardial infmction is the inability to predict recurrent 
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myocardial infarction (7,33). Angiographic studies have documented a reocclusion rate of the 
infarct-related coronary m"tery in up to 30% of the patients after successful thrombolytic therapy 
(19,20), whereas reocclusion following primary angioplasty is rare (4,35). A recent overview 
(22) confirms that recurrent myocardial ischemia and reinfarction are less frequent after primary 
angioplasty than after thrombolytic therapy. 
Study lill/itatious Only a limited number of patients were included in our trial. It is therefore pos-
sible that certain less pronounced differences between angioplasty and thrombolytic therapy in 
low risk patients do not show up in our results, and the confidence intervals of the relative risk 
reduction are wide. Therefore, although we found that the risk of reinfarction is lower after pri-
mary angioplasty, the magnitude of this effect is not clear. The diagnosis of reinfarction can be 
difficult early after reperfusion therapy for acutc myocardial infarction. For this reason we requi-
red a second episode of chest pain with ST-T segment changes and enzymatic confirmation befo-
re this diagnosis was made, and most of these patients had new Q waves. Although another stra-
tegy may also prevent recurrcnt infarction -thrombolysis followed by angiography and inter-
vention a few days later, as has recently been suggested by the DANish Trial in Acute Myocar-
dial Infarction (DANAMI) study (36)- many reinfarctions occur early and can therefore not be 
prevented by this approach. 
Couelusiolls alld clillical ill/plicatiolls Simple clinical data, readily available during the 1st 15 
min of hospital admission for acute myocardial infarction, can be used to stratify patients accor-
ding to risk, and the results can be incorporated in the therapeutic strategy. Even in patients with 
a low risk of adverse events, primary coronary angioplasty results in a better clinical outcome, 
in particular a lower reinfarction rate, at 6 months than does thrombolytic therapyand it docs not 
cause an increase in total medical charges. In hospitals with an existing infrastnlcture for inter-
ventional cardiology all patients with symptoms of acute myocardial infarction and ST segment 
elevation should be offered immediate coronary angiography and primary coronary angioplasty. 
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Abstract 
Objective - To investigated the feasibility of primary coronary angioplasty as a treatment option 
in patients with acute myocardial infarction after initial diagnosis in a local cOIlllllunity hospital. 
Setti1lg - Referral centre for interventional treatment of coronary artery disease. 
iWetllOds - During a five yem' period, 520 candidates for primary coronary angioplasty were tre-
ated in our institution, 104 after transfer from a community hospital. The transferred and the 
non-transferred patients (N=416) were compared with regard to baseline clinical characteristics, 
time intervals from symptom onset to treatment, and clinical outcome at six months. 
Results - In this setting, the influence of transportation on total ischaemic time was limited, and 
there was no difference in clinical outcome between the transferred and the non-transferred 
patients. Clinical outcome was mainly dependent on the indication for transfer. 
COllclusi01ls - Safe and expedient transportation may facilitate the more widespread use of pri-
mary angioplasty in patients with acute myocardial infarction. A large randomised multicentre 
trial is needed to compare the relative merits of intravenous thrombolytic treatment in a local 
hospital with primary angioplasty after transfer in selected high risk patients with acute myo-
cardial infarction. 
(Heart 1997;78:333-336) 
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Introduction 
Several rHlldomised hials have recently shown that primary coronary angioplasty -defined as 
angioplasty performed on the infarct related vessel - during the early hours of acute myocardial 
infarction, without the use of thrombolytic agents, offers certain advantages over intravenous 
thrombolytic therapy (l-4). Rapid and sustained patency of thc infarct related vessel is obtained 
in most patients, resulting in a lower mortality and less reinfarction without exposing them to 
the bleeding risks associated with thrombolytic treatment (5). The mqior limitation of primary 
angioplasty as first line treatment of acute myocardial infarction is its restricted availability. 
Even in Europe and North America, most hospitals do not have facilities for coronary angio-
plasty. For paticnts admitted to a hospital without angioplasty facilities this implies transporta-
tion to a hospital with interventional cardiology services. The time loss and the risks associated 
with transportation might negate (part of) the bcnefits of primary angioplasty compared to 
thrombolytic treatment. To compare intravenous thrombolytic treatment in a local facility with 
primary coronary angioplasty after transportation to a referral centre for interventional treatment 
of coronary artery disease, a multicentre randomised trial is cunently planned in The Nether-
lands. This trial will enroll selected high risk patients with acute myocardial infarction with a 
substantial risk of adverse clinical events. 
To investigate the feasibility, safety and logistic implications of the emergency transportation of 
these categories of patients we performed a retrospective analysis of all patients who underwent 
such a procedure in our institution. To put the clinical outcome of these transfened patients into 
perspective, we made a comparison with the primary angioplasty patients admitted directly to 
our hospital, although it is clear that the baseline characteristics of these two groups of patients 
arc different. However, at present more appropriate data for comparison are not available. 
Methods 
The Weezenlanden Hospital is a referral centre for interventional treatment of cardiac diseases. 
Four interventional cardiologists perform 1600 coronary angioplasties per year and fOUf thora-
cic surgeons perform 1400 cardiac surgical procedures per year. In our referral area, we and 14 
other hospitals serve a population of 1.4 million. Transportation from most refelTal hospitals to 
our hospital is possible within 40 minutes, as the ambulance services are well organised and coo-
perative, and are used to working in close collaboration with coronary care units and catheteri-
sation laboratories. Transportation of patients for elective and urgent coronary angioplasty pro-
cedures for stable and unstable angina are daily routine. Traffic congestion is rare in our part of 
The Netherlands. During the night and weekend an interventional cardiologist and catheterisa-
tion staff are on call. There are two catheterisation laboratories. There is 24 hours surgical back-
up. When a telephone call is received from a referring physician during the daily programme, it 
is always possible to have one of the two rooms prepared the moment the patient arrives in our 
hospital. The transported patients are accompanied by well trained paramedics of the ambulan-
ce services. In cases of marked haemodynamic or electrical instability, a physician from the refe-
rring hospital travels with the patient. 
Patiellts 
Between August 1990 and April 1995, 729 patients with symptoms of acute myocardial infarc-
tion and ST segment elevation on at least 2 contiguous electrocardiographic leads presented to 
or were referred to our institution. Of the patients who presented directly to our hospital, 87% 
participated in one of our trials (l,2,4,6). Thrombolytic treatment was given to 205 patients and 
520 were candidates for primary angioplasty. Of these 520 patients, 416 presented directly to our 
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hospital, and 104 patients were initially admitted to another hospital without a catheterisation 
laboratory or angioplasty expertise and were transferred by ambulance for immediate angio~ 
graphy with a view to primary angioplasty after an initial diagnosis of acute myocardial infarc-
tion has been made at the local facility. When the decision to transfer was made, the patient was 
included in this analysis, inespective of whether primary angioplasty was actually performed. 
None of the transported patients participated in one of our reported trials( I ,2,4,6) as the decision 
to go for primary angioplasty had already been made and communicated to the patient as well 
as to relatives by the refelTing physician. Transferred patients were directed immediately 
towards the cardiac catheterisation laboratory to avoid additional delay resulting from a second 
assessment in an emergency room or coronary care unit. 
Illdic{(tiollS for trallsfer 
In all the 14 hospitals that transferred these patients, thrombolysis is the first choice reperfusion 
therapy for acute myocardial infarction. Predefined indications for transfer for primary coronary 
angioplasty were: contraindications to thrombolytic treatment, with electrocardiographic evi-
dence of a large myocardial territory at risk (31 %); Killip class 3 or 4 (14%); and anterior wall 
infarctions with 2 mV cumulative ST segment elevation (67%). 
i.l1aill Outcome jl1easlIl'es 
Time of symptom onset, times of hospital admission, and transfer time, defined as time betwe-
en first and second hospital admission, were recorded. Clinical end points, defined as previously 
described (1). and additionall'evascularisation procedures were assessed, at 6 months to compa-
re the transferred and the non-transferred patients. 
Statistics 
Data are expressed as mean ±SD. Categorical data were analysed by Fisher's exact test or the 
Chi-Square test. Continuous variables were analysed by the unpaired Student's t-test. A p value 
of < 0.05 was considered statistically significant. 
Results 
Illitial therapy {(lid clillical characteristics 
One patient with cardiogenic shock died during transportation and one patient in the non-trans-
ferred group died in the emergency room shortly after admission. Coronary angiography was 
performed in all other patients (n=518), Primary angioplasty lVas performed in 486 patients 
(94%) with a procedural success rate, defined as previously described (4) of 97%. A conservati-
ve approach was followed in 23 patients (4.4%) and 9 patients (1.7%) had emergency coronmy 
artery bypass grafting without an attempt at angioplasty. Baseline characteristics of the 2 patients 
groups are shown in table I. 
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Table 1. 
Baseline characteristics and initial therapy 
Non-transferred Transferred 
(n=416) p (n = 104) 
Age (yr) 61 ± II NS 59 ±- II 
Male (%) 78 NS 77 
Prior MI (%) 19 NS 22 
Anterior MI (%) 42 <0.001 67 
Killip class 3 or 4 (%) 6 <0.05 12 
CI for tln'ombolysis (%) 13 <0.001 31 
Multivessel disease (%) 60 NS 59 
Initial treatment 
Primary angioplasty (%) 93 NS 98 
Conservative approach (%) 4 NS I 
Emergency CABG (%) 3 NS I 
r..n, myocardial infarction; el, contraindication; CABG. coronary artery bypass grafting 
Complications in the transferred patients during coronary angiography and angioplasty occurred 
in 15 (14.4%) cases. Two patients died during the procedure in cardiogenic shock, despite exten-
sive resuscitation efforts. Six patients needed defibrillation and one needed a temporary pace-
maker for third degree atrioventricular block. :r..1ajor dissections occurred in 5 patients and were 
managed by bail-out stenting (3 patients) or, in the presence of severe triple vessel disease by 
coronary artery bypass grafting (2 patients). Two patients had allergic skin reactions and hyper-
tension probably due to the contrast agent. ]n the transferred patients, hospital mortality was 
6.7%, in-hospital reinfarction occurred in 2.9% of patients, and additional revascularisation pro-
cedures were performed in 17.3%. Four patients underwent a second angioplasty procedure -in 
2 of them because of signs of reocclusion- and 14 patients had coronary artery bypass grafting 
for triple vessel or left main disease. 
Trallspol'tatioll alld time delays 
One patient died during transportation (l %). This patient lVas ah'eady in profound cardiogenie 
shock before being transported. Dnring transportation 10 patients (9.6%) were in eardiogenic 
shock. All were on inotropic support. One patient needed mechanical ventilation before trans-
portation, and one additional patient was intubated during transport. In addition to the 14 patients 
who were in Killip class 3 or 4 before transportation, 2 patients required treatment for hypoten-
sion (fluid expansion and intravenous dobutamine). Ventricular tachycardia occurred in 1 patient 
and was treated with intravenous lidocaine. 1\\'0 patients were defibrillated for ventricular fibri-
llation during transportation. No other adverse events occurred during or as a result of transpor-
tation. Travel distances of the transferred patients were < 25 km in 61 %, between 25 and 50 km 
in 30%, and> 50 km in 9%. The time from symptom onset to first balloon inflation in the 2 
groups of patients is shown in table 2. 
- 99 -
TrallSferring Patients for Primm)' Angioplasty 
Table 2. 
Time between symptom-onset and first balloon inflation 
Non-transfel1'ed Transferred 
Hours % % 
0-2 II 6 
2-4 52 52 
4-6 22 20 
>6 15 22 
As patient delay (7) is the predominant determinant of time to treatment in patients treated after 
6 hours, the detailed analysis of time delays shown in table 3 is restricted to patients treated wit-
hin 6 hours. Differences in baseline characteristics (table I) may be responsible for the shorter 
time from symptom onset to initial hospital presentation of the transferred patients (table 3), as 
sicker patients tend to call for help earlier after symptom onset. 
Table 3. 
Time delays of patients treated within 6 hours. 
Non-transferred Tmnsfcrred 
(n = 416) (n = 104) 
symptom-onset to hospital admission 129 (± 69) 91 (± 60) 
admission local community 
hospital-admission WZL 70 (± 27) 
admission WZL-first balloon inflation of 
primary coronary angioplasty procedure 67 (± 28) 39 (± 31) 
Total ischemic time 196 (± 74) 200 (± 62) 
All times are in minutes (±SD); WZL, hospital De Weezenlanden. 
An additional 28 minutes is gained back from the time lost during transfer by rapid in-hospital 
transfer to the catheterisation laboratory. As a result of these differences, the time delay betwe-
en Hrst and second hospital admission is not reflected in the comparable total ischaemic periods 
of 196 and 200 minutes in the two groups of patients, as shown in table 3. 
Clillical Olltcollle 
Clinical outcome at 6 months is shown in table 4. The high percentage of patients in the trans-
ferred group with baseline characteristics known to be associated with a higher risk of untoward 
events (8-10) results in a somewhat higher incidence of rev3scularisation procedures, non-fatal 
reCUlTent infarction, and death, although none of these differences reach statistical significance. 
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Table 4. 
Clinical outcome at 6 months 
Non-transfened Transferred 
(n = 416) I' (n = 104) 
% % 
Re-PTCA 12.5 NS 12.5 
CABG 13.7 NS 17.3 
Rc-MI 2.6 NS 3.8 
Death 6.7 NS 8.7 
Re-PTCA, repeated percutaneous transluminal coronary angioplasty; CABO, coronary artery bypass grafting; Re-111, recu-
rrent myocardial infarction. 
Discussion 
Outcome after myocardial infarction can be improved by prompt reperfusion of the infarct rela-
ted coronary artery. Primary coronary angioplasty and thrombolysis are complementary methods 
of reperfusion treatment and both strategies are still evolving. Angioplasty equipment and tech-
luque (stents?), improved dosing regimens and new dl1lgs for thrombolysis, and improved 
adjunctive treatment such as antithrombin and anti platelet agents for both types of treatment are 
ongoing developments that can be expected to improve outcome further, and will influence the 
balance between these methods of of treatment, along with economic and logistic issues. Emer-
ging data support a role for primary coronary angioplasty, where it is available and accessible, 
but the extent and limitations of this role require further clarification (II-IS) At this moment the 
large majority of patients with an acute myocardial infarction is admitted to hospitals without a 
catheterisation laboratory or angioplasty expertise. even in Europe and North America. Tills 
means that additional transportation, with inherent risks and time delay, will be necessary for 
many patients if a strategy of primary coronary angioplasty is introduced into clliucal practice. 
Several trials are currently being prepared to compare optimal thrombolytic treatment at a local 
hospital. or even prehospital thrombolysis, with primary coronary angioplasty after transfer to a 
hospital with intcrventional cardiology. Although not yet based on evidence from randonused 
trials, transfer of selected patients may be appropriate if the benefits of primary angioplasty are 
likely to outweigh the risk of transportation and the negative impact of the additional time delay. 
Patients with contraindications for thrombolytic treatment and a large myocardial territory at 
risk. patients with extensive anterior wall infarctions and those with clear evidence of hae-
modynamic instability during the early hours of infarction may benefit from this approach. 
Emergency interhospital transport of patients during the early hours of acute myocardial infarc-
tion has been described to be feasible and safe (19,20). However. in these previous reports 
patients usually had thrombolytic treatment before transportation to a tertiary facility for coro-
nary angiography. Mortality and morbidity during transportation were low but the additional 
time delay averaged more than 2 hours, resulting in al1'ival in the catheterisation laboratory 
around 6 hours after symptom onset. In particular, if myocardial salvage is one of the goals of 
the therapeutic strategy then the time to repeIiusion is crucial. In contrast with these previous 
reports(l9.20) in our setting a large proportion of patients is treated within the time frame that 
makes myocardial salvage possible, as 5S% of transfelTed patients had a first balloon inflation 
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within 4 hours and 78% within 6 hours after symptom onset. As primmy coronary angioplasty 
results in a patency rate -defined as TIM! 3 flow (4) - of more than 90%, in theory this would 
be better than thrombolytic treatment at a local facility (21) in particular if less than I hour is 
lost in transfer. This is a strong argument in favour of a large multicentre study. 
Limitations 
It should be recognised that the transferred patients were selected for this treatment by the refe-
ITing physicians on the basis of limited available information, usually consisting of a (short) his-
tory, the most pertinent findings from physical examination, and a 12-lead electrocardiogram. 
Although no patients were transfened who did not fulfil one of our predefined indications, we 
do not know how many patients who fulfIlled these criteria were not transferred, as we have no 
systematic data concerning all hospital admissions with myocardial infarction in the referring 
hospitals. In particular, we do not know how many patients were deemed too sick to transfer, alt-
hough personal communication from the refening physicians suggests that tIus is rare. Although 
some refen-ing hospitals have portable intra-aortic balloon pumps, they are used very seldom for 
this indication, as the additional delay resulting from the insertion procedure before transporta-
tion offsets the advantage of this support device. 
Conclusions and Clinical Implications 
Our data show, that at least in certain circumstances, primary coronmy angioplasty after trans-
portation to a referral centre for interventional treatment of cardiac disease, can be llsed in 
patients initially admitted to a hospital without angioplasty facilities. The risk of death due to 
transportation is low and the effect on total ischaemic time (time from symptom onset to ballo-
on inflation) is small. A large randomised lllulticentre trial is needed to compare the relative 
rnerits of intravenous thrombolytic treatment in a local hospital with primary angioplasty after 
transfer in selected high risk patients with acute myocardial infarction. 
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Abstract 
Background: Rcperfusion therapy by primary coronary angioplasty has been shown to be bene-
ficial for patients who present themselves up to 12 h after the onset of symptoms. However, the 
relationship between outcome and ischaemic time for patients who present relatively late after 
the onset of symptoms is still uncertain. The aim of this study was to inves-tiga-te differences in 
patient characteristics, left ventricular function and clinical outcome between early «3 h), inter-
mediate (3-6 h) and late (6-24 h) treated patients. 
Methods and Results: From August 1990 until December 1995, we studied 496 patients who 
underwent ptimary coronary angioplasty for acute myocardial infarction. Patients who under-
went reperfusioll therapy between 6 and 24 h were more often of female gender and more often 
had diabetes. Primmy coronary angioplasty was less successful with later time to reperfusion. 
Patients who had reperfusion therapy within 6 h showed recovery of left ventricular function at 
6 months follow-up, while the len vcntricular function of patients treated late had deteriorated. 
Reocclusion of the infarct- related vessel at follow-up coronary angiography was highest for 
patients with an ischaemic time of more than 6 h. They more often suffered a repeat myocardial 
infmction and had a significantly higher 6 months mortality. After adjustment for age, heart rate 
at presentation, gender, and the presence of diabetes by multivariate analysis, ischaemic time 
remained an independent predictor of both left ventricular function recovery and 6 month mor-
tality. 
Conclusions: The time from symptom onset to reperfusion is related to some baseline clinical 
characteristics, procedural success rate, left ventricular function and clinical outcome. 
(EliI' Heal'l J 1998;19;118-123) 
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Introduction 
It has been shown convincingly that reperfusion therapy for acute myocardial infarction started 
within 6 h after symptom onset results in an important mortality reduction (1,2), but there is no 
certainty about the relationship between the ischaemic time and clinical outcome. Although there 
is clear evidence that very early treatment, especially within the first Hgolden hour" results in a 
considerable mortality benefit (3,4), few studies have addressed the influence of time to treat-
ment, including patients who are treated later than 6 h after the onset of symptoms. Most studies 
report on patients treated with thrombolytic therapy. In these patients it is not known whether 
reperfusion actually occurs, and if so, the time is uncertain. Therefore we compared patient cha-
racteristics and outcome of patients divided into 3 different groups according to time intervals 
between onset of symptoms and opening of the infarct-related vessel in a cohort of consecutive 
myocardial infarct patients treated with primary coronary angioplasty. 
Patients and methods 
From August 1990 to December 1995,496 patients with symptoms of acute myocardial infarc-
tion persisting for more than 30 min and at least I n1111 ST segment elevation in two contiguous 
leads underwent primary coronary angioplasty at our institution, according to the protocol of the 
Zwolle Myocardial Infarction trial. Inclusion and exclusion criteria for this trial have previously 
been described (5). Patients who presented more than 6 h after symptom onset were only inclu-
ded if there was evidence of continuing ischae-ll1ia, which was defined as the presence of persis-
tent chest pain and ST segment elevation. Patients were transported to the catheterization labora-
tory immediate-Iy after the diagnosis was made and corona-ry angioplasty was pelfonned using 
standard techniques. Ischaemic time was defined as the time from symptom onset uIltil the first 
balloon inflation. Flow tln'ough the in-farct-rela-ted vessel was scored aecor-ding to the Tluom-
boly-sis in Myocarhdial Infarchtion (TIMI) classifi-cation (6). Primmy angioplasty was conside-
red successful if TIM! 3 flow was present after the procedure. Colla-terals to the infarct-rela-ted 
vessel were clas-si-fied as proposed by Rentrop et al (7). Grade 0: no visible filling of any colla-
teral channels, grade I: filling by means of collateral channels of side branches of the vessel but 
without any dye reaching the epi-cardial segment of that vessel, grade 2: partial filling via colla-
tenll ehalmels of the epicardial segment of the vessel, grade 3: complete filling of the epicardial 
vessel. Follow-up coronmy angiography was planned for all patients, with the exception of those 
who underwent emoly coronmy motery bypass surgety or who had an unsuccessful angiop-Iasty. 
The left ventriculmo ejection fraction was measu-rcd before dischmoge and at 6 months follow-up, 
by radio-nuclide ventIiculograp-hy using the multiple gated equilibIium method, as has beeu previ-
ously des-cri-bed (8). For patients in whom both an ejection fraction was measured before hospi-
tal discharge and at follow-up, the change of left ventricular function was defined as the differen-
ce between the two values (DEF). 
Recurrent myocardial infarction was defined as the combination of chest pain, changes in the ST-
T segment at rest, and a second increase in the creati-ne kinase level to more than twice the upper 
limit of normal, or an increase of more than 200 U per litre over the previous value if the level had 
not dropped below the upper limit of normal. Total mortality was assessed at 6 months follow-up. 
Statistical Analysis 
Differences between group means were tested by analysis of variance. A chi-square method or 
the Fischer exact test, adapted to analyse trends, were used to test differences between propor-
tions. The Fi-scher exact test was used if there was an expected cell value < 5. Continuous base-
line and outcome variables are given as means ± SD, with the exception of ischaemic time, 
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which is reported by median and percentiles 25 and 75 as this variable has a "non-Gaussian" dis-
tribution. Discrete variables are given as percentages. Diffe-rences were considered statistically 
signifi-cant if the two-sided P value was <0.05. The outcome measures were analysed irrespec-
tive of whether the angioplasty procedure was successful. A stepwise logistic regression proce-
dure was used to determine independent predictors associated with mortality or left ventricular 
function. For tIus analysis, continuous variables were converted into binary variables, with the 
75th percentile as the cut off point. 
Results 
The ischaemic time was recorded in 490 patients (98%). This was less than 3 h in 44% of patients, 
defined as the "EARLY" group. Thilty-eight percent of patients had an ischaemic time between 3 
and 6 h, the "INTERMEDIATE" group and 18% of patients were treated between 6 and 24 h of 
symptom onset because of signs of continuing ischaenua. This latter group was classified as the 
"LATE" group. Median time from onset of symptoms to the first balloon inflation was 2.4 h, 4.1 
hand 9.0 h for the three groups, respectively. Baseline characteristics are descdbed in Table 1. 
Table 1. 
Baseline characteristics 
Ischaemic time 
Early Intermediate Late Trend analysis 
(n=215) (n=187) (n=88) P 
Ischemic time (min) 143 243 538 <0.0001 
(25 perc-75 perc) (118-160) (210-287) (420-838) 
Male gender 86% 81% 67% 0.0003 
Diabetes 3% 10% 12% 0.003 
Successful PA 94% 87% 85% 0.006 
Age (years) 59±11 61±12 61±11 0.14 
Family history of CAD 44% 49% 34% 0.30 
Previous angina 49% 45% 58% 0.31 
Previous PTCA 7% 6% 5% 0.39 
Hypertension 20% 23% 24% 0.36 
Previous CABG 3% 2% 5% 0.78 
Heart rate (beats/min) 
Killip 1(82%) 72±15 73±16 78±17 0.003 
Killip 2 (12%) 89±29 87±25 90±19 0.89 
Killip 3+4 (6%) 96±24 99±27 89±27 0.61 
Smoking 51% 51% 51% 0.87 
Multivessel disease 53% 58% 51% 0.89 
Previous Ml 13% 15% 12% 0.91 
Anterior MI 51% 43% 58% 0.98 
Ischaemic time=time from symptom onset to first balloon inflation; 1U=myocardial infarction; CABG=coronary artery 
bypass surgery; PTCA= percutaneous transluminal coronary angioplasty; CAD=coronary artery disease. Successful is defi-
ned as TIMI 3 flow of the infarct-related artery; PA= primary angiopiasty. 
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There was a signifIcant trend towards a higher percentage of female patients and patients with dia-
betes and a longer ischaemic time. The other baseline characteristics were comparable in the three 
groups. The success rate of the primary angioplasty procedure, howevel; was highest in patients 
treated within 3 h. Results of the left ventricular ejection fraction for both in-hospital and at 
follow-up are described in Table 2. These measurements were available pre-discharge in 418 
(85%) patients and at follow-up in 376 (82% of surviving patients). In patients with unsuccessful 
angioplasty the ejection fraction was measured in 33 patients (65%) pre-discharge and in 28 (78% 
of patients alive) at 6 months follow-up. Both pre-discharge and follow-up measurements (paired 
data) were available in 358 patients. Although there is a trend towards a lower ejection fraction 
with longer ischaemic time, this did not reach statistical signitlcance. However, the change of left 
ventricular ejection fraction function between pre-discharge and 6 months follow-up was related 
to ischaemic time. Patients with an ischaemic time of less than 3 h showed an increase in ejection 
fraction of 1.6 %. For patients with an ischaemic time between 3 and 6 h the ejection fraction 
increased 1.3 %. In the patients who had their fIrst balloon inflation after 6 h, the ejection frac-
tion decreased by 1.9 %. After exclusion of patients with an occluded infarct-related vessel at 
follow-up angiography, these values for DEF were 1.5 %, 1.4%, and -1.5% respectively. 
Table 2. 
Left ventricular ejection fraction 
Ischaemic time 
Early Intermediate Late Trend analysis 
P 
All patients 
LVEF pre discharge 
(n=418) 46±12 46±11 44±13 0.35 
LVEF follow-up 
(n=376) 47±1l 46±12 44±13 0.23 
Patients with paired EF measurements 
LVEF pre discharge 
(n=358) 46±12 46±11 45±13 0.88 
LVEF follow-up (n=358) 47±11 47±12 43±13 0.08 
DEF (n=358) +1.6±7.5 +1.3±7.3 -1.9±8.3 0.008 
Patients who underwent successful PA 
DEF (n=326) +1.6±7.7 +1.7±7.2 -2.1±8.1 0.007 
Patients with a patent infarct-related vessel at follow-up 
DEF (n=343) +1.5±7.6 +1.4±7.4 -1.5±S.2 0.03 
LVEF=lcft ventricular ejection fraction measured by radionuclide ventriculography. DEF=difference between the ejection 
fraction predischarge and at follow-up. PA=primary angiopiasty. 
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Clinical and angiographic outcome at follow-up is described in Table 3. In patients for whom a 
follow-up angiogram was planned, tIlis procedure was performed in 162/183 (89%) of early, in 
1211139 (87%) of the intermediate, and in 59171 (83%) of the late-entry patients (p=0.27). No 
patient was lost to follow-up. Reinfarction, death and reocclusion of the infarct-related vessel at 
follow-up angiography were related to ischaemlc time, with the best outcome for patients trea-
ted within 3 h, and the poorest outcome for patients treated after 6 h of symptom onsct. 
Table 3. 
Reocclusion, reinfarction and death at 6 months follow-up 
Ischaemic Time 
Early Intermediate Late Trend 
P 
Reocclusion 5% 8% 14% 0.04 
Reinfarction 3 (1%) 6 (3%) 7 (8%) 0.01 
Death 7 (3%) 16 (8%) II (13%) 0.003 
Death (-failed PAl 5 (3%) 8 (5%) 3 (4%) 0.36 
The results of the multivariate analysis are shown in Table 4. Ischaemic time was related to both 
6-l11onth mortality and change in ejection fraction independent of age, heart rate at presentation, 
gender or the presence of diabetes. 
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Table 4. 
Multivariate analysis 
End point: 6 month mortality 
Odds ratio 9S% CT P-value 
Age (>70 years) 4.38 (2.IS - 8.93) O.OOOOS 
Heart rate> 70 beats/min 3.26 (1.68 - 6.34) O.OOOS 
Multivessel disease 2.41 (1.l9 - 4.87) 0.01 
Ischemic time (per class) I.S3 (1.0 I - 2.32) 0.04 
Diabetes 1.46 (0.87 - 2.46) 0.16 
Female gender I.S9 (0.78 - 3.24) 0.20 
Anterior infarction 1.27 (0.66 - 2.44) 0.48 
Previous infarction 0.94 (0.39 - 2.24) 0.89 
End point: DEF (Odds ratios for 1V0rsening of EF) 
Odds ratio 9S% CI P-valuc 
Anterior infarction 0.S2 (0.33 - 0.80) 0.003 
Ischemic time (per class) 1.43 (1.06 - 1.94) 0.02 
Age (>70 years) 0.54 (0.28 - 1.02) 0.06 
Heart rate> 75/min 0.67 (0.43 - 1.03) 0.07 
Multivessel disease 1.50 (0.97 - 2.34) 0.07 
Previous infarction 1.62 (0.84 - 3.13) 0.15 
Diabetes 1.47 (0.71 - 3.05) 0.30 
Female gender 0.91 (0.50 - 1.65) 0.7S 
C[= confidence interval. DEF=difference in left ventricular ejection fraction pre-discharge and at 6 month follow-up 
(n=358). 
Discussion 
Two previous studics of patients treated with primary coronary angioplasty for acute myocardial 
infarction suggested that the time delay to repelfusion, even after 6 h, did not affect outcome 
(9,10). However, this study shows that the time from symptom-onset to first balloon inflation is 
related to some baseline clinical characteristics, left ventricular functional recovery and clinical 
outcome. 
Baseline Characteristics 
The difference in baseline characteristics between the 3 groups of patients is consistent with the 
findings from other studies (11,12), who found female gender and diabetes to be independent 
variables for increasing patient delay. Ottesen et al (12) found that older age and pre-infarction 
angina were also a predictor for a long paticnt delay. Although our data show a trend in this 
direction, this was not significant. None of the other baseline characteristics were related to 
ischaemic time. Previous infarction, previous bypass surgelY or hypertension, which were found 
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to be variables predictive of later time to presentation in the GUSTO trial (11), were equally dis-
tributed amongst the 3 groups in our study, This inability to detcct some of these differenccs may 
be related to the relative small number of patients in our study. 
Succcss of Ptimary Angioplasty 
Our data show that the likelihood of achieving TIM! 3 flow of the infarct-related coronary artery 
is dependent on ischaemic time. Previous studies in patients treated with primmy angioplasty did 
not find such a relationship (9,10). However, from a pathophysiological perspective, it is unders-
tandable that flow to a region with extensive necrosis due to prolonged occlusion of the infarct-
related artery, may become less often normal. In patients with a longer ischaemic time, a higher 
incidence of impaired flow in the infarct-related vessel after reperfusion has been found by intra-
coronary Doppler measurements in humans as well as in an animal model (13,14). 
Left Ventricular Function 
Left ventricular ejection fraction of patients treated after 6 h was not significantly lower com-
pared to patients treated within 6 h, although there was a trend in tlus direction. There was a sig-
nificant difference in the extent of recovery of left ventricular function during follow-up bet-
ween the three groups. After adjustment for differences in baseline characteristics by multiva-
riate analysis, it was shown that ischaenuc time independently predicted left ventricular function 
recovery (Table 4), This is consistent with the findings ofHassche et al (15), who found the same 
in patients treated with thrombolytic therapy. An explanation for Hus lack of recovery of left ven-
tricular function for patients treated late might be relatcd to a more extensive necrosis with 
absence of viable myocardium in the infarct region in late-treated patients. Studies using myo~ 
cardial contrast echocardiography show that the left ventricular function in these patients bene-
fit less from repcrfusion therapy compared to patients who have evidence of continued viability 
(16,17), The lower success rate of the angioplasty procedure or the lower patency rate of patients 
treated late docs not explain the lack of recovery of left ventricular function. After exclusion of 
patients with an unsuccessful procedure or an occluded infarct-related vessel at follow-up, the 
difference in extent of recovery of left ventricular function persisted (Table 2), 
Clinical and Angiographic Outcome 
Early treated patients have a better clinical and angiographic outcome at follow-up, compared to 
patients treated later. There is a substantial difference in mortality at follow-up. The difference 
in mortality is related to the difference in success rate of the angioplasty procedure between the 
three groups of patients. After exclusion of failed procedures, there is no longer a significant dif-
ference in 6 month mortality between the groups (Table 3), Although it was recently reported 
that diabetes is an independent predictor of mortality after myocardial infarction (i8), the diffe-
rence in incidence in diabetes between the groups docs not explain the difference in mortality. 
Multivariate analysis showed that ischaenuc time is an independent predictor of 6 month morta-
lity, after adjustment for the differences in baseline characteristics between the groups (Table 4), 
Patients treated after 6 h more often had reocclusion of the infarct-related vessel. There is a 
wealth of information which shows that late patency of the infarct-related vessel is a strong pre-
dictor of long-term clinical outcome (19). However, this study reported on reocclusion rates and 
not patency rates, because follow-up angiography was performed in patients after a successful 
angioplasty procedure. If one assumes that the infarct-related vessel of the patients who under-
went an unsuccessful procedure remained occluded (TIMI<3), patency rates at follow-up can be 
estimated. This is described in Table 5 and shows a siglut1cantly lower patency with later time 
to reperfusiol1, A lower patency rate at follow-up angiography for later-treated patients is in 
- 112 -
Chapter 5-1 
accordance with a study pelfonned by Simmi et al in 1986, who showed that time to reperfusion 
was a determinant of early reocclusion after angioplasty for acute myocardial infarction (20). 
This may also explain the increased incidence of reinfarction in late treated patients. 
Table 5. 
Patency rates before and after primary angioplasty (PA) and at follow-up 
Em'ly Intermediate Late P-value 
Before PA 11% 13% 12% 0.72 
After PA 95% 87% 85% 0.006 
Follow-up' 90% 82% 75% 0.002 
*Assumption: infarct related vessel after non-successful angioplasty remains non-patent at follow-up. 
Limitations of the study 
We described a relatively small number of patients who underwent late reperfusion therapy. 
Baseline charactetistics between the 3 groups were not similar for all variables: this probably 
reflects a true difference between patients treated early or late. Therefore this study is not merely 
a reflection of the effect of difference in time to treatment on outcome. This is a post-hoc analy-
sis of the influence of ischaemic time on outcome in a large data-set of consecutive myocardial 
infarct patients treated with primary angioplasty. So fm', the only studies in which the effect of 
time to reperfusion can be evaluated separately from confounding variables are those snldies 
which randomize between pre-hospital and in-hospital thrombolysis (21-22). 
Late entry patients were only treated with reperfusion therapy if there were signs of continuing 
ischaemia, i.e. chest pain and ST-segment elevation. This may have introduced a selection bias. 
Inclusion of all late entry patients, irrespective of signs of viable myocm'dium, would probably 
have resulted in different findings in this group, as repelfusion therapy seems most beneficial in 
patients with evidence of continued viability (23). 
Conclusions 
This study shows that in patients, undergoing primary coronary angioplasty for acute myocar-
dial infarction, the time from symptom-onset to first balloon inflation is related to some baseli-
ne clinical characteristics, procedural success rate, left ventricular functional recovery and clini-
cal outcome. In patients treated within 3 h or between 3 and 6 h there is an improvement of the 
left ventricular ejection fraction during follow-up. Patients treated after 6 h are more often fema-
le and have a higher incidence of diabetes and a poorer clinical outcome. 
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Abstract 
Objectives. The purpose of this analysis was to detel1lline the influence of an additional treat-
ment delay inherent in transfer to an angioplasty center for ptimary angioplasty of patients with 
acute myocardial infarction who are first admitted to hospitals without angioplasty facilities. 
Background. Several randomized trials have demonstrated the benefits of primary angioplasty 
in acute myocardial infarction. In recent years increasing numbers of patients with myocardial 
infarction, initially admitted to hospitals without angioplasty facilities are transported to our hos-
pital for primary angioplasty. However, the additional delay due to the transport may have a 
deleterious effect on infarct size and clinical outcome. 
Methods. In a three year period (December 1993 - November 1996), 207 consecutive patients 
who were transfelTed for primary angioplasty were analyzed in a matched comparison with non-
transferred patients. Matching criteria were age, sex, infarct location, presentation delay and 
Killip class. 
Results. Patients who were transfelTed had an additional median delay of 43 minutes. This resul-
ted in a larger enzymatic infarct size and a lower ejection fraction measured at 6 months. The 
rate of angioplasty success defined as TIM! grade 3 flow, and the 6 month mortality rate (7%) 
were comparable in both groups. 
Conclusion. The additional delay had a deleterious effect on myocardial salvage, reflected by a 
larger infarct size and a lower left ventricular function. However the patency rate and 6 month 
clinical outcome were not affected by this delay. 
(J Alii Coli Cmdio/, ill press) 
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Abbreviations 
CABG 
IRV 
IU 
LDH 
LVEF 
MI 
PTCA 
TIMI 
= Coronary artery bypass grafting 
= Infarct related vessel 
= International units 
= Lactate dehydrogenase 
;:::; Left ventricular ejection fraction 
= Myocardial infarction 
= Percutaneus transluminal coronary angioplasty 
= Tln-ombolysis in Myocardial Infarction 
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Introduction 
The time related effect of treatment on survival and myocardial salvage in patients with acute 
myocardial infarction (MI) has been demonstrated in thrombolysis trials (1-6). Besides timing 
of treatment, the grade of flow achieved with reperfusion is important for the long term outco-
me (7-10). Primary angioplasty for patients with acute MI has been shown in randomized trials 
(11-14) to be a very effective reperfusion therapy, and high rates of complete and sustained 
patency have been repOlied. Achieving complete reperfusion as defined by Thrombolysis in 
Myocardial Infarction (TIMI) grade 3 flow after reperfusion is an important factor in short and 
long term survival. In patients treated with thrombolytic therapy there is an inverse relationship 
between time to treatment and patency rate. TIlls relationship is not so evident in patients trea-
ted with primary angioplasty (15,16). A previous study in infarct patients who were admitted 
directly to our hospital and treated with primary angioplasty did demonstrate differences in 
patency rates with increasing ischemic times, but also found important differences in patient 
characteristics related to the time from symptom onset to treatment (17). A registry study has 
shown that transferring patients for primary angioplasty to our hospital is safe and effective, and 
with an acceptable delay due to transportation (18). In tlus analysis an attempt is made to quan-
tify the effect of an additional delay inherent in transfer to an angioplasty center. 
Methods 
Study patiel/ts. 
The study was approved by the committee on ethics and research at our institution. For this 
analysis we retrospectively evaluated patients who were registered in our infarct database. We 
included patients with acute MI who were first admitted to a community hospital without angio-
plasty facilities and were transferred to our hospital for primary angioplasty. Only patients who 
underwent primary angioplasty were included in the analysis. They were compared to patients 
admitted directly to our hospital, who were also registered in our database for acute NIl patients. 
In this database all consecutive patients with acute MI are prospectively registered. The transfer 
patients and the control patients are contemporaneous. The following definitions of the time 
intervals were used: the first part between symptom onset and hospital admission (for referral 
patients admission at the community hospital) is called presentation delay. The second part is 
called treatment delay, and is defined as time from hospital admission to fIrst balloon inflation. 
The additional delay due to the inter-hospital transport is the subject of this analysis. Only 
patients who underwent primary angioplasty for acute MI were included to allow assessment of 
the time to reperfusion, defIned as time to first balloon inflation. In addition, Tnvrr flow grade 
was assessed. To study the influence of treatment delay due to transportation. each of the trans-
ferred patients (n;::; 207) was matched to one non-transfened patient. Criteria for matching were: 
age. sex, infarct location, presentation delay and Killip class. Timc intervals (onset of chcstpain. 
presentation delay, transportation time, fIrst balloon inflation) as well as all clinical and angio-
graphic data have been prospectively recorded in our database. Transfer patients were transfe-
ned from 15 connnunity hospitals to our hospital for primary angioplasty from December 1993 
to November 1996. Our hospital serves as angioplasty center in the region with approximately 
1.5 million inhabitants. Travel distances range from 2 to 43 miles. 
Study desigll. 
Acute MI was diagnosed if a patient had persistent symptoms of chestpain lasting more than 30 
minutes and had ST segment elcvation of;::: llllm in at least 2 contiguous leads. The indications 
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for transfer were: electrocardiographic evidence of an anterior or large inferior infarction, con-
tra-indications for tlnombolytic therapy (relative or absolute) or hemodynamic instability (Killip 
class> I). The cumulative sum of ST elevation was scored on the diagnostic electrocardiogram. 
The exclusion critelia were identical as previously described (II). All transfer patients under-
went immediate coronary angiography followed by primary angioplasty if indicated; patients 
were not treated with primary angioplasty if they had severe multi vessel coronary artery disea-
se or involvement of the left main coronary artery which made subsequent urgent coronary 
bypass grafting (CAB G) necessary. Patients with an open infarct related vessel (lRV) in whom 
no reperfusion therapy was indicated, were treated conservatively. After primary angioplasty, 
flow through the lRV was scored according to the TIM] classification. The angiograms were all 
read by two cardiologists blinded for group allocation and clinical data. Primary angioplasty was 
considered successful if the residual stenosis in the lRV was less than 50% and TIMI grade 3 
flow was present after the procedure. 
EI/zymatic il//al'ct size 
Infarct size was determined by measurements of enzyme concentrations with lactate dehydro-
genase as reference enzyme (LDH Q72). A two-compartment model was used, which has been 
validated in studies on the turnover of radio-labeled plasma proteins and circulating enzymes. 
Cumulative enzyme release was calculated from selia I measurements up to 72 h after symptom 
onset. Samples were obtained on admission and every 12 h to 72 h thereafter. From these mea-
surements, an area under the curve was calculated, from at least five measurements. Further 
details of this methods have been described before (11,13,19,20). 
Le/t vel/h'icl/lal'/I/I/ctiol/ 
At 6 month follow up left ventticular ejection fraction (LVEF) was measured with a radionucli-
de technique as previously described (11,13). Measurements were done by the multiple-gated 
equilibrium method after labeling of red blood cells with technetium 99m pertechnetate. A g-
camera (General Electric, Milwaukee, WI, USA) was used. The global LVEF was calculated 
with the PAGE program (version 2.3). 
Clil/icalol/tcome 
Follow-up information was obtained for all patients. Hospital records of patients who visited our 
outpatient clinic were reviewed. Information on transferred patients was obtained from refenal 
cardiologists. If necessaL)', additional information was gathered by telephone contact with gene-
ral physicians or patients. 
Clil/ical parametel's 
In this analysis we compared the following clinical parameters: ellzymatic infarct size (LDH 
Q72), LVEF and TIM! flow after ptimary angioplasty was scored. At 6 month follow up mor-
tality (of all causes) and recurrent MI were evaluated in both groups. Recurrent MI was defined 
as the combination of chest pain, changes in the ST-T segment at rest, and a second increase in 
the creati-ne kinase level to more than two times the upper limit of normal, or an increase of 
more than 200 IU per liter over the previous value if the level had not dropped below the upper 
limit of nonnal (11). Recurrent infarction and mortality were assessed at 6 month follow-up. 
Statisticalmetltods 
Time intervals are presented as medians with 25th and 75th percentiles. Data were analyzed as 
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a matched pairs study. The Wilcoxon signed rank test was used to compare means of continuous 
variables and the chi-square test or Fischer exact test for discrete variables. 1\vo sided P-values 
< 0.05 were considered to be significant. 
Results 
During a three year period 236 patients with acute MI were transferred from referral hospitals. 
Of these. 213 patients were treated with primary angioplasty. Eight patients with severe multi-
vessel coronary artery disease or involvement of the left main coronary artery underwent urgent 
CABG. In another 8 patients the TRV was open and no reperfusion therapy was indicated. Mat-
ching criteria were available for all of the patients who underwent primary angioplasty. No 
match could be found for 6 (3%) of the transferred patients, so 207 transfer patients were one to 
one matched to non transferred patients. The matching procedure resulted in an equal distribu-
tion of all matched baseline characteristics as shown in table 1. 
Table 1. 
Baseline characteristics 
Transfer group Non transfer group 
n ~ 207 n ~ 207 
Age (years) (median, SD) 58 (II) 58 (10) 
Male sex (%) 85 85 
Anterior infarct location (%) 76 76 
Heart rate (beats/min) (mean, SD) 79 (19) 76 (19) 
Killip class 1-2 (%) 92 92 
Killip class 3-4 (%) 8 8 
Previous angina (%) 61 54 
Contraindication for thrombolysis (%) 12 7 
Median presentation delay (min) 90 100 
(25th, 75th) (60, 145) (67, 180) 
Cumulative sum of ST elevation (mm) (SD) 14 (10) 14 (II) 
Previous MI (%) II 14 
Previous CABG (%) I 0.5 
Multivessel disease (%) 55 48 
Diabetes (%) 5 7 
CABO = coronary artery bypass surgery 
There were more patients with a contraindication for thrombolysis and with muHivesscl disease 
in the transfer patients, but these differences were not significant. The cumulative sum of ST ele-
vation showed no difference between thc groups. Also the presence of other baseline characte-
ristics such as previous infarction, previous CABd, multivessel disease and diabetes were 
equally divided. The transfer patients were slightly younger (58 years ± II) than patients who 
were enrolled in our infarction trials in the past years, and a larger majority had an anterior 
infarct location (Table I). For the 207 matched transfer patients the median treatment delay was 
103 min compared to 60 minutes in the non transferred patients, so the transfer resulted in an 
additional delay in time to reperfusion of 43 minutes (Table 2). 
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Table 2. 
In-hospital clinieal outcome 
Transfer group P-value Non transfer group 
n = 207 n = 207 
Median treatment delay (min) 103 <0.0001 60 
(25th. 75th) (80, 130) (45,80) 
Non fatal reinfarction 4 (2%) NS 5 (2%) 
Non fatal ischemic stroke I (0.5%) NS 0(0%) 
Death 10 (5%) NS 7 (3%) 
TIMI grade 3 flow after PTCA 178 (86%) NS 186 (90%) 
n = 137 n = 137 
Enzymatic infarct size (LDHQ72) I 1536 IU I < 0.005 I 1235 IU 
NS = not signifIcant; TThlI = Thrombolysis in Myocardial Infarction; PTCA = percutaneous transluminal coronary angio-
plusty; LDB = lactate dehydrogenase 
III-hospital clillical olltcome 
TIMI grade 3 flow was obtained in most patients; 86% in the transfer group and in 90% in the non 
transfer group (Table 2). During the hospital pedod 10 transfer patients (5%) died and 7 (3%) non 
transfer patients. Five patients died within the first 48 h, before serial enzyme release could be 
determined. Cumulative enzyme release during the first 72 h could be calculated in 145 (70%) of 
the transfer patients (mean enzyme release: 1544 IU, SD 1106 IU) and in 193 (93%) of the non 
transfer patients (mean enzyme release: 1196 IU, SD 1004lU). This resulted in 137 matched pairs 
(66%) in whom enzyme release could be calculated and compared. For 49 (24%) patients in the 
transfer group and for 16 (8%) patients in the non transfer group, there were inadequate data for 
analysis. The enzymatic infarct size was 1536 IU in the trallsfeITed patients, compared to 1235 IU 
in the non transfer patients (P-value < 0.005) (Table 2). 
Six 1I10llth follow-lip 
At 6 month a total of 15 (7%) patients in the transfer group and 12 patients in the non transfer 
group (6%) had died. Reinfarction had occurred in 8 (4%) of the transfer patients and in 6 (3%) 
of the non transfer patients (Table 3). LVEF was measured at 6 month, in 139 matched pairs 
(72%) of the survivors. Non transfer patients had an ejection fraction of 47% vs 43% in the trans-
fer patients (P = 0.003). In 27 (13%) patients in the transfer group and in 17 (8%) patients in the 
non transfer group a LVEF measllrernent was not available, in a small number of patients the test 
was pelformed but inconclusive due to an inegular heart rhythm (three patients in the transfer 
group and two in the non transfer group). Reasons for not pelfonning this test were inability to 
return to our hospital (e.g. travel distance) or patients refusal. 
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Table 3. 
Six months clinical outcome 
Transfer group P-value Non transfer group 
n = 207 n = 207 
Non fatal reinfarction 8 (4%) NS 6 (3%) 
Non fatal ischemic stroke 1 (0.5%) NS 2 (1%) 
Death 15 (7%) NS 12 (6%) 
n = 139 n = 139 
Ejection fraction 43% 0.003 47% 
NS = not significant 
Discussion 
Treatmel/t delay 
In this study we analyzed the treatment delay in patients who were transfened from hospitals 
without angioplasty facilities to our center for ptimary angioplasty. In this setting patients who 
were transferred had an additional treatment delay of 43 minutes. Although the time delay had 
no effect on the patency rate after the angioplasty procedure, there was more extensive myocar-
dial damage. As patency is the major determinant of survival, this results in a comparable 6 
months clinical outcome of transfened patients compared to non-transferred patients. However, 
long term survival is yet unknown and LVEF may become more important over time. The analy-
sis shows that in tlils cohort of patients the myocardial damage due to the additional delay inhe-
rent to transfer to an angioplasty center in high risk patients with acute MI may be outweighed 
by the high rate of early, sustained and complete reperfusion as a result of the primary angio-
plasty procedure. This high rate of successful angioplasty applies to patients with ischemic times 
up to 6 h, as most of the transfer patients had short presentation delays (median 90 min) and the 
additional delay caused by the transfer was limited. Few patients with longer presentation delays 
were transferred, but it may be expected that procedure success rates will be lower after 6 h (17). 
Myocardia/ salvage 
The effects of treatment delay could be measured in enzymatic infarct size as well as LVEF. 
However more factors may playa role in the degree of myocardial salvage. The presence or 
absence of collaterals, the size of the infarct area, history of previous infarction or previous angi-
na, will be responsible for a wide range of outcomes in individual patients. Nevertheless, for 
these patient groups a difference in measured infarct size and LVEF was found in relation with 
a median treatment delay of 43 minutes. 
TmllsJer Jor pritl/{II)' allgiop/asty 
Only a limited number of hospitals have angioplasty facilities and most patients with acute MI will 
be admitted to hospitals without these facilities. Urgent transfer of infarct patients to angioplasty 
centers is an alternative option to treatment with thrombolysis administered at the community hos-
pital. By evaluation of this cohOlt of patients who have been transfened for primary angioplasty to 
our hospital it is demonstrated that this treatment strategy is safe and can be done effectively. Inter-
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hospital delays are minimized by timely refelTal by the physician at the refelml hospital. On arri-
val at the angiopJasty center the patient can be brought to the catheterization laboratory immedia-
tely. Measures to prepare the catheterization laboratory can be made during the patient transport. 
Study limitations 
This study population represents a selected group of patients, slightly younger than the usual 
infarct population and with a shOit presentation delay. Concerning the high percentage of ante-
rior infarctions the transfer patients are a population at higher tisk. This fact has probably con-
tributed to the differences found in enzymatic infarct size and LVEF. In patients with non-ante-
rior infarctions, the area at risk would be smaller, and differences expressed in infarct size and 
LVEF might not be measurable. Also the fact that the total delay before treatment for both 
groups was within the period of myocardial salvage may have contributed in the difference bet-
ween the transported patients and matched controls. A bias might be introcuced by the fact that 
some of the clinically better patients did not return for the LVEF test, but only in 13% of the 
transported patients and in 8% of the matched controls LVEF measurement was not available. 
The large majority of patients had completed data for enzymatic infarct size and LVEF, but in a 
matched comparison the percentage of available results in patient pairs is obviously lower. This 
analysis does not answer the question whether it would be more beneficial to transfer a patient 
for primary angioplasty than to trcat these patients immediately with thrombolysis. This compa-
rison can only be made by means of a randomized trial. 
Conclusions 
Tilis analysis demonstrates that the success of primary angioplasty in patients with acute MI is 
not influenced by an additional delay due to inter-hospital transfer. Analysis of time intervals 
showed that in our setting the additional delay is limited and only 43 minutes longer in patients 
transferred from conmlllnity hospitals compared to patients admitted directly to the angioplasty 
center. Therefore total time from symptom onset to fIrst balloon inflation is witllin a 6 h time 
window for most patients. The effect of the additional treatment delay on myocardial salvage 
measured in enzymatic infarct size and in LVEF at 6 month was estimated by a matched pair 
analysis. Although the additional delay was limited there was a measurable effect on myocardial 
salvage, which indicates the need to reduce time to treatment in patients treated with primary 
angioplasty. In this particular setting and infrastructure the transfer of patients for primary angio-
plasty is safe and can be done with a limited loss of time. The high success rate in the transfer 
patients is encouraging to apply this treatment strategy for patients with high risk features (con-
traindications for thrombolysis, anterior infarct location andlor hemodynamic instability). 
However, in each individual patient it should be clear that an additional delay during the first 
hours of acute Ml results in more extensive myocardial damage. If transfer for primary angio-
plasty is the treatment strategy of choice then the 11I1e "time is muscle" still holds good. 
Clinical implications 
The strategy to transfer patients with acute MI admitted to a community hospital without angio-
plasty facilities to an angioplasty center is safe and effective. If the time from symptom onset to tre-
atment does not exceed the pedod in which myocardial salvage is possible, the results of ptimary 
angioplasty will be comparable to those obtained in patients directly admitted to an angioplasty cen-
ter. Reductions in time to treatment can result in substantial additional myocardial salvage. 
We appreciate the complementary advice and critical review by Freek Verheugt, MD, PhD. We 
thank the refelml doctors from the 15 community hospitals in the region for their cooperation. 
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Abstract 
Background: Previous studies have suggested that restenosis and reocclusion occur frequently 
in patients with acute coronary syndromes. Tills study was undertaken to assess the incidence 
and predictors of restenosis in a cohort of patients who underwent successful primm)' coronary 
angiopiasty for acute myocardial infarction. 
~'Icthods: 312 patients, who underwent successful primary angioplasty of a native coronary ves-
sel, were candidates for follow-up coronary angiography. This was performed in 284 patients 
(92%) at 3 or 6 months follow-up. Quantitative coronary angiography was pelfonned using the 
eMS-system. !vlultivariate analysis was performed to determine independent predictors of res-
tenosis 
Results: Restenosis, defined as a diameter stenosis of more than 50%, occurred in 27% of 
patients at 3 months and in 37% of patients at 6 months follow-up. Rcocclusion occurred in 4% 
and 6% respectively. Reference diameter (vessel size) was related to restenosis. Age and lumen 
diameter immediately after angioplasty were independent predictors of restenosis. Young 
patients «SO years) and patients with a nllillmalluminal diameter of more than 2.5 nun, had res-
tenosis rates of less than 25%. The radiolluclide ejection fraction was 46% in patients with res-
tenosis compared to 47% in patients without restenosis. 
Conclusions: The incidence of restenosis after successful primary coronary angioplasty for 
acute myocardial infarction is comparable to the reported incidence after elective coronary 
angioplasty for stable angina. Restenosis is related to age and the lumen diameter after angio-
plasty and does not affect left ventricular function in this population. 
(Alii Heart J, ill press) 
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Introduction 
Primary coronm)' angioplasty has been shown to be an effective strategy in the treatment of 
patients with acute myocardial infarction. Beneficial immediate and long term results have been 
described with regard to patency of the infarct-related vessel, preservation of left ventricular 
function and reduction of mortality (1-4), A number of studics have described latc clinical out-
come and found recurrent ischemia to occur in 10%-23% of patients (5-8). However, resteno-
sis and reocelusion may occur without symptoms and therefore may be undetected. It has been 
suggested that restenosis in patients with acute myocardial infarction might be more prevalent 
compared to restenosis after angioplasty for stable coronary artery disease due to a high throm-
bus content of the lesion. This may predispose to restenosis and in particular to reocclusion in 
patients with unstable angina (9,10). A detailed quantitative description of restenosis and reoc-
elusion after primary angiop1asty in patients with acute myocardial infm'ction has not yet been 
performed. The aim of this sttldy is to assess restenosis and reocelusion by quantitative coronary 
angiography (QCA) in a cohort of consecutive infarct patients successfully treated with ptimary 
angioplasty, and to describe the clinical and angiographic variables that are related to restenosis. 
As reocelusion may have an impact on left ventricular function and mortality in thrombolytic 
treated patients (11,12) and in patients treated with primary angioplasty (13,14), we also descri-
be left ventricular function and clinical outcome. 
Materials and Methods 
Stlldy poplliatioll 
From August 1990 until December 1995, 312 consecutive patients were included, who met the 
following criteria: I) acute myocardial infarction characterized by symptoms that persisted more 
than 30 minutes, accompanied by ST elevations of more than 1 ml11 (0.1 mY) in two or more 
contiguous electrocardiographic leads; 2) an age less than 75 years; 3) presentation within 6 
hours after symptom onset or between 6 and 24 hours if there was evidence of continuing ische-
mia; 4) a successful primary angioplasty procedure of a native infarct-related artel)', defined as 
TIMI 3 flow of the infarct-related vessel and a diameter stenosis of less than 50%, measured by 
quantitative coronary angiography. Patient selection is described in Figure 1. 
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Figure 1. 
Flow chart 
N=497 Primary Angioplasty (PA) 
N=8: graft 
N=16: stent 
N=473 Balloon Angioplasty of native vessel 
N=37 TIMId 
N=29 DS>50% 
N=407 Successful PA 
------... ~ N=69 Referred Patients 
N=338 Follow-Up (FU) anticipated 
------... ~ N=26 CABG within 6 montllS for triple vessel disease or left nmin disease 
N=3l2 Candidates for FU angiography 
N=lI died 
N=17 no FU angiogram 
N=284 FU angiography 
Patients were excluded when follow-up in our hospital could not be anticipated (N=69), if pri-
mary stenting of the infarct related vessel was pelformed (N=16) or if patients underwent urgent 
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or semi-elective bypass surgery, based on the findings of the initial coronary angiogram (N=26). 
Of the 312 patients who met the inclusion criteria, 284 patients had repeat angiograms suitable 
for quantitative coronary angiography (92%). Eleven patients (3%) died before the follow-up 
angiogram was performed and from 17 patients (5%) no angiogram was available, because of 
either patient refusal or contraindications to follow-up-angiography. Of the total study popula-
tion of 284 patients, A group of 115 patients (40%) had their follow-up angiograms plmmed at 
3 months (112 days), according to the protocol of the first Zwolle trial (I). The other 169 patients 
(60%), part of the second Zwolle trial (15), were scheduled for recatheterization at 6 months. 
Patients who were reinvestigated before their appointed time because of evidence of recurrent 
ischemia were analyzed in their initially assigned follow-up group. 
Corol/my AI/giography al/d AI/giopiasty. 
All patients were treated with intravenous acetylsalicylic acid and intravenous nitroglycerin in a 
dose to maintain a systolic blood pressure of 110 mm Hg. Intravenous heparin was gi ven in a 
bolus of 10,000 U and thereafter in a continuous infusion in a dosage to keep the activated par-
tial thromboplastin time between 2 and 3 times the normal value for at least 2 days. Ischemic 
time was calculated as the time from symptom onset to the first balloon inflation. The angio-
plasty procedure was pelformed using standard techniques. Flow through the infarct-related ves-
sel was scored according to the Thrombolysis in Myocardial Infarction (TIMI) classification 
(16). Data of the coronary angiography and angioplasty procedures were collected and graded 
by two of the investigators. Consensus on collateral flow, procedural success, TIMI flow before 
and after the angioplasty procedure, identification of the infarct-related vessel, and extent of 
coronary artery disease was reached in all cases. TIMI flow before angioplasty was judged at 
first injection of contrast material. Collaterals to the infarct-related vessel were classified as pro-
posed by Rentrop et al (17). Grade 0: no visible filling of any collateral channels, grade I: filling 
by means of collateral channels of side branches of the vessel but without any dye reaching the 
epicardial segment of that vessel, grade 2: partial filling via collateral challllels of the epicardial 
segment of the vessel, grade 3: complete filling of the vessel. Restenosis was defined as the pre-
sence of a more than 50% diameter stenosis at follow-up angiography, including the vessels with 
reocclusion. Reocdusion was defined as a reduction in TIMI perfusion grade 3 to TTh11 grades 
o or 1. 
Qual/titative Corol/my AI/giography (QCA). 
A quantitative analysis of all infarct-related vessels was performed with a personal-computer-
based QCA system, (CMS: Cardiovascular Measurement System, Software version 2.0, Medis 
Medical Imaging Systems, Nuenen, the Netherlands). This has been described previously (1,18). 
The system uses a high-quality cine-to-video converter that allowed a selected cine frame to be 
projected onto a digital video camera tln'ough an optical zoom lens. The video signal of the mag-
nified region of interest was subsequently digitized. For calibration, the boundaries of a nonta-
pering part of the catheter were determined automatical1y over a length of approximately 2 cm. 
To detennine the contours of the vessel the user had only to indicate the beginning and end of 
the coronary segment to be analyzed, after which a path was computed connecting these two 
points. The contour procedure was then petiol1ned iteratively by resampling the image along 
scan lines perpendicular to the path computed in the first iteration. Next, a matrix of cost coef-
ficients was computed that represented for each point in the resampled matrix the edge strength 
based on the weighted sum of the first and second derivative functions. The initial contours were 
found by the minimal-cost contour-detection technique applied to the cost-coefficient matrix. In 
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the second iteration, the contours determined in the first iteration functioned as models for the 
subsequent determination. The edge strengths were corrected for the limited resolution of the 
entire imaging chain, a procedure that is particularly important for the accurate measurement of 
small vessels. From the final contours a new center line was computed. A diameter was deter-
mined in absolute terms (in millimeters) by computing along the vessel center line the shortest 
distances between the left and right contours. The reference diameter was defined as previously 
described (19). As the computer algorithm is unable to measure total occlusions, a value of 0 nun 
was substituted for the MLD and a value of 100% for the percent diameter stenosis. 
Left Vellh'iclIlar FlIlICtioll 
Left ventricular ejection fraction was measu-red with a radio-nuclide technique before hospital 
discharge and during follow-up. The technique used in our hospital has been previ-ously des-ct1-
bed (I). Briefly, it involved the Illultiple-gated equilibrium method after the labeling of red blood 
cells with [99mTcl pertechnetate. A gannna camera (General Electric Milwaukee) with a low-
energy, all purpose, parallel-hole collimator was used. The global ejection fraction is calculated 
automatically by a computer (Star View, General-Electric), with the PAGETh! program. The data 
on ejection fractions were gathered by a specialist in nuclear medicine, who was blinded to the 
clinical data. 
Statistical allalysis. 
Differences between group means were tested by a two-tailed Student t test. A chi-square met-
hod was used to test differences between proportions. The Fisher exact test was used if there was 
an expected cell value < 5. Statistical significance was defined as a P value < 0.05. Restenosis 
was the primary outcome variable and defined as a categoric variable. Univariate and multiva-
riate predictors of restenosis were analyzed according to a model previously described by Hirsh-
feld et al (20). In bdef: a two by two chi-square analysis was used to examine the relation of 
categoric variables to restenosis and for continuous variables both univariate logistic regression 
and 4 by 2 chi-square analysis was done after division of the variables into quartiles. A multiva-
riate logistic regression analysis was pelformed to find independent variables related to resteno-
sis. Only variables which were (borderline) significantly related to restenosis after univariate tes-
ting were included in the multivariate analysis. 
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Table 1. 
Baseline and Angiographic characteristics of 284 patients with sllccessful Primary Angioplasty 
3 months 6 months P-value 
(N=115) (N=169) 
Day of FU-angiogram 94 ± 64 135 ± 82 <0.001 
Agc 58 ± to 57 ± 11 0.28 
Male Gender 99 (86%) 134 (79%) 0.14 
Anterior Infarction 59(51%) 99 (59%) 0.23 
Previous PTCA 6 (5%) 8 (5%) 0.85 
Previous CABG 2 (2%) 2 (1%) 0.53 
Previous Infarction 20 (18%) 13 (8%) 0.01 
Preinfarction Angina 641108 (59%) 8511 69 (50%) 0.14 
Hypertension 23 (20%) 31 (18%) 0.73 
Smoking 54 (47%) 84 (50%) 0.65 
Family History of CAD 49 (43%) 73 (43%) 0.92 
Ischaemic Time (min) 254 ± 221 268 ± 215 0.61 
multi-YO 66 (57%) 80 (47%) 0.10 
IRY 
LAO 49 (43%) 97 (57%) 0.01 
CX 16 (14%) 17 (10%) 0.24 
RCA 48 (43%) 54 (32%) 0.09 
QCA before PA 
OS(%) 95 ± 11 94 ± 14 0.63 
MLO (mm) 0.16 ± 0.39 0.19 ± 0.40 0.54 
QCAafierPA 
OS (%) 25 ± 9 31 ± II <0.0001 
MLO (mm) 2.30 ± 0.49 2.12 ± 0.48 0.003 
Ref Oiam (mIll) 3.07 ± 0.64 3.07 ± 0.54 0.92 
Balloonsize (mm) 2.93 ± 0.40 3.01 ± 0.37 0.10 
Balloon to Artery ratio 0.98 ± 0.15 0.99 ± 0.13 0.65 
Any dissection (N=252) 30/111 (27%) 50/141 (36%) 0.16 
FU: follow-up, PTCA: Percutaneous T'ransluminal Coronary Angioplasty, CABG: Coronary Artery Bypass Grafting, CAD: 
Coronary Artery Disease, Iscbaemic Time: time from symptom onset to the first balloon inflation, VD: Vessel Disease, JRV: 
Infarct-Related-Vessel. LAD: Left Anenor Descending Artery, CX: Circumflex Coronary Artery, RCA: Right Coronary 
Artery, QCA: Quantitative Coronary Angiography, PA: Primary AngiopJasty, MLD: Minimal Luminal Diameter, Ref Dium: 
Reference Diameter 
Results 
Baseline characteristics of patients in the two groups are listed in Table I. The mean time from 
angioplasty to follow-up angiography in the 3 and 6 months group was 94 days and 135 days 
respectively. Baseline characteristics were comparable between the two groups, apart from a 
lower percentage of patients with a previous myocardial infarction and a higher number of 
patients with an occluded left anterior descending artery in the patients. who were recatheteri-
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zed at 6 months. These differences are dne to the study design of the 2 consecutive Zwolle trials 
(l, 15). The first Zwolle trial randomized all patients to thrombolytic therapy or primm)' angie-
plasty (I) wheras the second Zwolle trial randomized only low lisk patients and treated all high 
lisk patients with primary angioplasty (15). The results of the quantitative coronm)' angiography 
analysis in the 284 patients who had angiographic follow-up are shown in Table 2 and Figure 2. 
Figure 2. 
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Graph showing cumulative distribution of percentage diameter stenosis immediately after primary coronary angioplasty and 
at follow~up. PA: Primary Angioplasty, DS: Diameter Stenosis 
Patients in the 3 months group had a lower diameter stenosis and a higher minimal luminal dia-
meter immediately after prlmm'y angioplasty. At follow-up angiography, a trend is present 
towards a more severe diameter stenosis and a smaller minimal luminal diameter with later 
follow-up angiography. The absolute change in diameter stenosis and millimalluminal diameter 
from post angioplasty to follow-up, is not different between the two groups. 
- 136 -
Chapter 6 
Table 2. 
Results of Quantitative Coronary Angiography at 3 and 6 months 
3 months 6 months P-vaille 
(N=ll5) (N= I 69) 
DS (%) 
Post PA 25 ± II 31 ± 11 0.00003 
FU 38 ± 23 46 ±21 0.003 
DDS +13 ± 23 +15 ± 23 0.51 
MLD (mm) 
Post PA 2.30 ± 0.49 2.12 ± 0.48 0.003 
FU 1.76 ± 0.90 1.55 ± 0.90 0.06 
DMLD -0.54 ± 0.84 -0.57 ± 0.87 0.80 
Ref Diam (mm) 
Post PA 3.07 ± 0.64 3.07 ± 0.54 0.93 
FU 3.03 ± 0.67 3.16 ± 0.57 0.10 
D Ref Diam -0.05 ± 0.55 +0.07 ± 0.38 0.04 
DS: Diameter Stenosis, PA: Primary Angioplasty, FU: Follow-Up, MLD: ivlinimal Luminal Diameter, Ref Diam: Referen-
ce Diameter, D: difference behveen Follow Up and Post Angioplasly measurements 
Restenosis is present in 27% of patients at 3 months and in 37% at 6 months follow-up. Reoc-
elusion occurs in 4% and 6% of patients respectively (Table 3). 
Table 3. 
Restenosis and Reocclusion at 3 and 6 months follow-up 
3 months P-value 6 months 
(N=II5) (N=169) 
Restenosis* 27% 0.09 37% 
Reocclusion** 4% 0.56 6% 
*Restenosis is defined as a Diameter Stenosis of more than 50% by quantitative coronary angiography, **Reocclusion is 
detlned as a reduction ofTIlvlI 3 to TThli 0 or I flow 
Categoric and continuous variables related to restenosis by univariate analysis are described in 
Table 4A and 4B and C respectively. Age, as clinical variable and balloonsize, balloon to artery 
ratio, minimal luminal diameter and reference diameter after angioplasty as angiographic varia-
bles were significantly different in patients with and without restenosis. After multivariate analy-
sis only age and minimal luminal diameter after angioplasty were independent predictors of res-
tenosis (Table 5). 
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Table 4A. 
Univariate Analysis: Categorical Variables 
Variable No Restenosis Restenosis P value 
67% (191) 33 % (93) 
Baseline 
Male Gender 159 (83%) 74 (80%) 0.45 
Killip class 1 160/189 (85%) 83/92 (90%) 0.20 
Anterior Infarct 102 (53%) 56 (60%) 0.21 
Previous PTCA 7 (4%) 7 (8%) 0.16 
Previous CABG 3 (2%) 1(1%) 0.60 
Previous Infarction 19 (10%) 14 (15%) 0.21 
Previous Angina 941184 (51%) 55/93 (59%) 0.20 
Hypertension 33 (17%) 21 (23%) 0.29 
Smoking 94 (49%) 44 (47%) 0.76 
Family History of CAD 83 (44%) 39 (42%) 0.81 
Diabetes 13/188 (7%) 7/93 (8%) 0.85 
Pre procedure Related 
Multi-VO 96 (50%) 50 (54%) 0.58 
lRV (%) 
LAD 95 (51%) 50 (54%) 0.55 
CX 25 (13%) 8 (9%) 0.27 
RCA 69 (36%) 33 (36%) 0.94 
Collaterals Rentrop > 0* 6l/178 (34%) 27/75 (36%) 0.78 
OpenlRV before PA ** 32/188 (17%) 18/79 (23%) 0.27 
Postprocedure Related 
Balloonsize > 3mm 511188 (27%) 12/91 (13%) 0.01 
Any Dissection 50/171 (29%) 30/81 (37%) 0.21 
IABP treatment 41 (22%) 17 (18%) 0.53 
PTCA: Percutaneous Transluminal Coronary Angioplasty, CABG: Coronary Artery Bypass Grafting, CAD: Coronary 
Artery Disease, YO: Vessel Disease, IRV: Infarct-Related-Vessel, LAD: left Anerior Descending Artery, CX: Circumflex 
Coronary Artery, RCA: Right Coronary Artery, *: angiographic collaterals visible on the pre-treatment angiogram during 
injection of the contralateral coronary artery, **: TI~H 2 or 3 flow on the pre-treatment angiogram, IABP: Intra Aortic 
Balloon Pumping 
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Table 4B. 
Univariate Chi-Square Analysis: Continuolls Variables 
Variable Quartile 1 Quartile 2 Quartile 3 Quartile 4 Chi Square 
Range Range Range Range (p-value) 
Restrrotal Restrrotal Restrrotal Rest!Total 
(%) (%) (%) (%) 
Baseline Variables 
Age (years) 30 to 50 51 to 58 59 to 66 67 to 81 
17176 25173 25/67 26/68 5.36 
22% 34% 37% 38% (0.15) 
Ischemic Time (min) 40 to 148 149 to 185 186 to 283 248 to 1534 
20170 26171 22173 24/69 1.39 
29% 37% 30% 35% (0.71) 
Postprocedurc Variables 
DS (%) 1 to 22 23 to 28 29 to 36 37 to 50 
20/71 24172 26/82. 23/59 1.77 
28% 33% 32% 39% (0.69) 
MLD (mm) 1.26 to 1.85 1.86 to 2.14 2.15 to 2.51 2.52 to 4.03 
33174 23170 20/69 17171 7.66 
45% 33% 29% 24% (0.05) 
Ref Diall1 (1l11l1) 1.89 to 2.64 2.65 to 3.01 3.02 to 3040 3041 to 5.03 
23/71 33175 21168 16170 7.53 
32% 44% 31% 23% (0.06) 
Balloon to AltelY ratio 0.63 to 0.89 0.90 to 0.96 0.97 to 1.09 1.10 to 1041 
21/71 18/63 26175 26170 1.56 
30% 29% 35% 37% (0.67) 
Ischacmic Time: timc from symptom onset to the first balloon inflation, DS: Diameter Stenosis, !-.H.D: Minimal Luminal 
Diameter, Ref Diam: Referencc Diameter 
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Table 4C. 
Univariate Logistic Regression Analysis: Continuous variables 
P value 
Baseline Variables 
Age 0.08 
Ischemic Time 0.23 
Preprocedllre Variables 
DS(%) 0.73 
MLD (lmn) 1.00 
Postprocedure Vadables 
DS (%) 0.26 
MLD (mm) 0.002 
Ref Diam (mm) 0.Q2 
Balloon to Artery ratio 0.95 
Ischaemic Time is defined as time from sYlllpton onset to the first balloon inflation, DS: Diameter Stenosis, ~:fLD: lvlinimal 
Luminal Diameter, Ref Diam: Reference Diameter 
A radionuclide ejection fraction measurement was available in 274 (95%) patients pre~dischar­
ge and in 251 (91 %) of patients at follow-up. Left ventricular ejection traction at follow-up was 
not significantly different between patiellts with and without restenosis or reocclllsion (Table 6), 
Table 6. 
Clinical and Angiographic characteristics of patients with and without restenosis 
No Restenosis P-value Restenosis 
67% (191) 33 % (93) 
EF pre discharge (%) 47 ± 11 0.62 46 ± 12 
EF Follow up (%) 48 ± II 0.56 47 ± 11 
reM! I (0.5%) 0.02 5 (5%) 
re PTCA 24 (13%) <0.0001 31 (33%) 
CABG 11 (6%) 0.04 12 (13%) 
Death 1 (0.5%) 0.60 1 (1%) 
Collaterals* 
Rentrop 0 (%) 96 <0.0001 65 
Rentrop I (%) 3 0.001 20 
Rentrop 2 (%) 1 0.001 15 
EF: Ejection Fraction, lvll: i\Iyocardial Infarction, PTCA: Percutaneous Transluminal Coronary Angioplasty, CABG: Coro-
nary Artery Bypass Grafting, *: angiographic collaterals visible on the follow-up angiogram during injection of the contra-
lateral coronary artery 
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During the follow-up period of 6 months, 6 patients (2%) suffered a non-fatal reinfarction, 55 
patients (19%) had a repeat angioplasty procedure and 23 patients (8%) underwent coronary 
bypass surgery. Patients with restenosis or reocclusion had a higher incidence of recurrent myo-
cardial infarction and coronary revascularization procedures. From the 93 patients with docu-
mented angiographic restenosis, 41 patients (44%) had either a second percutaneous coronary 
angioplasty procedure or underwent surgical revascularization. Patients with restenosis more 
often had visible collaterais on their follow-up angiogram compared to patients without reste-
nos is. Table 7 summarizes the clinical consequences of reocclusion. At follow-up 84% of 
patients received Aspirin, 14% Coumadin, 13% Nitrates, 51 % a b-blocker, 26% a Ca-antagonist, 
12% Diuretics, and 26% of patients received an ACE-inhibitor. 
Thble 7. 
Clinical consequences of reocclusion 
Patient age gender 112/3 VD day IRV collaterals' symptoms revascula- QCAafterPA 
rization (OS (%), Ref 
Diam (mm)) 
I 55 m 1 131 RCA none - 33, 2.70 
2 52 m 2 118 RCA 2 none - 34, 4.44 
3 73 f 1 123 LAD 2 SA PTCA 36, 2.26 
4 51 m 2 5 CX 0 UA PTCA 4, 2.65 
5 64 m I 108 CX 2 SA - 28, 2.59 
6 48 f I 86 LAD 3 SA CABG 31, 2.66 
7 34 m I 7 LAD 0 MI PTCA 12, 2.75 
8 64 f 3 104 CX SA CABG 35, 3.00 
9 69 m I 10 LAD MI PTCA 26, 2.73 
10 56 m 3 I RCA 0 MI PTCA+stcnt 14, 2.82 
II 34 f I 165 RCA 2 none - 10, 2.93 
12 43 m I 122 RCA 2 none - I, 3.12 
13 59 m 1 176 CX 3 none - 16, 3.21 
VD: Vessel Disease, JRV: Infarct-Related-Vessel, LAD: Left Anerior Descending Artery, CX: Circumflex Coronary Artery, 
RCA: Right Coronary Artery, *: angiographic col1aterals visible on the pre-treatment angiogram during injection of the con-
tralateral coronary artery, QCA: Quantitative coronary angiography, PA: Primary Angioplasly, DS: Diameter Stenosis, 
IIIILD: l\linimal Luminal Diameter, Ref Diam: Reference Diameter 
Discussion 
Res/ellosis 
This study shows that restenosis after successful primary angioplasty for acute myocardial 
infarction occurs in 37% of patients 6 months after the index myocardial infarction. These fin-
dings are very similar compm'ed to the results of conventional balloon angioplasty for stable 
angina patients (21) and compare favorably with the restenosis rate after elective angioplasty for 
chronic total occlusions or for patients with unstable angina pectoris (22,23). 
Previous studies in patients who underwent primary angioplasty for acute myocardial infarction 
reported restenosis rates varying from 17% to 45% (1,6,8,24). Brodie et al (6) describes angio-
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graphic restenosis, measured with a caliper technique in a subset of 65% of patients with a 
follow-up angiogram, and found restenosis to occur in 46 % of patients. This study included 
patients who had an unsuccessful primary angioplasty procedure as well. Nakagawa et al (24) 
recently reported a serial angiographic follow-up of a selected group of patients, who all had a 
100% occluded infarct-related-vessel before intervention. They found a slightly higher resteno-
sis rate at 4 months follow-up of 43%, mainly due to a higher rate of reocclusion. 
Predictors of restellosis 
Age was found to be an independent predictor of restenosis. This has also been described in stu-
dies of restenosis after elective PTCA for stable angina (25). In Table 4B it is shown that espe-
cially a young age «50 years) is related to a low restenosis rate. No significant interaction bet-
ween age and any baseline variable that might influence restenosis was found. A possible expla-
nation might be the fact that in young patients an acute thrombotic occlusion occurs on a relati-
ve healthy coronary artery without much underlying coronary artery disease. Dilatation of the 
occlusion may mainly be matter of "thrombus squeezing". Other baseline characteristics, like 
diabetes and hypertension, which were found to be related to restenosis after angioplasty for sta-
ble or unstable angina (25), were not predictive in this cohort of infarct patients. 
There was a strong relation between the occurrence of restenosis and the angiographic charac-
teristics of the vessel after the angioplasty procedure. In Figure 2 it is shown that the follow-up 
diameter stenosis curve tends to diverge instead of making a parallel shift to the right. This 
shows that a wider lumen after the procedure is associated with less restenosis. Tius is confir-
med by multivariate analysis in which the nUlumallununal diameter after angioplasty is inde-
pendently related to restenosis. The reference diameter of the vessel was related to restenosis as 
well. Patients with a reference diameter less than 3.0 nun had a significantly higher restenosis 
rate compared to patients who had a reference diameter greater than 3.0 nun (38% vs 27%, 
p=0.03). Reference diameter (vessel size) is related to lumen diameter after angioplasty, and 
therefore reference diameter was no longer predictive of restenosis after correction for minimal 
luminal diameter by multivariate analysis (Table 5). 
Table 5. 
Multivariate analysis 
Odds Ratio 95%CI P-value 
Baseline Variable 
Age (per quartile) 1.27 1.0 I - 1.60 0.04 
Postprocedure Varia~les 
MLD post (per quartile) 1.46 1.07 - 2.01 0.02 
Ref Diam post (per quartile) 0.86 0.60 - 1.24 0.42 
Balloon to Artery ratio (per quartile) 0.91 0.68 - 1.22 0.55 
Balloon Diameter 1.10 0.52 - 2.34 0.81 
i\-ILD: minimal luminal diameter; Ref Diam: Reference Diameter 
These findings are in accordance with previous snldies, both in patients after elective angio-
plasty for stable angina as in myocardial infarct patients treated with either thrombolytic therapy 
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or primary angioplasty (24,26,27), who fonnd the residual lumen diameter after repelfusion the-
rapy to be strongly related to restenosis. This makes primary stenting, by which a large luminal 
diameter of the infarct-related vessel can be achieved, an attractive alternative therapy. Prelimi-
nary findings of this therapy indeed suggest superior angiographic and clinical results in patients 
with acute myocardial infarction, who are candidates for primary stenting (28). 
Clillicaf cOllseqllellces of restellosis 
Patients with restenosis had a significantly higher rate of reinfarction and more often had repe-
at coronary revascularization procedures, compared to patient without restenosis. However, 
most patients with angiographic restenosis could be managed without a second intervcntion. 
Only patients with chest pain and non-invasive evidence of reversible ischemia were candidates 
for a second revascularization procedure. This is in accordance with recent findings of Brodie et 
aI, and Nakagawa et ai, who managed 55% and 51% of patients with angiographic restenosis 
without rcintervention (6,24), and suggests that a strategy of watchful waiting in patients with 
restcnosis after angioplasty for acute myocardial infarction is applicablc (29). 
Reocc/us;oll 
Reocclusion of the infarct-related vessel was seen in 5% of the study population. This is not hig-
her than the reported reocclusion rate in a large patient cohort, who underwent elective balloon 
angioplasty for stable or unstable angina (9,10,30), and considerably lower than the reocclusion 
rate after successful thrombolytic therapy, in which rates varying between 10% and 3-5% have 
been described (11,31). 
IlIfll/e/lce of restellosis or reocc/l/siOIl 011 feft ,'ellh'icl/farfl/llctioll 
Recent rcports state that reocclusion of the infarct related vessel has detrimental consequences 
for left ventricular function (11,12). Our data do not confirm these findings. Although there is a 
trend towards a lower left vcntricular ejection fraction in patients with restenosis or reocclusion, 
this difference is not significant. This is probably related to the small Humber of patients with 
reocclusion, but might also be related to a concomitant increase in collateral circulation in 
patients with restenosis and reocclusion: patients without restenosis or reocclusion alnlost never 
had visible collaterals on their follow-up angiogram (Table 6). Patients with reocclusion had the 
highest grade of angiographic documented collaterals on their follow-up angiogram: 21 % Ren-
trap class I, 43% Rentrop class 2, and only 36% of patients with reocclusion did not have visi-
ble collaterals. 
Time to follow l/p al/giogmphy 
Studies performed in patients with stable angina showed that restenosis is a time related pheno-
menon with an increasing number of patients with restenosis with latcr time to follow-up angio-
graphy (32,33). Tllis study was not designed to assess the influence of time to follow up angio-
graphy on restenosis. Comparison of the rcstcllosis rate of the 2 groups who had angiography at 
different time intervals show that restenosis increases from 27% at 94 days to 37% at a mean of 
135 days after angioplasty. However, the higher restenosis rate in the 6 months group might 
otherwise be explained by the smaller luminal diameter after angioplasty in this group, which 
has been shown to be an independent risk factor for development of restcnosis. 
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Limitatiol/s of the study 
Tlus study describes restenosis in selected patients treated with primary angioplasty during a 5 
year period and therefore results cannot be extrapolated to all patients treated with primary 
angioplasty. The excluded patients (N~213) were older (62 vs 58 years), more often had a pre-
vious myocardial infarction (21 % vs 9%) and more often had multi vessel disease (60% vs 50%). 
They had a significantly smaller minimal luminal diameter after primary angioplasty (1.97 vs 
2.20 mm). Based on the findings of our study, it is to be expected that restenosis in this cohort 
of excluded patients nught be higher compared to the study patients. Previous studies on reste-
nosis after angioplasty for stable angina however, excluded the same kind of patients from 
follow up angiography (32,33). One might discuss the exclusion of refen'ed patients from analy-
sis. However, this patient group itself is a selected group of high risk infarct patients, and adding 
these patients to the study group might decrease the generalis ability of the results. 
Conclusion 
Restenosis or reocclusion after successful primary coronary angioplasty for acute myocardial 
infarction occurred in 27% of the patients at 3 months and in 37% of patients at 6 months follow-
up. Independent predictors of restenosis were age and lumen diameter immediately after angio-
plasty. Young patients «50 years) and patients with a mitumalluminal diameter of more than 
2.5 nun had a restenosis rate less than 25%. A second revascularization procedure was perfor-
med in 44% of patients with restenosis. Although the incidence of reinfarction was higher in 
patients with restenosis, there was no significant difference in left ventricular ejection fraction 
between patients with and without restenosis. 
Clinical Implications 
This study, which shows that the minimal luminal diameter immediately after primary angio-
plasty is an independent predictor of restenosis, suggests that primary stenting or other inter-
ventions that improve the minimal luminal diameter after the angioplasty procedure, may redu-
ce the restenosis rate and therefore reduce the need for subsequent re-interventions and hospital 
re-admissions. 
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General Discussion 
This thesis describes various aspects of primary coronary angioplasty in patients with acute 
myocardial infarction: reperfusion at the tissue level, additional stent or lABP therapy, treatment 
of low risk patients, the feasibility and safety of transporting infarct patients to a centre with 
PTCA facilities, the importance of ischemic time and transportation delay for outcome and res-
tenosis and reocclusion of the infarct related vessel. 
Monitoring Repelfllsion 
In the first trials which evaluated the efficacy of thrombolytic therapy, the agent was administe-
red directly into the coronary artery. Reperfusion could be monitored by repeated injections of 
contrast into the infarct related artery. Later, when patients were treated with intravenous lytic 
agents, sllccessful reperfusion was defined as a combination of electrocardiographic, biochemi-
cal and clinical features. This combination was excellent in risk stratifying patients shortly after 
the event, but was of limited value in the prediction of the patency status of the infarct related 
vessel (I). This thesis showed that this is due to limitations ofTIMI flow for assessment of COlll-
pleteness of reperfusion. It was shown that, in part of the patients, persistent ST segment eleva-
tion was present, suggestive of impaired reperfusion, despite TL\lI 3 flow in the infarct related 
artery. By means of 12-1ead electrocardiography, important information was obtained about the 
success of rcperfusion therapy. Thus it was possible to risk stratify patients at a very early stage 
after the acute event. 
So far, no simple clinical parameter was available to obtain information about the extent of myo-
cardial repelfusion. We have previously described the relation between myocardial flow reserve 
assessed by densitollletric analyses of contrast medium passage in the infarcted myocardiulll and 
left ventricular function (2). However, this semiquantitative method has several pitfalls and limi-
tations and is not applicable in routine clinical practice (3). Other available tools, like myocar-
dial contrast echocardiography (4,5), dobutamine stress echocardiography (6,7), TIM! ti-ame 
count (8), post angioplasty intracoronary now measurements (9-12), Positron Emission Tomo-
graphy (PET) scanning (13,14), or MRl (15) are also not readily available during the first hours 
after repeifusion therapy. Both the extent of ST segment elevation recovelY on the 12-lead elec-
trocardiogram and the myocardinl blush on a routine angiogram can be used for risk stratifi-
cation after primary angioplasty in patients with acute myocardial infarction. 
Myocardial blllsh 
The blush of myocardial tissue is the ret1ection of filling of the small arterioles of the myocar-
diulll with contrast (Figure 1). This blush is present on every diagnostic coronary angiogram and 
has been used in studies to calculate myocardial flow reserve (3). Decreased blushing of myo-
cardial tissue suggests that some epicardial flow bypasses the microcirculation and shunts 
directly into one of the greater cardiac veins. It is therefore questionable whether "normal" TIMI 
flow and absent myocardial blush may coexist. As mentioned in the article in chapter 2, "nor-
mal" TIMI flow is probably not "normal" in these patients. In an article in which intracoronary 
flow measurements were performed in patients with acute myocardial infarction, TTh1I 3 flow 
varied from 17 to 40 cm per second and considerable overlap existed in blood flow between 
patients with TIMI 2 and TIM! 3 t10w (10,16). This highlight the limitation of TIM! t10w assess-
ment. In our opinion, qualifying not only epicardial but myocardial t10w (blush) as well might 
reduce some of these limitations of TlNlI flow grading. 
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Figure I showing different blush grades after succesful opening of the infarct related vessel. The left panel shows adequa-
te staining of repeliused myocardium with contrast. The right panel shows no staining of myocardium. 
Primal)' Allgiop/asly fol' w/tom? 
Previous studies showed that high risk patients benefit pmiiculmly from treatment with pIimary 
angioplasty, compared to thrombolytic therapy (17-19). Tllis thesis shows that low tisk patients, par-
ticular patients with inferior infarction, benefit from primmy angioplasty as well, primmily because 
of a lower rate of reinfarction. Tlus has been accomplished without an increase in totalmcdical char-
ges. It has been concluded that in hospitals with an existing infrastructure for intervenlional cm'dio-
logy primary coronary angioplasty should be considered in all patients with symptoms of acute 
myocardial infarction and ST segmcnt elevation. This study is the first to randomise low risk 
patients to different types of rcpcrfusion therapy. A recent overview concluded that adnulustering 
repelfusion therapy to low risk patients with inferior infarction (ST elevation in leads II, ill, and AVF 
only) should be reconsidered, as baseline mOltality tisk in these patients is only 2-4% (20). 
If the benefit of treating low risk infarct patients with primary angioplasty is only a reduction in 
reinfarctions, what price should be paid for prevention of reinfmction? Would it be cost-effecti-
ve to put a low Iisk patient on transport to a tertiary centre with the aim to perform primary 
angioplasty to prevent reinfarction? A recent study presented a model for choosing different 
types of reperfusion therapy, based on risk estimation and gain in life-expectancy (21). In this 
model, primary angioplasty will only be considered if the expected gain in life expectancy would 
be more than 12 months or if an increased risk of intracranial haemorrhage is present. In hospi-
tals without angiopJasty facilities, this model may help the physician in deciding for the best and 
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most cost-effective reperfusion strategy and when to put a patient on transport to a tertiary cen-
tre. New patient groups are identified, which lllay especially benefit from reperfusion therapy by 
primary angioplasty compared to thrombolytic therapy. The European Society of Cardiology 
recently stated in its guidelines that primary angioplasty may have a special role in the treatment 
of patients with cardiogen.ic shock and in those with contra-indications for thrombolytic therapy 
(22,23). Diabetic patients (24), patients over 75 years of age (25), and patients with evidence of 
concomitant right ventricular infarction (26-28) might be added to the list of high risk patients 
which may be candidates for transportation to a hospital with angioplasty facilities. However, as 
was concluded in this thesis, whenever angioplasty facilities are available 24 hours round the 
clock, all patients with ST segment elevation and evidence of continuing ischemia may benefit 
from primary angioplasty without increasing costs. 
PrimalY Stelltillg 
In our single-centre study, primary coronary stenting resulted in a significant decrease in the 
incidence of the combined end point of death, non-fatal reinfarction and revascularisation of the 
infarct related vessel at 6 months follow-up. This was also found in the FRESCO (Florence Ran-
domised Elective Stenting in Acute Coronary Occlusions) trial (29). The recently presented data 
of the large multicentre Stent-PAMI trial however, failed to show additional benefit of primmy 
stenting at one month follow-up, except for a slight reduction in re-PTCA's (30). Our study 
results show that primary stenting did not affect left ventricular function, measured during the 
in-hospital phase , myocardial blush grades or ST segment elevation recovery nor reduced 
infarct size or pre-discharge left ventricular function (Table I ). 
Table 1. 
TIMI flow, l\1yocardial blush, ST segment elevation resolution, enzymatic infarct size and left 
ventricular function in patients randomised to primary stenting or balloon angioplasty. 
balloon stent P 
(N~1l5) (N~1l2) value 
TIMI 3 flow (%) 94% 90% 0.35 
Myocardial Blush (N~203)* 
normal (%) 28 23 0.31 
moderate (%) 50 57 0.37 
minimal or no (%) 23 24 0.98 
ST recovery (N~ 183)* 
complete (%) 47 48 0.94 
partial (%) 34 42 0.27 
no (%) 19 10 0.08 
Enzymatic Infarct size (N~ 147)** 1266 ± 1014 1317±1052 0.22 
Ejection Fraction (N~ 135)# 44 ± II 43 ± 10 0.42 
*- as defined in chapter 2, "'''' LDHQ72 :calculated from at least 5 serial measurements of lactate dehydrogenase up to 72 
hours atkr rcperfusion. #: calculated with radionuclide angiography at 6 months follow-up 
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These results make it questionable whether every eligible patient should receive a stenL An 
important aspect is cost-effectiveness. We estimated total costs of primary coronary stenting 
compared to balloon angioplasty and showed that, although initial costs were higher for primary 
stenting, this was largely compensated by a reduced need for second revascularisation procedu-
res during one year follow-up. 
Intra-aortic Balloon Pllmping 
OUf data show that there is no additional benefit of routine intra-aortic balloon pumping after 
primary angioplasty in high risk patients with acute myocardial infarction. This is consistent 
with the findings of a large randomised trial, who reported similar results (31). In patients in car-
diogenic shock, however, insertion of an intra-aortic baBoon pump may be indicated (32). The 
benefit of balloon pumping has bcen the prevention of (re)occlusion of the infarct related vessel 
(33,34). Before insertion of an intra-aortic balloon pump, the risk of 8 % major complications 
must be weighted against the scant evidence of a positive effect on clinical outcome in high risk 
infarct patients treated with reperfusion therapy. Especially in elderly patients (>75 years), the 
risk may outweigh the benefit (35). 
Other additional thempies 
Studies are undertaken or ongoing on other adjunct or additional therapies in patients after pri-
mary angioplasty. Recently the efficacy and safety of glycoprotein llbllIIa receptor antagonists 
have shown its value in patients during and after elective coronary angioplasty (36-38). The 
aggressive blockade of thrombocyte aggregation is of great importance shortly after angioplasty 
to prevent recurrent ischemia and reocclusion, especially since it has been shown that the lcvel 
of platelet activation is increased by primary angioplasty (39). The RAPPORT (ReoPro® in 
acute myocardial infarction and Primary PTCA Organisation and Randomisation Trial) trial has 
evaluated this drug in patients treated with primary angioplasty for acutc infarction and found a 
lower OCCUlTence of the combined incidence of death and reinfarction in this patient group (40). 
Recently two pilot studies have been pedonned with high dose heparin or abciximab, a glyco-
protein IIblllla receptor blocker, as pre-treatment of patients with acute myocardial infarction 
with the aim to increase patency before primary angioplasty. Patients with TlLvlI 3 flow of the 
infarct related vessel at acute angiography can be treated safely without intervention, have small 
infarctions and an excellent in-hospital outcome (41). It has been shown that both heparin and 
abciximab have thrombolytic potential (42,43) and may be indicated for patients before trans-
portation to a hospital with angioplasty facilities. A pilot study showed a significantly higher 
patency rate of the infarct related vessel before angioplasty in patients who were pretreated with 
a megadose of intravenous heparin (either 20.000 or 30.000 IU as a bolus) compared to a mat-
ched population of patients who received the normal pretreatment of oral aspirin without the 
high dose heparin (TIM! 2 and 3 !low: 35% vs 12%, p~O.OOI, 44). However, preliminary results 
of a larger randomised trial failed to show a difference in patency rate before angioplasty bet-
ween patients pre-treated with or without high-dose hepmill (45). Abciximab, however, do seem 
to have lytic capacity. The GRAPE (Glycoprotein Receptor Antagonist in Early Patency trial) 
pilot study (46), the earlier mentioned RAPPORT study (40), and the recently presented TIMI 
14 study (47), found a patency rate (TIM! 3 !low) of 18%, 22% and 32% respectively. The lat-
ter result is comparable to the rate of TlLvIl 3 flow achieved with intravenous streptokinase. 
The importallce of tisslle repelillsion 
As is shown in the first part of tltis thesis, a high degree of reperfusion at the myocardial, cellu-
lar level is of paramount importance for a good prognosis after primary angioplasty. This was 
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found especially for patients who presented in a higher Killip class. Despite reperfusion therapy, 
mortality remains unacceptably high in these patients. A recent study however, showed that, 
using an aggressive stratcgy of systematic and stent-supported direct angioplasty (which was 
successful in 85% of patients) in-hospital mortality could be reduced to 26% (48). Figure 2 
shows that patients in Killip class 2 or higher with a high grade of myocardial blush (grade 2 or 
3) after angioplasty have a good to excellent prognosis. 
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Future additional therapies should therefore be aimed at improvement of impaired myocardial 
reperfusion shortly after coronary angioplasty. Various agents, with different Ill:echanisms of 
action, have shown beneficial results in this regard: A glycoprotein IIb/ITIa receptor antagonist 
(Abciximab,49,50), intracoronary Verapamil or Nifedipine (51-53), Glucose-Insulin-Potassiulll 
(GIK,54), Adenosine (55, 56), Nicorandil or Cromakalim (57,58), a Na+-H+ exchange inhibitor 
(59) or an anti-apoptotic agent (60). Although one agent, ReoThRx" has shown beneficial 
effects as adjunct therapy in thrombolytic treated patients (61), the same agent proved not to be 
effective as adjunct in patients treated with primary angioplasty (62). However, as both reco-
very of ST segment elevation and myocardial blush grade were related to total ischemic time, 
the most effective "additional therapy" might be to keep the time from symptom onset to reper-
fusion as short as possible. 
Transporting patients with acute myocardial iufarctioll. 
Transporting high risk patients with acute myocardial infarction to a centre with angioplasty 
facilities is feasible and safe, as is discussed in this thesis. However, these results were obtained 
in an area with excellent transportation facilities in a non-urbanised region and may therefore not 
be extrapolated to other regions in other countries. In highly urbanised arcas (traffic jams), as 
well as in remote areas, as for example northern Scotland, the time needed to transport a patient 
to the nearest intervention centre, may be much longer than the 70 minutes from Ollr study. 
One must be aware of the logistic burden, which may be the consequence of the extension of 
indications for transportation of patients for ped'orming primary angioplasty. Using the Rotter-
dam model (21), only 5% to 10% of all infarct patients are candidates for treatmcnt with primary 
angioplasty. In 1997,29.000 patients were hospitalised under the diagnosis of (acute) l11yoear-
dial infarction in the Netherlands (63). Assuming that two third of these patients are candidates 
for reperfusion therapy, primary angioplasty should be considered in a total of 1900 patients 
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annually. The majority of these patients will be presented in hospitals without angioplasty faci-
lities. Assuming that all 13 angioplasty centres will be equally involved, about 120 patients 
annually (2 to 3 patients weekly) are presented from elsewhere per centre. Extension of the indi-
cation for primary angioplasty to 20% of reperfusion eligible patients would double the number 
of patients with an indication for transportation to a tertiary centre. The annual number of 
patients transferred to our centre for performing primary angioplast)' increased from 25 patients 
per year in the early nineties to more than 100 in recent years. 
The price oJ /ral/spor/a/iol/ 
Transportation of high risk patients to a centre with angioplasty facilities may be done, at the 
cost of an increase in il1f~1rct size, but without a negative intluence on the success rate of primary 
angioplasty and 6 month mortality. This was found in a selected population of patients with large 
anterior infarctions who had a mean presentation delay of only 90 minutes. The study was a mat-
ched control study, and not a randomised comparison. The exact inOuence of extra time delay 
on outcome can only be determined by deliberately delaying time to reperfusion and this would 
be unethical. Furthermore, our study results are applicable for the Zwolle situation only. Tie-
fenbrunn and colleagues recently reported a significantly higher mortality in patients who had a 
2.3 hours extra delay due to transportation in an observational study of more than 10.000 patients 
(64). The American College of Cardiology-American Heart Association Guidelines recommend 
performing primary angioplasty if it can be performed within 90 minutes of diagnosis (65). An 
alternative strategy is followed in the Limburg region of the Netherlands (66). During the delay, 
associated with transportation, patients were treated with thrombolytic therapy. In Baltimore, 
USA, thrombolysis before transfer is advised only if anticipated delay exceeds 120 minutes (67). 
A randomised trial between direct transportation and performing primary PTCA versus direct 
transportation after thrombolytic therapy and performing rescue angioplasty in case of failed 
thrombolysis, is ongoing in the Maastricht area. Results of the pilot study showed that there were 
no differences in outcome between the groups, although patients allocated to primary angio-
plast)' had the highest rate of TlMl 3 flow and the lowest rate of second interventions (68). A 
large Illulticentre trial and perhaps the ongoing PACT (Plasminogen Activator-Angioplasty 
Compatibility Trial) (69) may answer the question whether transportation delay plays ~1I1 essen-
tial role in patients treated with primary angioplasty, and if or when patients might benefit from 
additional pre-transportation fibrinolytic therapy. 
Time to repelfusioll 
In patients treated with primary angioplasty the relationship between presentation delay and cli-
nical outcome in patients with acute myocardial infarction was not evident, according to a recent 
report (70). No difference in mortality was found between patients treated early «3 hours) or 
late (>3 hours). Tllis thesis however, showed that ischemic time (time from symptom onset to 
first balloon inflation) in patients treated with primary angioplasty is an independent predictor 
of both mortality and left ventricular function recovery. Especially the finding that later mecha-
nical opening of the infarct-related vessel led to a decreased rate of TIMI 3 flow has not pre-
viously been reported in patients treated with primary angioplasty. In 1987 this had already been 
shown for patients treated with thrombolytic therapy in the TlMI phase I trial (71), and this is 
probably one of the reasons why earlier thrombolytic therapy leads to a better outcome (72). The 
articles in chapter 1 show that myocardial reperfusion, as retlected by ST segment elevation 
recovery and myocardial blush grade, is correlated with ischemic time. The earlier the vessel is 
opened, the better the ST elevation recovery and the higher the blush grade. 
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Should late elltly patieuls receil'e repel/usioll Iherapy? 
Although our study found that patients treated after 6 hours had the worst outcome, compared 
to patients treated earlier, it does not mean that reperfusion therapy in these patients should not 
be given. A rate ofTlMl 3 flow of 83% in these patients is far higher than the spontaneous reca-
nalisation rate in patients not given reperfusion therapy (which is about 20% 12 hours after 
symptom onset (73), and although reopening of the infarct related vessel in these patients pro-
bably does not directly lead to myocardial salvage, a patent vessel is beneficial possibly by gre-
ater infarct healing and electrical stability (74). 
In our study it was found that female and elderly patients and patients with diabetes presented 
later after symptom onset. These patients arc belonging to a high risk group (35,75), and there-
fore reperfllsion therapy should be started instantaneously on ani val of these patients at the hos-
pital, despite the fact that these patients at1"ive later than 6 hours after symptom onset. Especially 
in female patients and in patients who are older, considerable underutilisation of therapies is 
reported, while these patients might particular benefit from late opening of the infarct related 
vessel (24,25, 76, Figure 3). This wiB have consequences for the future as a large increase in the 
number of patients with myocardial infarction in the older age groups may be expected (77). 
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ResteJ10sis and Reocclllsioll 
Restenosis or reocclusion of the infarct related vessel occurred in 37% of the patients after suc-
cessful primary coronary angioplasty at 6 months follow-up. The 6% reocclusion rate is com-
parable to the reocclusion rate of patients after elective angioplasty for stable angina. Patients 
who were younger than 50 years of age and patients whose minimal luminal diameter after suc-
cessful angioplasty exceeded 2.5 1111l1, had a restenosis rate of less than 25%. Therefore it is ques-
tionable whether these patients Illay benefit from additional stenling. There are more data which 
support the theory that in patients with a stent-like result, additional stenting is of limited value 
(78), although the recently published FRESCO trial showed superior outcome for stent treated 
patients compared to optimal balloon angioplasty (29). A recent perspective advised to use coro-
nary stenting as an adjunct to balloon angioplasty and not as an alternative, mainly because of 
the difficult-to-treat problem of in-stent restenosis (79). Preserl'ing stents for patients with the 
highest benefit may also be more cost-effective. Preliminary data of ollr randomised tdal, des-
cribed in chapter 2, showed that reslenosis occurred in only 8% of patients treated with primary 
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stenting, compared to 36% for the angioplasty only group (80). However, one mllst be aware that 
these results are obtained in a selected population of patients with vessels over 3 mm in size. 
A recent study (non-randomised, matched control) showed a restenosis rate of 27% for patients 
treated with bailout or primary stenting, compared to a restenosis rate of 52% for patients trea-
ted with primary angioplasty (38% restenosis, 14% reocclusion) (81). This high rate of resteno-
sis was due to inclusion of patients who had unsuccessful angioplasty as well. The minimallumi-
nal diameter after angioplasty of 1.97 mm recorded in this study is exactly the same compared 
to the minimallulllinal diameter of our patients which were excluded from the trial (unsuccess-
ful procedure, CABG< 6 months, death< 6 months). Assuming that these 213 excluded patients 
have a rate of restenosis comparable to the French group, the rate of restenosis in our total popu-
lation of 497 consecutive patients who underwent primary angioplasty during a 6 year period, 
would be 41 %. 
The issue "the bigger the better" suggests that using more aggressive intervention techniques, 
like rotablator or coronary atherectomy, which maximise luminal diameter, would reduce reste-
nosis. However, in one study, which lIsed coronary atherectomy in patients with acute myocar-
dial infarction, clinical outcome was not improved compared to plain old balloon angioplasty, 
mainly because of significant late loss of minimal luminal diameter at long term (90 days) 
follow-up (82). 
Future research 
Tllis thesis addressed various questions about the role and effectiveness of primary coronary 
angioplasty in patients with acute myocardial infarction, but also showed its limitations. There-
fore further research is necessary. The following questions might lead to a more optimal therapy 
for patients with acute coronary syndromes. 
Qllestioll 1 
According to the new definition of succcssful repelfusion (TIM! 3 flow with evidence of myo-
cm"dial reperfusion), would it be possible to achieve this in more than 90 % of patients treated 
with ptimary angioplasty? 
The GUSTO angiographic substudy has shown that early and complete reperfusion is the essen-
tial goal of reperfusion therapy, but this was achieved in only 35%-65% of patients (83). Primary 
angioplasty however, with early and successful opening of the infarct related vessel is possible 
in more than 90% of patients. Despite this high rate of epicardial reperfusion, only 60-70% of 
patients had evidence of myocardial reperfusion. Therefore future research should be aimed at 
improving myocardial reperfusion at the cellular level. ST segment recovery and angiographic 
myocm"dial blush may help in identifying high and low risk patients and monitoring the effect of 
treatment modalities. 
Qllestioll 2 
What should be indications for transfer of an infarct-patient to a tertiary centre? 
Recently Pasceri suggested that future research on primary angioplasty should aim at finding 
subgroups of patients who have an adverse prognosis with standard treatment (84). 
Preliminary data suggest that patients with diabetes (24), patients over 75 years of age (25), or 
with evidence of right ventricular infarction (26-28), may especially benefit from treatment with 
primary angioplasty compared to thrombolytic therapy. 
Qllestioll 3 
Is primary stenting for acute myocardial infarction cost-effective? 
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Although it was calculated that total costs were not higher for patients treated with primary steH-
ting, the comparative cost-effectiveness needs to be established. To improve cost-effectiveness. 
further research should be aimed at finding subgroups of patients. which benefit 1110st from pri-
mary stenting. 
Questiol/ 4 
How can treatment delay ("diagnosis to balloon" time) be further reduced? 
Treatment delay for our patients is about 60 minutes, and did not further decrease since 1991. 
However, from the studies on pre-hospital thrombolysis it became evident that the diagnosis of 
acute myocardial infarction can be reliably made in the ambulance. A prehospitaJ electrocardio-
gram resulted in further reduction of treatment delay and a higher number of patients who recei-
ved of reperfusion therapy (85), Recent studies showed that an additional 20-50 minutes can be 
saved by preparation of the CCU unit or catheterisation laboratory (86.87). Outcome may be 
improved if these patients are pre-treated with agents like Aspirin (88), high dose heparin, or a 
glycoprotein lIbfllIa rcccptor blocker (abciximab) during transportation (89). Furthermore, it 
should be evaluated if the decision, whether a patient is a candidate for primary angioplasty can 
be made in the ambulance. Thc Rotterdam model (21) might hclp in identifying these patients. 
By doing so, unnecessary admission in non-tertiary centres can be avoided. A feasibility study 
to test this hypothesis has been started in the Zwolle region with support from health care orga-
nisations and ambulance services. 
Questioll 5 
Can the risk of reocclusion and reinfarction after primary angioplasty be reduced by stenting, the 
use or a glycoprotein IIbifIIa receptor blocker (Abciximab) or both? 
Our data showed that reocclusion occurred in only 6% of patients after successful primary angio~ 
plasty. However, othcr centres report rates of 10-15%. Either coronary stenting (81) and the use 
or glycoprotein lib/IlIa receptor antagonists (40), or both (90) have resulted in a reduction of 
recurrent ischemic events and reocclusion of the infarct related vessel. A recent report sugges-
ted that the combination of primary stenting and the use of a glycoprotein JIblIIIa receptor anta-
gonist (Abciximab (ReoPm,» results in an increased procedural result and a better coronary 
flow (91). New studies should be aimed at identirying high risk patients for which additional 
stenting or pharmacological intervention or both is cost effective. 
Questioll 6 
Should immediate angiography be considered in patients with suspected myocardial infarction 
without ST segment elevation? 
Recent data showed that between 20% and 40% of patients with acute myocardial infarction are 
not candidates for reperfusion therapy because the electrocardiogram made on admission is not 
diagnostic (92, 93). Especially patients with acute posterior infarction are often excluded from 
reperfusion therapy, because the electrocardiogram only show ST segment depression or no 
repolarisation abnormalities at aiL A recent perspective showed that many patients with nOI1- ST 
segment elevation myocardial infarction do not receive even the most fundamental forms ofthe-
rapy (94). Little or no ST segment elevation may be a sign of preserved flow (either antegrade 
or retrograde) to the infarcted myocardium and in 1989 Rentrop suggested thal the time window 
of benefit for repelfusion therapy may be much wider in these patients (95). Furthermore, an 
immediate angiogram may be used as risk stratification in patients with a non-diagnostic ECG, 
as a proportion of them may have underlying severe triple vessel disease or even left main dise-
ase (96). 
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Questio1l 7 
How can fatality outside the hospital from acute coronary syndromes be reduced? 
Two-thirds of deaths from acute coronary syndromes occur outside the hospital. Tills has not 
changed the last 25 years(97). This lVas found especially for patients under 55 years of age, in 
which a case fatality rate of 90% lVas reported (98). Therefore further large reductions in mor-
tality can be accomplished only by primary prevention, secondary prevention or intervention 
before admission. This emphasises the need for better preventive programs, especially since the 
ongoing trend for increased smoking behaviour amongst young teenagers. 
Closi1lg Remarks 
The final common pathway of the treatment of acute myocardial infarction is to open the infarct 
related vessel as good and as quick as possible. In a hospital without angioplasty facilities, the 
question remains whether to start the lytic (earlier, but less effective) or to wait for the balloon 
(iater, but more cffective), or both. \Vith modern telecommunication, ambulance personnel and 
equipment, any patient with suspected acute myocardial infarction should receive the most opti-
mal reperfusion strategy. This requires good co-operation between intervention and non-inter-
vention centres. 
O'Neill et al. concluded that all institutions committed to a mechanical reperfusion approach 
should pursue 90% patency rates or more, an emergency-room-to-cath-lab-time of less than I 
hour, and mortality rates of thrombolytic eligible patients and patients with cardiogenic shock of 
3% and less than 50% respectively (76). These targets should not be restricted to patients under-
going primary angioplasty but should be aimed for every patient with an acutc myocardial 
infarction, independent the centre he or she presents. 
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How to perform Primary Angioplasty? 
10 commandments 
I. In suspected myocardial infarction, initial assessment < 15 minutes: 
TIME = MUSCLE = LIVES 
2. When diagnosis of myocardial infarction is corumned before hospital arrival, go to 
cathetarization lab, and not to emergency room or CCU. 
3. Do not forget aspirin, heparin, nitrates (Beta-blocker). 
4. Visualise both coronary arteries. 
5. Use a balloon and perhaps a stent, forget other techniques. 
6. Consider conservative management and acute or elective CABG. 
7. Be sure that somebody looks after the patient when you perform angiography and 
angioplasty. 
8. Beware of and prepair for reperfusion arrhythmias, bradycardia and hypotension. 
9. Do not undersize. 
10. Stent the plague, not the vessel. 
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Chapter 1 
Introdnction 
Pdmary coronary angioplasty, i.e. angioplasty in patients with acute myocardial infarction wit-
hout antecedent thrombolytic therapy, has been evaluated as a means of reperfusion therapy 
since the early nineteeneightees. The results of the first trials were promising, however, after the 
disappointing results of angioplasty after (failed) thrombolytic therapy, much of the initial ent-
husiasm was lost. In 1993, the publication of three tdals, which randomly compared throm-
bolysis with primary angioplasty, resulted in a revival of primary angioplasty as an effective 
repelfusion modality in patients with acute myocardial infarction. In 1996, both the American 
and European Heart Association recommended primary angioplasty as a first treatment option, 
especially for patients in cardiogenic shock and for patients with contra-indications for throm-
bolytic therapy. This thesis addresses some aspects of patients treated with pdmmy angioplasty. 
Chapter 2 
ST segment elevation resolution 
A simple clinical method to stratify patients for risk who have had successful reperfusion the-
rapy after myocardial infarction is lacking. We investigated the clinical value of the 12-lead elec-
trocardiogram (ECG), in 403 patients after successful reperfusion therapy by primmy coronary 
angioplasty, in relation to infarct size measured by enzyme activity, left-ventricular function, and 
clinical outcome. ECGs were analyzed to find the extent of the ST-segment-elevation resolution 
I h after reperfusion therapy. A normalized ST segment was seen in 51 % of patients, a partly 
normalized ST segment in 34%, and 15% had no ST-segment-elevation resolution. Enzymatic 
infarct size and ejection fraction were related to the extent of the early resolution of the ST seg-
ment. The relative risk of death among patients with no resolution compared with patients with 
a normalized ST segment was 8.7 (95% CI 3.7-20.1), and that among patients with partial reso-
lution compared to patients with a normalized ST segment was 3.6 (1.6-8.3). Our findings sug-
gest that ECG patterns reflect the effectiveness of myocm'dial reperfusion. Patients for whom 
reperfusion therapy by pdmmy angioplasty was successful and who had normalized ST seg-
ments had limited damage to the myocardium and an excellent outlook during follow-up. 
Patients with persistent ST elevation after reperfusion therapy may need additional interventions 
since they have more extensive myocardial damage and have a higher mortality rate. 
Myocardial Blush 
In the second part of chapter 2, we studied 777 patients who underwent primary coronmy angio-
plasty during a 6 year period and investigated the value of angiographic evidence of myocardial 
reperfusion (myocardial blush grade) in relation to the extent of ST segment elevation resolu-
tion, enzymatic infarct size, left ventricular function and long term mortality. The myocardial 
blush immediately after the angioplasty procedure was graded by 2 experienced investigators, 
blinded to all clinical data: 0: no myocardial blush, I: minimal myocardial blush, 2: moderate 
myocardial blush, 3: normal myocardial blush. The myocardial blush was related to the extent 
of the early ST-segment elevation resolution on the 12-lead electrocm·diogram. Patients with 
blush grades 3, 2 and OIl had enzymatic infarct sizes of respectively 757, 1143 and 1623 
(P<O.OOOI) and ejection fractions of 50%,46% and 39%, (P<O.OOOI). After follow-up of 1.9 ± 
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1.7 years, mortality rates of patients with myocardial blush grades, 3, 2 and 0/1 were 3%, 6% 
and 23% (P<O.OOOI) respectively. Multivariate analysis showed that the myocardial blush grade 
was a predictor of long term mortality, independent of Killip class, TIMI flow, left ventricular 
ejection fraction and other clinical variables. This chapter emphasizes that reperfusion therapy 
in patients with acute myocardial infarction should not only be aimed at opening the epicardial 
vessel, but also at achieving a high level of reperfusion at the myocardial. cellular level. 
Chapter 3 
Primary Stenting 
Although the benefits of primary angioplasty in aCllte myocardial infarction have been demons-
trated, several areas for improvement still remain. Therefore, a prospective randomized trial 
comparing primary stcnting with balloon angioplasty in patients with acute myoeardinl infarc-
tion was conducted. Patients with acute myocardial infarction were randomly assigned to under-
go either primary stenting (n=112) or balloon angioplasty (n=115). The clinical endpoints were 
death, recurrent infarction, subsequent bypass surgery 01' repeat angioplasty of the infarct-rela-
ted vessel. The overall mortality rate at 6 months was 2%. Recurrent infarction occurred in 8 
patients (7%) after balloon angioplasty, and in one (l %) after stenting (p=0.036). Subsequent 
target vessel revascularization was necessary in 19 (17%) and 4 (4%) patients, respectively 
(p=O.OOI6). The cardiac event-free survival rate in the stent group was significantly higher than 
in the balloon angioplasty group (95% vs 80%; p=0.012). It was concluded that in selected 
patients with acute myocardial infarction, primary stenting can be applied safely and effectively, 
resulting in a lower incidence of recunent infarction and a significant reduction in the need for 
subsequent target vessel revascularization, when compared to balloon angioplasty. 
Intra-aortic Balloon Pumping 
Further improvement in outcome after primary angioplasty can be achieved by using intra-aor-
tic balloon pumping. It may be effective in improving reperfusion and in achieving afterload 
reduction in high risk infarct patients treated with primary angioplasty. In the second part of 
chapter 3, high risk infarct patients referred from other centers for performing primary PTCA 
were randomized to treatment with or without TABP. The primary end point consisted of the 
combined incidence of death, non-fatal infarction, stroke or an ejection fraction < 30% at 6 
month follow-up. A weighted unsatisfactory outcome score (as previously described by Braun-
waId), enzymatic infarct size and left ventricular ejection fraction were secondary end points. 
During a 3,5 year period, 238 patients were randomized, 118 to IABP therapy and 120 to no 
IABP-therapy. None of the outcome scores were significantly different between both groups. 
Major complications occurred in 8% of patients who were treated with IABP pumping. It was 
concluded that systematic use of intra-aortic balloon pumping after primary angioplasty does not 
lead to myocardial salvage or to a better clinical outcome in high risk infarct patients. The devi-
ce should be reserved for patients with severe haemodynamic compromise. 
Chapter 4 
Primary AngiopIasty in low risk patients? 
Previous studies emphasized that especially high risk infarct patients benefit from treatment with 
primary angioplasty. In the tlrst part of chapter 4, we sought to compare primary coronary angio-
plasty and thrombolysis as treatment for low risk patients with an acute myocardial infarction. 
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We stratified 240 patients with acute myocardial infarction at admission according to risk. Low 
dsk patients (n=95) were randomized to primary angioplasty or thrombolytic therapy. The pri-
mary end point was death, nonfatal stroke or reinfarction dllling 6 months of follow-up. Left 
ventricular ejection fraction and medical charges were secondary end points. High risk patients 
(n= 145) were treated with primary angioplasty. In low risk patients, the incidence of the primary 
clinical end point (4% vs. 20%, p < 0.02) was lower in the group with primary coronary angio-
plasty than in the group with thrombolysis, because of a higher rate of reinfarction in the latter 
group. Mortality and stroke rates were low in both treatment groups. There were no differences 
in left ventricular ejection fraction or total medical charges. High risk patients had a 14% inci-
dence rate of the primmy clinical end point. It was concluded that even in low risk patients, pri-
mary coronary angioplasty results in a better clinical outcome at 6 months than does throm-
bolysis and does not increase total medical charges. 
Transfer of infarct patients 
In the second part of chapter 4 we investigated the feasibility of pdmmy coronary angioplasty 
as a treatment option in patients with acute myocardial infarction after initial diagnosis in a local 
community hospital. During a five year period, 520 candidates for primary coronary angioplasty 
were treated in our institution, 104 after transfer from a community hospital. The transfened and 
the non-transfelTed patients (N=416) were compared with regard to baseline clinical characte-
ristics, time intervals from symptom onset to treatment, and clinical outcome at six months. In 
this setting, the influence of transportation on total ischaemic time was limited, and there was no 
difference in clinical outcome between the transfened and the non-transferred patients. Clinical 
outcome was mainly dependent on the indication for transfer. It was concluded that safe and 
expedient transportation may facilitate the more widespread use of primary angioplasty in 
patients with acute myocardial infarction and that a large randomized muiticentl'e trial is needed 
to compare the relative merits of intravenous thrombolytic treatment in a local hospital with pri-
mary angioplasty after transfer in selected high risk patients with acute myocardial infarction. 
Chapier 5 
Time to Treatment 
The relationship between outcome and ischemic time for patients who present relatively late 
after the onset of symptoms is uncertain. The aim of the described study was to inves-tiga-te dif-
ferences in patient characteristics, left ventricular function and clinical outcome between early 
«3 hours), intermediate (3-6 hours) and late (6-24 hours) treated patients. From August 1990 
until December 1995, we studied 496 patients who underwent primary coronary angioplasty for 
acnte myocardial infarction. Patients who underwent reperfusion therapy between 6 and 24 
hours were more often of female gender and more often had diabetes. Primary coronary angio-
plasty was less successful with later time to reperfusion. Patients who had reperfusion therapy 
within 6 hours showed recovery of left ventricular function at 6 months follow-up, while the left 
ventricular function of patients treated late had deteriorated. Reocclusion of the infarct related 
vessel at follow-up coronary angiography was highest for patients with an ischemic time of more 
than 6 hours. They more often suffered a repeat myocardial infarction and had a significantly 
higher 6 months mortality. After adjustment for age, heart rate at presentation, gender, and the 
presence of diabetes by multivariate analysis, ischemic time remained an independent predictor 
of both left ventricular function recovery and 6 month mortality. 
An increasing number of patients with acute myocardial infarction who present at a local hospi-
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tal are transferred to a tertimy hospital with the aim to perform primary angioplasty. In the last 
part of chapter 5 we determined the influence of this extra treatment delay (due to transporta-
tion) in transfen'ed patients. In a three year period (December 1993 - November 1996), 207 con-
secutive patients who were transferred for primary angioplasty were analyzed in a matched com-
parison with non-transferred patients. Matching criteria were age, sex, infarct location, presen-
tation delay and Killip class. Patients who were transfcncd had an median additional delay of 
43 minutes. This resulted in a more extensive enzymatic infarct size and a lower ejection frac-
tion measured at 6 months. The rate of angioplasty success defined as TIMI grade 3 flow, and 
the 6 month mortality rate (7%) were comparable in both groups. It was concluded that the addi-
tional delay had a deleterious effect on myocardial salvage, reflected by a larger infarct size and 
a lower left ventricular function. However the patency rate and 6 month clinical outcome were 
not affected by this delay. 
Chapter 6 
Restenosis 
Previolls studies have suggested that restenosis and reocc1usion occur frequently in patients with 
acute coronary syndromes. This study was undertaken to assess the incidence and predictors of 
restenosis in a cohort of patients who underwent successful primary coronary angioplasty for 
acute myocardial infarction. 312 patients, who underwent successful primary angioplasty of a 
native coronary vessel, were candidates for follow-up coronary angiography. This was perfor-
med in 284 patients (92%) at 3 or 6 months follow-up. Quantitative coronary angiography was 
performed using the eMS-system. Multivariate analysis was done to determine independent pre-
dictors of restenosis. Restenosis, defined as a diameter stenosis of more than 50%, occurred in 
27% of patients at 3 months and in 37% of patients at 6 months follow-up. Reocclusion occu-
rred in 4% and 6% respectively. Reference diameter (vessel size) was related to restenosis. Age 
and lumen diameter immediately after angioplasty were independent predictors of restenosis. 
Young patients «50 years) and patients with a minimal luminal diameter of more than 2.5 n11n, 
had restenosis rates of less than 25%. The radionuclide ejection fraction was 46% in patients 
with restenosis compared to 47% in patients without restenosis. It was concluded that the inci-
dence of restenosis after successful primary coronary angioplasty for acute myocardial infarc-
tion is comparable to the reported incidence after elective coronary angioplasty for stable angi-
na. Restenosis is related to age and the lumen diameter after angioplasty and does not affect left 
ventricular function in this population. 
Chapter 7 
General Discussion 
This chapter discusses some of the issues of this thesis. HolY can tissue perfusion after primary 
angioplasty be ameliorated? Should low risk patients with acule myocardial infarction be tmns-
fen'cd to a hospital to perform primary PTCA? What will bc the consequences of transferring 
increasing numbers of patients? What is the additional value of primary stenting, except for a 
reduction in the rate of restenosis? How can treatment delay be further reduced and what addi-
tional therapies can be given during this delay? Further research should clarify some of these 
issues. 
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Samenvatting 
Hoofclstul< 1 
Introductie 
Primaire ballonangioplastiek, oftewel het "dotteren" bij patienten met cen acuut hartinfarct~ zan-
der dat hieraan voorafgaand trombolytische therapie is gegevcn, is bekcnd vanaf het begin van 
de tachtiger jaren. De tegcnvallende resultaten van "rescue"- en "deferred" angioplastick. na 
thrombolyse, zorgdcn ervoor dat oak de primaire ballonangioplastick naar de achtergrond verd-
ween. In 1993 leidde de gelijktijdige publicatie van 3 gerandomiseerde onderzoeken tussen 
trombolyse en primaire PTCA in de "New England Journal of Medicine". tot cen herwaardering 
van deze techniek als cell zeer effectieve manier van het open maken van de bij het infarct afges-
lotcn kransslagadcr. Dric jaar later stelden zO\vel de Europese als de Amerikaanse verenigingen 
voor Cardiologie primaire PTCA ais een eerste kells behandeloptic, met name bij patienten in 
shock en bij patienten met contra-indicaties voor trombolytische therapie. 
Hoofdstuk 2 
ST eIevatie resoIutie na geslaagde reperfusie. 
Tot voor kort bestond het belang van het ECG na reperfusie therapie uit het inschatten of de 
infarct-gerelateerde kransslagader opell of dicht zou zijll. Dit gelukte maar tell dele. met name 
bleek dat persisterende ST segment clevatie niet altijd gerelateerd was aan cen dichtzittend vat. 
In dit hoofdsnlk \\lordt getoond waarom. Bij 403 patienten, die succesvol waren behandeld met 
primaire PTCA werd het ECG vaal' reperfusie vergeleken met het ECG erna. Ondanks het volle-
dig open zijn van het vat (TIMI 3 flow) bleek bij 49% van de patienten nog ST elevaties aall-
wezig op het post PTCA ECG, suggestief voor een nog niet geheel geslaagde reperfusie. Deze 
patienten hadden een grotere enzymatische infmct grootte en een slechtere linker kamer rest-
functie, vergeleken met de patienten bij wie de ST elevaties volledig waren verdwenen. De mate 
van resolutie vall ST elevatie na geslaagde reperfusie bleek, na leeftijd ell Killip klasse, de belan-
gdjkste voorspeller te zijn vall ovcrlijden tijdens een 3 jarige follow-up peri ode. Deze bevin-
dingen laten zien dat persisterende ST elevatie heel goed kan optl'eden bij een volledig open 
infarct gerelateerd epicardiaal vat en dat dit waarschijnlijk een uiting is van een mindel' gesla-
agde reperfusie op myocardiaal niveau. Het al of niet geslaagd zijn van reperfusie is blijkbaar 
niet alleen door middel van het beoordelen van de doorstroming van het epicardiale vat (TIMI 
flow) te bepalen. 
Myocardiale Blush 
In het tweede deel van hoofdstuk 2 is gekeken of het angiogram ook infonnatie kan geven over 
het al of niet aanwezig zijn van myocardiale reperfusie. Dit werd gedaan door bij 777 patienten 
de post- PTCA gemaakte angiogrmmnen te scoren op de mate van contrast-aankleuring (blush) 
van het tevoren geYnfarceerde myocardiale weefsel. Wanneer het gei'nfarceerde myocard volle-
dig aankleurde (blush graad 3) bleek dit samen te gaan met een beperkte enzymatisehe infarct 
grootte en een goede linker kamer functie. Daarentegen bleek dat bij 30% van de patienten deze 
myocardiale aankleuring niet of nauwelijks aanwezig was en dat deze patienten een gemiddeld 
40% grater infarct en een matige linker kamer restfunctie hadden. De mate van myocardaan-
kleuring bleek cen belangrijke voorspellel' van overlijden te zijn, onalliankelijk van TThlI flow. 
Deze bevindingen benadmkken dat niet aileen een open epical'diaal vat van belang is vaal' reper-
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fusie, maar dat deze pas volledig geslaagde genoemd mag worden als er eveneens aanwijzingen 
zijn voor reperfusie op myocardiaal niveau. 
Hoofdstuk 3 
Primail'e Stenling 
De hoven genoemde gegevens maken duidelijk dat vel'dere verbetering van de resuitaten van 
reperfllsie therapie nodig is. Dam'om word gezocht naar aanvullende behandelingsvonnen, zoals 
stenting en behandeling met een intra-aortale ballonpomp. 
In het eerste gedeelte van hoofdstuk 3 worden de resultaten besehreven van een gerandomiseerd 
onderzoek naar de waarde van het primair stenten van het infarct-gerelateerd bloedvat. Bij de 
112 patienten, die door het lot een stent kregen toegewezen, bleek dat na 6 maanden minder re'in-
fareten waren opgetreden en minder tweede revaseularisaties (re-PTCA of CABG) waren geda-
an vergeleken met de 115 patienten die geen stent kregen. Het blijkt dus dat stentimplantatie vei-
lig toepasbaar is en klinisehe voordelen biedt bij een geselecteerde patienten populatie met een 
acuut hartinfarct. 
Intra-aortale ballonpomp 
In het twcede deel van hoofdstnk 3 wordt de waarde van de intra-aortale ballonpomp na primaire 
PTCA beschreven. Tijdens een periode van drie en een half jaar zijn 238 hoog risico infarct 
patienten gerandomiseerd naar weI (N=118) of geen (N=120) ballonpomp-behandeling. Na 6 
maanden follow-up bleek er tussen de 2 groepen geen versehil te bestaan in het gecombineerd 
voorkomen van overlijden, re'infarcering, CVA of een ejectiefractie van minder dan 30%. Ook 
blcek behandeling met een intra-aortale ballonpomp niet te lei den tot vennindering van enzy-
matische infarctgrootte of een betere pompfunctie van het hart. Daarentegen trad bij 8% van de 
patienten complicaties op ten gevoIge van de ballonpomp. Systematisch gebnlik van een intra-
aOltale ballonpomp bij hoog risico infarct patienten is derhalve niet van voordeel. 
Hoofdstuk 4 
Primaire PTCA vool' laag-risico palienten 
Vit eerder onderzoek kwam naar voren dat met name hoog risico infarct patH~nten baat hebben 
van behandeling met primaire PTCA, maar of dit ook gold voor patH~ntenmet bijvoorbeeld een 
onderwandinfarct was onhekend. Twee honderd veertig patienten werden aan de hand van sim-
pele klinischc criteria onderverdeeld in hoog of laag risico patienten. AIle 143 hoog risico 
paHenten werden behandeld met primaire PTCA, terwijl de 97 laag tisico patienten werden 
gerandomiseerd naar behandeling met streptokinase of primaire PTCA. Het gecombineerd voor-
komen van overlijden, CVA of reYnfarcering was lager in de met primaire PTCA behandelde laag 
risico groep, met name door een minder voorkomen van rei'nfarcten. Na 6 maanden bleken de 
kosten voor de behandeling met primaire PTCA niet hoger, met name door een geringer aantal 
heropnames, vergeleken met de patienten die streptokinase hadden gehad. Het feit dat ook laag 
risico infarct patienten baat hebben bij behandeling met primaire PTCA suggereert dat in een 
centrum waal' PTCA faciliteiten voorhanden zijn aile patiellten met een actInt hartillfarct op deze 
manier behandeld dienen te worden. 
Transport van infarct palienten 
Voor paticnten die een hartinfarct krijgen in een ziekenhuis waar geen PTCA kan worden 
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ve!Ticht bestaat de keuze tussen trombolytische therapie tel' plekke of primaire PTCA na trans-
port naar een PTCA centrum. In het tweede deel van hoofdstuk 4 wordt een onderzoek beschre-
ven nnar de veiligheid en haalbaarheid van transport van patienten met cen acuut hartinfarct. 
Honderdvier patienten die van elders kwamen werden vergeleken met 416 patienten die zich pri-
mairmeldden in het PTCA centnUll. De k:linische uitkomst na 6 maanden werd met name bepa-
aid door de indicatie van het transport en niet door het transpmt zelf. VerdeI' bleek dat door de 
betere voorbereiding van de cathetedsatiekamer de totale ischemische tijd (tijd van begin klach-
ten tot balloninflatie) niet langeI' was in de groep die op transport was gesteld. 
Hoofdstuk 5 
Tijd tot reperfosie 
Vit diverse studies bij patiCnten die behandeld zijn met thrombolytic a is duidelijk geworden dat 
het van groat belang is om cen patient met een myocardinfarct zo vroeg mogelijk te behandelen. 
Behandeling met primahe PTCA geef! het voordeel dat de exacte tijd van reperfusie bekend is 
(het leeg laten lopen van het ballonnetje na de eerste balloninflatie). Om deze reden is bij dit 
soort patienten goed vast te stellen wat de invloed is van ischemietijd op het uiteindelijke resul-
taat. Een groep van 496 patienten werd op grond van totale ischemietijd ingedeeld in 3 groepen. 
De groep patienten bij wie het vat binnen 3 uur na het begin van de klachten geopend werd ble-
ken vaker cen goede flow in dit vat te hebben en hadden een zeer lage mortaliteit 118 6 maanden 
(3%). Ook bleek het herstel van linker kamer functie afllankelijk te zijn van de tijd tol reperfu-
sie. Bij patienten die behandeld waren binncn 6 uur 11a begin klachten trad verbetermg op van 
de ejecliefractie na 6 maauden, terwijl de linker kamer functie gemiddeld genomen verslechter-
de in de groep die na 6 uur was behandeld. Dit bleek onafllankelijk van het hogere percentage 
patiCnten met reocclusie in deze laat behandelde groep. Verder bleek dat oudere patienten en 
patienten met diabetes mellitus vaak laat (> 6 uur) behandcld worden, met name doordat ze zich 
pas laat presenteren met klachten. Na conectie voor dit verschil in basiskenl11crken tllssen de 
drie groepen bleef de tijd tot reperfusie een onafhankelijke voorspeller van herstel van linker 
kamelfunctie en over/ijden na 6 maanden follow-up. 
Het tweede dee! van hoofdstuk 5 bekijkt wal het effect is van tijd, nodig voor transport van 
patienten van elders, op het resultaat van de behandeling. Om te zorgen dat aileen het effect van 
tijd zich zou openbaren werd een groep van 207 getransporteerde patienten gematched (01' leef-
tijd, geslacht, infarctlocatie en Killip klasse) met een populatie van niet getransporteerde patien-
ten. Het bleek dal een additionele transporttijd van 43 minulen leidde tot een grotere enzyma-
tische infaret grootte en een significant lagere linker kal11er fllnctie, ondanks een zelfde Sllcces-
percentage van de behandeling. De mortaliteit na 6 maanden bleek in beide groepen niet te vers-
ehillen. Het transport van infarct patH~nten naar een PTCA centrum heeft dus wei zijn prijs, maar 
belnvloedde in deze studie niel de 6 maands overleving. 
Hoofdstuk 6 
Restenose 
Er is lang gedacht dat restenose na PTCA bij patienten met instabiele coronaire syndromen fre-
quent optreedt. In dit hoofdsluk wordt het voorkomen van restenose bepaald in een populatie van 
312 patienten die succesvol waren behandeld met primaire PTCA in verband met een acuut har-
tinfarct. Restenose, gemeten met behulp van kwantitatieve coronairangiografie en gedefinieerd 
als cen diameterstenose van meer dan 50%, trad op bij 27% van de patienten na 3 maanden en bij 
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37% na 6 maanden follow-up. Reoeclusie trad op in sleehts 4 and 6% van de patientcn respeetie-
velijk. Leeftijd en diameter van het bloedvat na interventie bleken onafhankelijke voorspellende 
factoren voor het optreden van restenose. Patienten jongcr dan 50 jaar en patienten met cen dia-
meter van het bloedvat na PTCA van meer dan 2,5 Illlll hadden cen restenose percentage van min-
del' dan 25%. VerdeI' bleek dat rcstenosc en reoeclusie geen invloed hadden op linker kamer fune-
tie na 6 maanden. Het gevonden restenose percentage na PTCA vanwege cen aeunt hiu-tinfarct 
blijkt dus niet hoger dan gerapporteerde cijfers bij patienten die een PTCA ondergingen vanwe-
ge stabiele angina pectoris. 
Hoofdstuk 7 
Algemene Discnssie 
In dit hoofdstuk worden een aantal kanttekeningen geplaatst bij de gevonden resultaten. Het 
blijkt dat primaire stenting leidt tot cen reductic van reYuterventies en rei'nfarcten. Dit zorgt crvo-
or dat de initieel hogerc kosten voor de stcntimplantatie na 1 jaar l11imschoots worden terugver-
diend. Stenting resulteert echter niet in een bctem reperfusie of een reductie van enzymatische 
infaretgrootte of een betere linker kamerfunctie. VerdeI' wordt in dit hoofdstuk besproken wat de 
gevolgen zijn van uitbreiding van de indicatiestelling Vaal' behandeling met primaire PTCA. Het 
hoofdstuk word afgesloten met een aantal suggesties voor toekomstig onderzoek. Dit dient met 
name gericht te zijn op verbetering van myocardiale reperfusie en op verdere reductie van dc tijd 
tot behandeling. Recent onderzoek laat zien dat nag steeds een groep patienten met een acuut 
infarct geen vonn van repeliusietherapie krijgt. Thrombolytischc therapie en primaire PTCA 
dienen in dit opzicht niet als rivalen op te treden, maar als elkaar aanvullende behandelingsvor-
men, waarbij het uiteindelijke doel is am zoveelmogelijk patienten met een aCliut hartinfarct zo 
vroeg mogelijk te behandelen. 
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Bert Oikkeschei en Evelien van Voorst tot Voorst, en de afdeling Nucleaire Geneeskllnde, onder 
leiding van Stoffer Reiffers en Jaap KlIyvellhoven. AI die buisjes bloed, die "even" opgehaald 
en verwerkt Illoesten worden en die rust ejectiefracties. die v66r overplaatsing van een patient 
nag "even" tussen het programma door gingen. 
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Dank aan aBe verpleegkundigen, functielaboranten, team leiders, en afdeIingshoofden cardiolo-
gie die naast de zorg voor de patient, ook de zorg voor de wetenschap hoog in het vaandel heb-
ben. 
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Dank aan Vera Derks, voor het aanhoren van verhalen over Iliet slapen en Iieve kinderen, lllaar 
met name dank voor het aanpassen van aIle artikelen, dia's en voor die kleine dingen, die je vaal' 
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Dank aan aile huisartsen in de regio en het ambulance personeel, die hun leven in de waagschaal 
stellen om de tijd tot reperfusie maar zo kort mogelijk te houden. 
Natuurlijk veel dank aan aile Zwolse Infarct Studie (ZIS) patienten, zonders wiens medewerking 
dit proefschrift er nooit was geweest. 
Dank aan de afdeling cardiologie van het St. Antonius Ziekenhuis te Nieuwegein, met name Carl 
Ascoop en Norbert van Hemel, voor de gedegen vooropleiding die ik bij hen heb genoten. 
Professor I. Segal, dear Issidor. You were the one that made me enthusiastic for research and sho-
wed that doing research in South Africa is very special. 
Dank aan Marianne Eichholz, voor de hartelijke ontvangsten in Rotterdam en de ondersteuning 
bij de voorbereiding van de promotie. 
Gerard Metselaar en Ernesto de Ia Fuente, muchas gracias! 
Ruurd Buitenhuis en Rob Barnascolli, paranymfell en oud-huisgenoten. Ik vind het eeht gewel-
dig, jullie tijdens de verdediging aan mijn zijde te hebben. 
Dank aan mijn ouders, voor jaren van stenn, stimulans, sponsoring en belangstelling. 
Last, but not least, Karin, Marlou en Lasse, zonder jullie afleiding was "deze scriptie" maanden 
eerder klaar geweest, maar gelukkig bestaat het leven uit meer dan aIleen een boekje maken. 
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